{"text_format":"3","workbook":"xlsx","n_sheets":62,"sheets":["Cover Page","Condensed Consolidated Statemen","Condensed Consolidated Statem_2","Condensed Consolidated Balance ","Condensed Consolidated Balanc_2","Condensed Consolidated Statem_3","Condensed Consolidated Statem_4","Basis of Presentation and Summa","Business Combinations and Asset","Divestitures","Restructuring and Employee Seve","Goodwill and Other Intangible A","Long-Term Obligations and Other","Commitments, Contingent Liabili","Income Taxes","Fair Value Measurements","Financial Instruments","Shareholders' Equity","Earnings Per Share Attributable","Segment Information","Share-Based Compensation","Pay vs Performance Disclosure","Insider Trading Arrangements","Basis of Presentation and Sum_2","Business Combinations, Asset Ac","Restructuring and Employee Se_2","Goodwill and Other Intangible_2","Long-Term Obligations and Oth_2","Fair Value Measurements (Tables","Financial Instruments (Tables)","Shareholders' Equity (Tables)","Earnings Per Share Attributab_2","Segment Information (Tables)","Share-Based Compensation (Table","Basis of Presentation and Sum_3","Business Combinations and Ass_2","Discontinued Operations and Dis","Restructuring and Employee Se_3","Restructuring and Employee Se_4","Restructuring and Employee Se_5","Goodwill and Other Intangible_3","Goodwill and Other Intangible_4","Goodwill and Other Intangible_5","Long-Term Obligations and Oth_3","Commitments, Contingent Liabi_2","Income Taxes (Narrative) (Detai","Fair Value Measurements (Fair V","Financial Instruments (Narrativ","Financial Instruments Summary o","Shareholders' Equity (Narrative","Shareholders' Equity (Changes i","Earnings Per Share Attributab_3","Segment Information (Narrative)","Segment Information (Revenue by","Segment Information Revenue Fro","Segment Information (Segment Pr","Segment Information (Assets by ","Share-Based Compensation (Narra","Share-Based Compensation (Sched","Share-Based Compensation (Sch_2","Share-Based Compensation (Sch_3","Share-Based Compensation GIA (D"],"cells_cut":1,"read":"whole","date_system":"1900"}

{"sheet":"Cover Page","index":0,"n_rows":32,"n_cols":3,"rows_kept":32,"merged":[[0,0,1,0]]}
["Cover Page - shares","9 Months Ended"]
[null,"Mar. 31, 2025","Apr. 25, 2025"]
["Cover [Abstract]"," "," "]
["Document Type","10-Q"," "]
["Document Quarterly Report","true"," "]
["Document Period End Date","Mar. 31,  2025"," "]
["Document Transition Report","false"," "]
["Entity File Number","1-11373"," "]
["Entity Registrant Name","Cardinal Health, Inc."," "]
["Entity Central Index Key","0000721371"," "]
["Current Fiscal Year End Date","--06-30"," "]
["Document Fiscal Year Focus","2025"," "]
["Document Fiscal Period Focus","Q3"," "]
["Amendment Flag","false"," "]
["Entity Incorporation, State or Country Code","OH"," "]
["Entity Tax Identification Number","31-0958666"," "]
["Entity Address, Address Line One","7000 Cardinal Place"," "]
["Entity Address, City or Town","Dublin"," "]
["Entity Address, State or Province","OH"," "]
["Entity Address, Postal Zip Code","43017"," "]
["City Area Code","614"," "]
["Local Phone Number","757-5000"," "]
["Title of 12(b) Security","Common shares (without par value)"," "]
["Trading Symbol","CAH"," "]
["Security Exchange Name","NYSE"," "]
["Entity Current Reporting Status","Yes"," "]
["Entity Interactive Data Current","Yes"," "]
["Entity Filer Category","Large Accelerated Filer"," "]
["Entity Small Business","false"," "]
["Entity Emerging Growth Company","false"," "]
["Entity Shell Company","false"," "]
["Entity Common Stock, Shares Outstanding"," ",{"v":238677005,"d":"238,677,005 "}]

{"sheet":"Condensed Consolidated Statemen","index":1,"n_rows":29,"n_cols":5,"rows_kept":29,"merged":[[0,0,1,0],[0,1,0,2],[0,3,0,4]]}
["Condensed Consolidated Statements of Earnings - USD ($) shares in Millions, $ in Millions","3 Months Ended",null,"9 Months Ended"]
[null,"Mar. 31, 2025","Mar. 31, 2024","Mar. 31, 2025","Mar. 31, 2024"]
["Income Statement [Abstract]"," "," "," "," "]
["Revenue",{"v":54878,"d":"$ 54,878"},{"v":54868,"d":"$ 54,868"},{"v":162419,"d":"$ 162,419"},{"v":166960,"d":"$ 166,960"}]
["Cost of products sold",{"v":52755,"d":"52,755 "},{"v":52933,"d":"52,933 "},{"v":156453,"d":"156,453 "},{"v":161428,"d":"161,428 "}]
["Gross margin",{"v":2123,"d":"2,123 "},{"v":1935,"d":"1,935 "},{"v":5966,"d":"5,966 "},{"v":5532,"d":"5,532 "}]
["Operating expenses:"," "," "," "," "]
["Distribution, selling, general and administrative expenses",{"v":1315,"d":"1,315 "},{"v":1269,"d":"1,269 "},{"v":3898,"d":"3,898 "},{"v":3723,"d":"3,723 "}]
["Restructuring and employee severance",{"v":28,"d":"28 "},{"v":53,"d":"53 "},{"v":61,"d":"61 "},{"v":106,"d":"106 "}]
["Amortization and other acquisition-related costs",{"v":152,"d":"152 "},{"v":80,"d":"80 "},{"v":331,"d":"331 "},{"v":207,"d":"207 "}]
["Acquisition-related cash and share-based compensation costs",{"v":20,"d":"20 "}," ",{"v":20,"d":"20 "}," "]
["Impairments and (gain)/loss on disposal of assets, net",{"v":-17,"d":"(17)"},{"v":84,"d":"84 "},{"v":-15,"d":"(15)"},{"v":626,"d":"626 "}]
["Litigation (recoveries)/charges, net",{"v":-105,"d":"(105)"},{"v":80,"d":"80 "},{"v":-176,"d":"(176)"},{"v":28,"d":"28 "}]
["Operating earnings",{"v":730,"d":"730 "},{"v":369,"d":"369 "},{"v":1847,"d":"1,847 "},{"v":842,"d":"842 "}]
["Other (income)/expense, net",{"v":-9,"d":"(9)"},{"v":-1,"d":"(1)"},{"v":-11,"d":"(11)"},{"v":-10,"d":"(10)"}]
["Interest expense, net",{"v":74,"d":"74 "},{"v":28,"d":"28 "},{"v":141,"d":"141 "},{"v":42,"d":"42 "}]
["Earnings/(loss) before income taxes",{"v":665,"d":"665 "},{"v":342,"d":"342 "},{"v":1717,"d":"1,717 "},{"v":810,"d":"810 "}]
["Provision for income taxes",{"v":157,"d":"157 "},{"v":80,"d":"80 "},{"v":391,"d":"391 "},{"v":190,"d":"190 "}]
["Net earnings/(loss)",{"v":508,"d":"508 "},{"v":262,"d":"262 "},{"v":1326,"d":"1,326 "},{"v":620,"d":"620 "}]
["Less: Net earnings attributable to noncontrolling interests",{"v":-2,"d":"(2)"},{"v":-1,"d":"(1)"},{"v":-4,"d":"(4)"},{"v":-3,"d":"(3)"}]
["Net earnings attributable to Cardinal Health, Inc.",{"v":506,"d":"$ 506"},{"v":261,"d":"$ 261"},{"v":1322,"d":"$ 1,322"},{"v":617,"d":"$ 617"}]
["Earnings per common share attributable to Cardinal Health, Inc.:"," "," "," "," "]
["Basic (in shares)",{"v":2.11,"d":"$ 2.11"},{"v":1.07,"d":"$ 1.07"},{"v":5.47,"d":"$ 5.47"},{"v":2.51,"d":"$ 2.51"}]
["Diluted (in shares)",{"v":2.1,"d":"$ 2.10"},{"v":1.07,"d":"$ 1.07"},{"v":5.44,"d":"$ 5.44"},{"v":2.5,"d":"$ 2.50"}]
["Weighted-average number of common shares outstanding:"," "," "," "," "]
["Basic (in shares)",{"v":240,"d":"240 "},{"v":243,"d":"243 "},{"v":242,"d":"242 "},{"v":245,"d":"245 "}]
["Diluted (in shares)",{"v":241,"d":"241 "},{"v":245,"d":"245 "},{"v":243,"d":"243 "},{"v":247,"d":"247 "}]
["Cash dividends declared per common share",{"v":0.5056,"d":"$ 0.5056"},{"v":0.5006,"d":"$ 0.5006"},{"v":1.5168,"d":"$ 1.5168"},{"v":1.5018,"d":"$ 1.5018"}]
["Acquisition-related cash and share-based compensation costs",{"v":20,"d":"$ 20"}," ",{"v":20,"d":"$ 20"}," "]

{"sheet":"Condensed Consolidated Statem_2","index":2,"n_rows":11,"n_cols":5,"rows_kept":11,"merged":[[0,0,1,0],[0,1,0,2],[0,3,0,4]]}
["Condensed Consolidated Statements of Comprehensive Income - USD ($) $ in Millions","3 Months Ended",null,"9 Months Ended"]
[null,"Mar. 31, 2025","Mar. 31, 2024","Mar. 31, 2025","Mar. 31, 2024"]
["Statement of Comprehensive Income [Abstract]"," "," "," "," "]
["Net earnings/(loss)",{"v":508,"d":"$ 508"},{"v":262,"d":"$ 262"},{"v":1326,"d":"$ 1,326"},{"v":620,"d":"$ 620"}]
["Other comprehensive income/(loss):"," "," "," "," "]
["Foreign currency translation adjustments and other",{"v":-2,"d":"(2)"},{"v":1,"d":"1 "},{"v":-13,"d":"(13)"},{"v":-4,"d":"(4)"}]
["Net unrealized gain/(loss) on derivative instruments, net of tax",{"v":6,"d":"6 "},{"v":-6,"d":"(6)"},{"v":4,"d":"4 "},{"v":-5,"d":"(5)"}]
["Total other comprehensive income/(loss), net of tax",{"v":4,"d":"4 "},{"v":-5,"d":"(5)"},{"v":-9,"d":"(9)"},{"v":-9,"d":"(9)"}]
["Total comprehensive income",{"v":512,"d":"512 "},{"v":257,"d":"257 "},{"v":1317,"d":"1,317 "},{"v":611,"d":"611 "}]
["Less: Net earnings attributable to noncontrolling interests",{"v":-2,"d":"(2)"},{"v":-1,"d":"(1)"},{"v":-4,"d":"(4)"},{"v":-3,"d":"(3)"}]
["Total comprehensive income attributable to Cardinal Health, Inc.",{"v":510,"d":"$ 510"},{"v":256,"d":"$ 256"},{"v":1313,"d":"$ 1,313"},{"v":608,"d":"$ 608"}]

{"sheet":"Condensed Consolidated Balance ","index":3,"n_rows":35,"n_cols":3,"rows_kept":35}
["Condensed Consolidated Balance Sheets - USD ($) shares in Thousands, $ in Millions","Mar. 31, 2025","Jun. 30, 2024"]
["Current assets:"," "," "]
["Cash and equivalents",{"v":3326,"d":"$ 3,326"},{"v":5133,"d":"$ 5,133"}]
["Trade receivables, net",{"v":12666,"d":"12,666 "},{"v":12084,"d":"12,084 "}]
["Inventories, net",{"v":16158,"d":"16,158 "},{"v":14957,"d":"14,957 "}]
["Prepaid expenses and other",{"v":2398,"d":"2,398 "},{"v":2663,"d":"2,663 "}]
["Assets held for sale",{"v":47,"d":"47 "},{"v":47,"d":"47 "}]
["Total current assets",{"v":34595,"d":"34,595 "},{"v":34884,"d":"34,884 "}]
["Property and equipment, net",{"v":2664,"d":"2,664 "},{"v":2529,"d":"2,529 "}]
["Goodwill and other intangibles, net",{"v":11014,"d":"11,014 "},{"v":6450,"d":"6,450 "}]
["Other assets",{"v":1598,"d":"1,598 "},{"v":1258,"d":"1,258 "}]
["Total assets",{"v":49871,"d":"49,871 "},{"v":45121,"d":"45,121 "}]
["Current liabilities:"," "," "]
["Accounts payable",{"v":32812,"d":"32,812 "},{"v":31759,"d":"31,759 "}]
["Current portion of long-term obligations and other short-term borrowings",{"v":543,"d":"543 "},{"v":434,"d":"434 "}]
["Other accrued liabilities",{"v":3307,"d":"3,307 "},{"v":3447,"d":"3,447 "}]
["Total current liabilities",{"v":36662,"d":"36,662 "},{"v":35640,"d":"35,640 "}]
["Long-term obligations, less current portion",{"v":7136,"d":"7,136 "},{"v":4658,"d":"4,658 "}]
["Deferred income taxes and other liabilities",{"v":7971,"d":"7,971 "},{"v":8035,"d":"8,035 "}]
["Preferred shares, without par value:"," "," "]
["Authorized—500 thousand shares, Issued—none",{"v":0,"d":"0 "},{"v":0,"d":"0 "}]
["Common shares, without par value:"," "," "]
["Authorized—755 million shares, Issued—271 million shares and 327 million shares at March 31, 2025 and June 30, 2024, respectively",{"v":2946,"d":"2,946 "},{"v":2917,"d":"2,917 "}]
["Retained earnings/(accumulated deficit)",{"v":664,"d":"664 "},{"v":-286,"d":"(286)"}]
["Common shares in treasury, at cost: 32 million shares and 83 million shares at March 31, 2025 and June 30, 2024, respectively",{"v":-6382,"d":"(6,382)"},{"v":-5677,"d":"(5,677)"}]
["Accumulated other comprehensive loss",{"v":-176,"d":"(176)"},{"v":-167,"d":"(167)"}]
["Total Cardinal Health, Inc. shareholders' deficit",{"v":-2948,"d":"(2,948)"},{"v":-3213,"d":"(3,213)"}]
["Noncontrolling interests",{"v":1050,"d":"1,050 "},{"v":1,"d":"1 "}]
["Total shareholders’ deficit",{"v":-1898,"d":"(1,898)"},{"v":-3212,"d":"(3,212)"}]
["Total liabilities and shareholders’ deficit",{"v":49871,"d":"$ 49,871"},{"v":45121,"d":"$ 45,121"}]
["Preferred shares, authorized",{"v":500,"d":"500 "},{"v":500,"d":"500 "}]
["Preferred shares, issued",{"v":0,"d":"0 "},{"v":0,"d":"0 "}]
["Common shares, authorized",{"v":755000,"d":"755,000 "},{"v":755000,"d":"755,000 "}]
["Common shares, issued",{"v":271000,"d":"271,000 "},{"v":327000,"d":"327,000 "}]
["Common shares in treasury",{"v":32000,"d":"32,000 "},{"v":83000,"d":"83,000 "}]

{"sheet":"Condensed Consolidated Balanc_2","index":4,"n_rows":7,"n_cols":3,"rows_kept":7}
["Condensed Consolidated Balance Sheets (Parenthetical) - shares shares in Thousands","Mar. 31, 2025","Jun. 30, 2024"]
["Statement of Financial Position [Abstract]"," "," "]
["Preferred shares, authorized",{"v":500,"d":"500 "},{"v":500,"d":"500 "}]
["Preferred shares, issued",{"v":0,"d":"0 "},{"v":0,"d":"0 "}]
["Common shares, authorized",{"v":755000,"d":"755,000 "},{"v":755000,"d":"755,000 "}]
["Common shares, issued",{"v":271000,"d":"271,000 "},{"v":327000,"d":"327,000 "}]
["Common shares in treasury",{"v":32000,"d":"32,000 "},{"v":83000,"d":"83,000 "}]

{"sheet":"Condensed Consolidated Statem_3","index":5,"n_rows":92,"n_cols":7,"rows_kept":92}
["Condensed Consolidated Statements of Shareholders' Equity - USD ($) shares in Thousands, $ in Millions","Total","GIA Common Units","Retained Earnings","Treasury Stock, Common","Accumulated Other Comprehensive Income/(Loss)","Noncontrolling Interest"]
["Common shares in treasury"," "," "," ",{"v":76000,"d":"76,000 "}," "," "]
["Balance at beginning of period (in shares) at Jun. 30, 2023"," ",{"v":327000,"d":"327,000 "}," "," "," "," "]
["Balance at beginning of period at Jun. 30, 2023",{"v":-2957,"d":"$ (2,957)"},{"v":2746,"d":"$ 2,746"},{"v":-642,"d":"$ (642)"}," ",{"v":-151,"d":"$ (151)"},{"v":1,"d":"$ 1"}]
["Treasury, balance at beginning of period (in shares) at Jun. 30, 2023"," "," "," ",{"v":-76000,"d":"(76,000)"}," "," "]
["Treasury, balance at beginning of period at Jun. 30, 2023",{"v":-4911,"d":"(4,911)"}," "," "," "," "," "]
["Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",{"v":620,"d":"620 "}," "," "," "," ",{"v":3,"d":"3 "}]
["Net Income (Loss) Attributable to Parent",{"v":617,"d":"617 "}," "," "," "," "," "]
["Other Comprehensive Income (Loss), Net of Tax",{"v":-9,"d":"(9)"}," "," "," "," "," "]
["Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent",{"v":-9,"d":"(9)"}," "," "," ",{"v":-9,"d":"(9)"}," "]
["Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture"," ",{"v":0,"d":"0 "}," ",{"v":1000,"d":"1,000 "}," "," "]
["Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture",{"v":118,"d":"118 "},{"v":41,"d":"$ 41"}," ",{"v":77,"d":"$ 77"}," "," "]
["Purchase of treasury shares, net",{"v":-750,"d":"(750)"},{"v":-100,"d":"$ (100)"}," "," "," "," "]
["Treasury shares acquired (in shares)"," "," "," ",{"v":-9000,"d":"(9,000)"}," "," "]
["Dividends",{"v":-372,"d":"(372)"}," ",{"v":-372,"d":"(372)"}," "," "," "]
["Stockholders' Equity, Other Shares"," "," "," ",{"v":-1000,"d":"(1,000)"}," "," "]
["Other",{"v":0,"d":"0 "}," ",{"v":1,"d":"1 "}," "," ",{"v":1,"d":"1 "}]
["Balance at end of period (in shares) at Mar. 31, 2024"," ",{"v":327000,"d":"327,000 "}," "," "," "," "]
["Balance at end of period at Mar. 31, 2024",{"v":-3359,"d":"(3,359)"},{"v":2887,"d":"$ 2,887"},{"v":-396,"d":"(396)"}," ",{"v":-160,"d":"(160)"},{"v":3,"d":"3 "}]
["Treasury, balance at end of period (in shares) at Mar. 31, 2024"," "," "," ",{"v":-83000,"d":"(83,000)"}," "," "]
["Treasury, balance at end of period at Mar. 31, 2024",{"v":-5693,"d":"(5,693)"}," "," "," "," "," "]
["Treasury Stock, Value, Acquired, Cost Method",{"v":-759,"d":"(759)"}," "," ",{"v":-859,"d":"$ (859)"}," "," "]
["Common shares in treasury"," "," "," ",{"v":83000,"d":"83,000 "}," "," "]
["Balance at beginning of period (in shares) at Dec. 31, 2023"," ",{"v":327000,"d":"327,000 "}," "," "," "," "]
["Balance at beginning of period at Dec. 31, 2023",{"v":-3547,"d":"(3,547)"},{"v":2855,"d":"$ 2,855"},{"v":-535,"d":"(535)"}," ",{"v":-155,"d":"(155)"},{"v":2,"d":"2 "}]
["Treasury, balance at beginning of period (in shares) at Dec. 31, 2023"," "," "," ",{"v":-83000,"d":"(83,000)"}," "," "]
["Treasury, balance at beginning of period at Dec. 31, 2023",{"v":-5714,"d":"(5,714)"}," "," "," "," "," "]
["Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",{"v":262,"d":"262 "}," "," "," "," ",{"v":1,"d":"1 "}]
["Net Income (Loss) Attributable to Parent",{"v":261,"d":"261 "}," "," "," "," "," "]
["Other Comprehensive Income (Loss), Net of Tax",{"v":-5,"d":"(5)"}," "," "," "," "," "]
["Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent",{"v":-5,"d":"(5)"}," "," "," ",{"v":-5,"d":"(5)"}," "]
["Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture"," ",{"v":0,"d":"0 "}," ",{"v":0,"d":"0 "}," "," "]
["Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture",{"v":53,"d":"53 "},{"v":32,"d":"$ 32"}," ",{"v":21,"d":"$ 21"}," "," "]
["Dividends",{"v":-123,"d":"(123)"}," ",{"v":-123,"d":"(123)"}," "," "," "]
["Stockholders' Equity, Other Shares"," "," "," "," "," "," "]
["Other",{"v":-1,"d":"(1)"}," ",{"v":1,"d":"1 "}," "," "," "]
["Balance at end of period (in shares) at Mar. 31, 2024"," ",{"v":327000,"d":"327,000 "}," "," "," "," "]
["Balance at end of period at Mar. 31, 2024",{"v":-3359,"d":"(3,359)"},{"v":2887,"d":"$ 2,887"},{"v":-396,"d":"(396)"}," ",{"v":-160,"d":"(160)"},{"v":3,"d":"3 "}]
["Treasury, balance at end of period (in shares) at Mar. 31, 2024"," "," "," ",{"v":-83000,"d":"(83,000)"}," "," "]
["Treasury, balance at end of period at Mar. 31, 2024",{"v":-5693,"d":"$ (5,693)"}," "," "," "," "," "]
["Common shares in treasury"," "," "," ",{"v":83000,"d":"83,000 "}," "," "]
["Common shares in treasury",{"v":83000,"d":"83,000 "}," "," ",{"v":-83000,"d":"(83,000)"}," "," "]
["Balance at beginning of period (in shares) at Jun. 30, 2024",{"v":327000,"d":"327,000 "},{"v":327000,"d":"327,000 "}," "," "," "," "]
["Balance at beginning of period at Jun. 30, 2024",{"v":-3212,"d":"$ (3,212)"},{"v":2917,"d":"$ 2,917"},{"v":-286,"d":"(286)"}," ",{"v":-167,"d":"(167)"},{"v":1,"d":"1 "}]
["Treasury, balance at beginning of period (in shares) at Jun. 30, 2024",{"v":-83000,"d":"(83,000)"}," "," ",{"v":83000,"d":"83,000 "}," "," "]
["Treasury, balance at beginning of period at Jun. 30, 2024",{"v":-5677,"d":"$ (5,677)"}," "," "," "," "," "]
["Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",{"v":1326,"d":"1,326 "}," "," "," "," ",{"v":4,"d":"4 "}]
["Net Income (Loss) Attributable to Parent",{"v":1322,"d":"1,322 "}," "," "," "," "," "]
["Other Comprehensive Income (Loss), Net of Tax",{"v":-9,"d":"(9)"}," "," "," "," "," "]
["Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent",{"v":-9,"d":"(9)"}," "," "," ",{"v":-9,"d":"(9)"}," "]
["Noncontrolling Interest, Increase from Business Combination",{"v":1035,"d":"$ 1,035"}," "," "," "," ",{"v":1035,"d":"1,035 "}]
["Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture",{"v":1000,"d":"1,000 "},{"v":0,"d":"0 "}," "," "," "," "]
["Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture",{"v":80,"d":"$ 80"},{"v":28,"d":"$ 28"}," ",{"v":52,"d":"$ 52"}," "," "]
["Purchase of treasury shares, net",{"v":-765,"d":"$ (765)"}," "," ",{"v":-750,"d":"$ (750)"}," "," "]
["Treasury shares acquired (in shares)"," "," "," ",{"v":-6000,"d":"(6,000)"}," "," "]
["Retirement of treasury stock",{"v":0,"d":"0 "},{"v":-56000,"d":"(56,000)"}," ",{"v":-56000,"d":"(56,000)"}," "," "]
["Dividends",{"v":-370,"d":"$ (370)"}," ",{"v":-370,"d":"(370)"}," "," "," "]
["Payments to Noncontrolling Interests",{"v":7,"d":"7 "}," "," "," "," ",{"v":7,"d":"7 "}]
["Stockholders' Equity, Other Shares"," ",{"v":-1000,"d":"(1,000)"}," "," "," "," "]
["Other",{"v":1,"d":"$ 1"}," ",{"v":2,"d":"2 "}," "," ",{"v":0,"d":"0 "}]
["Balance at end of period (in shares) at Mar. 31, 2025",{"v":271000,"d":"271,000 "},{"v":271000,"d":"271,000 "}," "," "," "," "]
["Balance at end of period at Mar. 31, 2025",{"v":-1898,"d":"$ (1,898)"},{"v":2946,"d":"$ 2,946"},{"v":664,"d":"664 "}," ",{"v":-176,"d":"(176)"},{"v":1050,"d":"1,050 "}]
["Treasury, balance at end of period (in shares) at Mar. 31, 2025",{"v":-32000,"d":"(32,000)"}," "," ",{"v":-32000,"d":"(32,000)"}," "," "]
["Treasury, balance at end of period at Mar. 31, 2025",{"v":-6382,"d":"$ (6,382)"}," "," "," "," "," "]
["Treasury Stock, Value, Acquired, Cost Method",{"v":-757,"d":"(757)"}," "," ",{"v":-757,"d":"$ (757)"}," "," "]
["Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Vested",{"v":17,"d":"17 "}," "," "," "," ",{"v":17,"d":"17 "}]
["Common shares in treasury"," "," "," ",{"v":-29000,"d":"(29,000)"}," "," "]
["Balance at beginning of period (in shares) at Dec. 31, 2024"," ",{"v":271000,"d":"271,000 "}," "," "," "," "]
["Balance at beginning of period at Dec. 31, 2024",{"v":-2921,"d":"(2,921)"},{"v":2932,"d":"$ 2,932"},{"v":283,"d":"283 "}," ",{"v":-180,"d":"(180)"},{"v":70,"d":"70 "}]
["Treasury, balance at beginning of period (in shares) at Dec. 31, 2024"," "," "," ",{"v":29000,"d":"29,000 "}," "," "]
["Treasury, balance at beginning of period at Dec. 31, 2024",{"v":-6026,"d":"(6,026)"}," "," "," "," "," "]
["Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",{"v":508,"d":"508 "}," "," "," "," ",{"v":2,"d":"2 "}]
["Net Income (Loss) Attributable to Parent",{"v":506,"d":"506 "}," "," "," "," "," "]
["Other Comprehensive Income (Loss), Net of Tax",{"v":4,"d":"4 "}," "," "," "," "," "]
["Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent",{"v":4,"d":"4 "}," "," "," "," "," "]
["Noncontrolling Interest, Increase from Business Combination",{"v":963,"d":"963 "}," "," "," "," ",{"v":963,"d":"963 "}]
["Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture"," ",{"v":0,"d":"0 "}," ",{"v":0,"d":"0 "}," "," "]
["Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture",{"v":35,"d":"35 "},{"v":13,"d":"$ 13"}," ",{"v":22,"d":"$ 22"}," "," "]
["Purchase of treasury shares, net"," "," "," "," "," "," "]
["Treasury shares acquired (in shares)"," "," "," ",{"v":-3000,"d":"(3,000)"}," "," "]
["Retirement of treasury stock"," "," "," ",{"v":-56000,"d":"(56,000)"}," "," "]
["Dividends",{"v":-123,"d":"(123)"}," ",{"v":-123,"d":"(123)"}," "," "," "]
["Payments to Noncontrolling Interests",{"v":3,"d":"3 "}," "," "," "," ",{"v":3,"d":"3 "}]
["Stockholders' Equity, Other Shares"," "," "," "," "," "," "]
["Other",{"v":0,"d":"$ 0"},{"v":1,"d":"$ 1"},{"v":-2,"d":"(2)"}," "," ",{"v":1,"d":"1 "}]
["Balance at end of period (in shares) at Mar. 31, 2025",{"v":271000,"d":"271,000 "},{"v":271000,"d":"271,000 "}," "," "," "," "]
["Balance at end of period at Mar. 31, 2025",{"v":-1898,"d":"$ (1,898)"},{"v":2946,"d":"$ 2,946"},{"v":664,"d":"$ 664"}," ",{"v":-176,"d":"$ (176)"},{"v":1050,"d":"1,050 "}]
["Treasury, balance at end of period (in shares) at Mar. 31, 2025",{"v":-32000,"d":"(32,000)"}," "," ",{"v":-32000,"d":"(32,000)"}," "," "]
["Treasury, balance at end of period at Mar. 31, 2025",{"v":-6382,"d":"$ (6,382)"}," "," "," "," "," "]
["Treasury Stock, Value, Acquired, Cost Method",{"v":-378,"d":"(378)"}," "," ",{"v":-378,"d":"$ (378)"}," "," "]
["Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Vested",{"v":17,"d":"$ 17"}," "," "," "," ",{"v":17,"d":"$ 17"}]
["Common shares in treasury",{"v":32000,"d":"32,000 "}," "," ",{"v":32000,"d":"32,000 "}," "," "]

{"sheet":"Condensed Consolidated Statem_4","index":6,"n_rows":38,"n_cols":3,"rows_kept":38,"merged":[[0,0,1,0],[0,1,0,2]]}
["Condensed Consolidated Statements of Cash Flows - USD ($) $ in Millions","9 Months Ended"]
[null,"Mar. 31, 2025","Mar. 31, 2024"]
["Cash flows from operating activities:"," "," "]
["Net earnings/(loss)",{"v":1326,"d":"$ 1,326"},{"v":620,"d":"$ 620"}]
["Adjustments to reconcile net earnings to net cash provided by operating activities:"," "," "]
["Depreciation and amortization",{"v":581,"d":"581 "},{"v":524,"d":"524 "}]
["Impairments and (gain)/loss on disposal of assets, net",{"v":-15,"d":"(15)"},{"v":626,"d":"626 "}]
["Impairments and loss on sale of other investments",{"v":-2,"d":"(2)"},{"v":0,"d":"0 "}]
["Share-based compensation",{"v":91,"d":"91 "},{"v":88,"d":"88 "}]
["Provision for bad debts",{"v":41,"d":"41 "},{"v":28,"d":"28 "}]
["Change in operating assets and liabilities, net of effects from acquisitions and divestitures:"," "," "]
["Increase in trade receivables",{"v":-367,"d":"(367)"},{"v":-223,"d":"(223)"}]
["Increase in inventories",{"v":-1209,"d":"(1,209)"},{"v":-1258,"d":"(1,258)"}]
["Increase in accounts payable",{"v":954,"d":"954 "},{"v":2118,"d":"2,118 "}]
["Other accrued liabilities and operating items, net",{"v":-534,"d":"(534)"},{"v":-843,"d":"(843)"}]
["Net cash provided by operating activities",{"v":870,"d":"870 "},{"v":1680,"d":"1,680 "}]
["Cash flows from investing activities:"," "," "]
["Acquisition of subsidiaries, net of cash acquired",{"v":3855,"d":"3,855 "},{"v":1192,"d":"1,192 "}]
["Proceeds from divestitures, net of cash sold",{"v":2,"d":"2 "},{"v":9,"d":"9 "}]
["Additions to property and equipment",{"v":-315,"d":"(315)"},{"v":-318,"d":"(318)"}]
["Proceeds from disposal of property and equipment",{"v":3,"d":"3 "},{"v":10,"d":"10 "}]
["Purchases of investments",{"v":-6,"d":"(6)"},{"v":-3,"d":"(3)"}]
["Proceeds from investments",{"v":7,"d":"7 "},{"v":1,"d":"1 "}]
["Proceeds from net investment hedge terminations",{"v":2,"d":"2 "},{"v":28,"d":"28 "}]
["Payments to Acquire Restricted Certificates of Deposit",{"v":0,"d":"0 "},{"v":550,"d":"550 "}]
["Proceeds from short-term investment in time deposit",{"v":200,"d":"200 "},{"v":0,"d":"0 "}]
["Net cash used in investing activities",{"v":-3962,"d":"(3,962)"},{"v":-2015,"d":"(2,015)"}]
["Cash flows from financing activities:"," "," "]
["Proceeds from long-term obligations, net of issuance costs",{"v":2869,"d":"2,869 "},{"v":1139,"d":"1,139 "}]
["Reduction of long-term obligations",{"v":-434,"d":"(434)"},{"v":-23,"d":"(23)"}]
["Net tax proceeds/(withholding) from share-based compensation",{"v":-12,"d":"(12)"},{"v":23,"d":"23 "}]
["Dividends on common shares",{"v":-374,"d":"(374)"},{"v":-377,"d":"(377)"}]
["Purchase of treasury shares, net",{"v":-765,"d":"(765)"},{"v":-750,"d":"(750)"}]
["Net cash provided by financing activities",{"v":1284,"d":"1,284 "},{"v":12,"d":"12 "}]
["Effect of Exchange Rate on Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation",{"v":1,"d":"1 "},{"v":-7,"d":"(7)"}]
["Net decrease in cash and equivalents",{"v":-1807,"d":"(1,807)"},{"v":-330,"d":"(330)"}]
["Cash and equivalents at beginning of period",{"v":5133,"d":"5,133 "},{"v":4076,"d":"4,076 "}]
["Cash and equivalents at end of period",{"v":3326,"d":"$ 3,326"},{"v":3746,"d":"$ 3,746"}]

{"sheet":"Basis of Presentation and Summa","index":7,"n_rows":4,"n_cols":2,"rows_kept":4,"merged":[[0,0,1,0]]}
["Basis of Presentation and Summary of Significant Accounting Policies","9 Months Ended"]
[null,"Mar. 31, 2025"]
["Accounting Policies [Abstract]"," "]
["Basis of Presentation and Summary of Significant Accounting Policies","1. Basis of Presentation and Summary of Significant Accounting Policies Basis of Presentation Our condensed consolidated financial statements include the accounts of all majority-owned or consolidated subsidiaries, and all significant intercompany transactions and amounts have been eliminated. The results of businesses acquired or disposed of are included in the condensed consolidated financial statements from the date of the acquisition or up to the date of disposal, respectively. We report our financial results in two reportable segments: Pharmaceutical and Specialty Solutions (\"Pharma\") segment and Global Medical Products and Distribution (\"GMPD\") segment. All remaining operating segments that are not significant enough to require separate reportable segment disclosures are included in Other, which is comprised of Nuclear and Precision Health Solutions, at-Home Solutions, and OptiFreight ® Logistics. References to \"we,\" \"our,\" and similar pronouns in this Quarterly Report on Form 10-Q for the quarter ended March 31, 2025 (this \"Form 10-Q\") are to Cardinal Health, Inc. and its majority-owned or consolidated subsidiaries unless the context requires otherwise. Our fiscal year ends on June 30. References to fiscal 2025 and 2024 in these condensed consolidated financial statements are to the fiscal years ending or ended June 30, 2025 and June 30, 2024, respectively. Our condensed consolidated financial statements have been prepared in accordance with the U.S. Securities and Exchange Commission (\"SEC\") instructions to Quarterly Reports on Form 10-Q and include the information and disclosures required by accounting principles generally accepted in the United States (\"GAAP\") for interim financial reporting. The preparation of financial statements in conformity with GAAP requires us to make estimates, judgments and assumptions that affect amounts reported in the condensed consolidated financial statements and accompanying notes. Actual amounts may differ from these estimated amounts. In our opinion, all adjustments necessary for a fair presentation of the condensed consolidated financial statements have been included. Except as disclosed elsewhere in this Form 10-Q, all such adjustments are of a normal and recurring nature. In addition, financial results presented for this fiscal 2025 interim period are not necessarily indicative of the results that may be expected for the full fiscal year ending June 30, 2025. These condensed consolidated financial statements are unaudited and, accordingly, should be read in conjunction with the audited consolidated financial statements and related notes contained in our Annual Report on Form 10-K for the fiscal year ended June 30, 2024 (our \"2024 Form 10-K\"). Revision of Prior Period Consolidated Financial Statements As previously disclosed in the 2024 Form 10-K, we revised our prior period financial statements to correct for an accounting error related to the at-Home Solutions operating segment that was not material, individually or in the aggregate, to our previously issued Consolidated Financial Statements, as well as other unrelated immaterial errors. The appropriate revisions to our historical condensed consolidated financial statements and the notes thereto are reflected herein. See Note 1 and Note 16 to the \"Consolidated Financial Statements\" in the 2024 Form 10-K for additional information. Major Customers On April 22, 2024, we announced that our pharmaceutical distribution contracts with OptumRx, which expired at the end of June 2024, would not be renewed. Sales to OptumRx generated 17 percent of our consolidated revenue in fiscal 2024. Variable Interest Entities We evaluate our ownership, contractual, and other interests in entities to determine if they are a variable interest entity (“VIE”), if we have a variable interest in those entities, and the nature and extent of those interests. These evaluations may involve management judgment and the use of estimates and assumptions based on available historical information, among other factors. Based on our evaluations, if we determine we are the primary beneficiary of such VIEs, we consolidate such entities into our financial statements. Consolidated Variable Interest Entities We consolidate a VIE when we have the power to direct the activities that most significantly impact the VIE’s economic performance and the obligation to absorb losses or the right to receive benefits of the VIE and, as a result, are considered the primary beneficiary of the VIE. On January 1, 2020, GI Alliance (\"GIA\") entered into a management services arrangement with Texas Digestive Disease Consultants, PLLC (“TDDC”) that authorized GIA to perform certain management services in the manner that it deemed reasonably appropriate to meet the day-to-day business needs of TDDC. In exchange for the management services provided, GIA is entitled to receive an annual management fee equal to a percentage of TDDC’s net operating income. The agreement has a 15 year term with two successive 5 year terms set to renew automatically. Based on these determinations, we concluded that TDDC is a VIE and that GIA is the primary beneficiary. The VIE does not have a material impact on our condensed consolidated statements of earnings or condensed consolidated statements of cash flows. Total assets and liabilities included in the consolidated balance sheets for the VIE were $524 million and $249 million, respectively, as of March 31, 2025. Noncontrolling Interests Noncontrolling interests represent the portion of net earnings, comprehensive income and net assets that is not attributable to Cardinal Health. Noncontrolling interests as of March 31, 2025 primarily represents third-party equity interests in GIA and ION. The net earnings attributable to noncontrolling interests in GIA contain certain call and put rights, however, the exercise of these options is fully within the control of Cardinal Health. and the associated noncontrolling interest has therefore been determined to be nonredeemable and classified within permanent equity. The fair value was estimated using the implied enterprise value based on the purchase price paid for the controlling interest. See Note 2 , for additional information on the acquisition of GIA. Recently Issued Financial Accounting Standards and Disclosure Rules Not Yet Adopted We assess the adoption impacts of recently issued accounting standards by the Financial Accounting Standards Board (\"FASB\") on our condensed consolidated financial statements as well as material updates to previous assessments, if any, from our fiscal 2024 Form 10-K. Segment Reporting In November 2023, the FASB issued Accounting Standards Update (\"ASU\") 2023-07 Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which enhances reportable segment disclosure requirements, primarily through disclosures of significant segment expenses. This guidance will be effective for us in our fiscal 2025 Form 10-K and the guidance must be applied retrospectively to all prior periods presented. We have evaluated the impact of adoption of this guidance on our disclosures and this will be reflected in our fiscal 2025 Form 10-K. Income Tax Disclosure In December 2023, the FASB issued ASU 2023-09 Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which enhances income tax disclosures primarily related to the rate reconciliation and income taxes paid information. This guidance also includes certain other amendments to improve the effectiveness of income tax disclosures. This guidance will be effective for us in fiscal 2026 Form 10-K and should be applied on a prospective basis, with retrospective application permitted. We are currently evaluating the impact of adoption of this guidance on our disclosures. Disaggregation of Income Statement Expenses In November 2024, the FASB issued ASU 2024-03 Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40), which requires disaggregated disclosures of certain categories of expenses which are included in any relevant income statement expense caption on an annual and interim basis. Additionally, the guidance requires the disclosure of total selling expenses and, in annual reporting periods, an entity's definition of selling expenses. This guidance will be effective for us in fiscal 2028 Form 10-K and should be applied on a prospective basis, with retrospective application permitted. We are currently evaluating the impact of adoption of this guidance on our disclosures. Recently Adopted Financial Accounting Standards There were no new material accounting standards adopted during the nine months ended March 31, 2025."]

{"sheet":"Business Combinations and Asset","index":8,"n_rows":4,"n_cols":2,"rows_kept":4,"merged":[[0,0,1,0]]}
["Business Combinations and Asset Acquisitions","9 Months Ended"]
[null,"Mar. 31, 2025"]
["Business Combination, Asset Acquisition, Transaction between Entities under Common Control, and Joint Venture Formation [Abstract]"," "]
["Business Combination","2. Acquisitions Integrated Oncology Network (\"ION\") On December 2, 2024, we completed the acquisition of ION, a physician-led independent community oncology network, for a purchase price of $1.1 billion in cash, subject to certain adjustments. ION is a management services organization that supports more than 50 practice sites in 10 states representing more than 100 providers. ION supports a continuum of care across its member sites including medical oncology, radiation oncology, urology diagnostic testing and other ancillary services. As part of the transaction, ION practices will be integrated into Navista, our managed services organization intended to enhance efficiency for providers and patients, enable additional capabilities, and increase practice profitability of independent community oncologists. We report ION results within our Pharma segment. The portion of ION net earnings attributable to noncontrolling interest holders is reported as a reduction to net earnings in the condensed consolidated statements of earnings. The acquisition was funded with available cash on hand. Transaction and integration costs associated with the ION acquisition were $6 million and $25 million during the three and nine months ended March 31, 2025, respectively, and are included in amortization and other acquisition-related costs in the condensed consolidated statements of earnings. GI Alliance (\"GIA\") On January 30, 2025, we completed the acquisition of 73 percent ownership interest in GIA, a gastroenterology management services organization, for a purchase price of approximately $2.8 billion in cash, subject to certain adjustments. Beginning on the third anniversary of the closing, we have the ability to exercise a call right to purchase up to 100 percent of the remaining outstanding equity. GIA's management services organization platform includes over 900 physicians across 345 practice locations in 20 states and has the ability to further expand both geographically and in other key therapeutic areas. We have accounted for the acquisition of the ownership interest in GIA as a business combination in accordance with ASC 805. We consolidate the results of GIA in our condensed consolidated financial statements and report those consolidated results within our Pharma segment. The portion of GIA net earnings attributable to noncontrolling interest holders is reported as a reduction to net earnings in the condensed consolidated statements of earnings. Transaction and integration costs associated with the GIA acquisition were $59 million and $69 million during the three and nine months ended March 31, 2025, respectively, and are included in amortization and other acquisition-related costs in the condensed consolidated statements of earnings. On April 14, 2025, we announced that we entered into a definitive agreement to acquire Urology America. This transaction is subject to the satisfaction of customary closing conditions, including receipt of required regulatory approvals. Advanced Diabetes Supply Group (\"ADSG\") On April 1, 2025, we completed the acquisition of ADSG, one of the country's leading diabetic medical supplies providers, for a purchase price of approximately $1.1 billion in cash, subject to certain adjustments. ADSG serves approximately 500,000 patients annually by providing the latest innovations in diabetes therapies from leading manufacturers. ADSG will become part of our at-Home Solutions operating segment and we will report ADSG results in Other. We financed the acquisition of ADSG with a combination of cash on hand and cash proceeds from new debt financing as described in Note 6 . Specialty Networks On March 18, 2024, we completed the acquisition of Specialty Networks for a purchase price of $1.2 billion in cash. Specialty Networks creates clinical and economic value for providers and partners across multiple specialty group purchasing organizations (\"GPOs\"): UroGPO, Gastrologix and GastroGPO, and United Rheumatology. Specialty Networks results are reflected within our Pharma segment. Transaction and integration costs associated with the Specialty Network acquisition were $2 million and $6 million during the three and nine months ended March 31, 2025, respectively and transaction costs were $15 million during the three and nine months ended March 31, 2024. These are included in amortization and other acquisition-related costs in the condensed consolidated statements of earnings. Fair Value of Assets Acquired and Liabilities Assumed The allocation of the purchase price for the acquisitions of ION and GIA are not yet finalized and are subject to adjustment as we complete the valuation analysis of these acquisitions. The purchase prices are also subject to adjustment based on working capital requirements as set forth in the acquisition agreements. The pro forma results of operations and the results of operations for these acquisitions have not been separately disclosed because the effects were not significant compared to the consolidated financial statements. The following table summarizes the estimated fair values of the assets acquired and liabilities assumed as of the acquisition date for ION and GIA: (in millions) ION GIA Identifiable intangible assets: Customer contracts (1) $ 235 $ — Trademarks (2) 78 256 Non-competition agreements (3) — 24 Total identifiable intangible assets acquired 313 280 Identifiable net assets/(liabilities): Cash and equivalents 8 76 Trade receivables, net 59 195 Inventories 4 21 Prepaid expenses and other 5 13 Property and equipment, net 32 67 Other assets 45 287 Accounts payable (10) (89) Current portion of long-term obligations and other short-term borrowings (3) (1) Other accrued liabilities (38) (171) Long-term obligations, less current portion (14) (15) Deferred income taxes and other liabilities (88) (209) Total identifiable net assets/(liabilities) acquired 313 454 Noncontrolling interest (151) (884) Goodwill 908 3,241 Total net assets acquired $ 1,070 $ 2,811 (1) The weighted-average useful life of customer contracts is 20 years. (2) The weighted-average useful life of trademarks is 10 years. (3) The weighted-average useful life of non-competition agreements is 4 years. The valuation of identifiable intangible assets utilizes significant unobservable inputs and thus represents a Level 3 nonrecurring fair value measurement. The discount rates used to arrive at the present values of the identifiable intangible assets were 9.5 percent and 10.0 percent for ION and GIA, respectively, and reflect their internal rates of return and uncertainty in the cash flow projections, which is reflective of market participant assumptions. The estimated fair value of ION customer contracts were determined using an income-based approach, which includes market participant expectations of the cash flows that an asset could generate over its remaining useful life, discounted back to present value using an appropriate rate of return. The fair value of the ION and GIA trademark intangible assets were determined utilizing the relief from royalty method, an income-based approach. Under this method, a royalty rate based on observed market royalties is applied to projected revenue supporting the trademarks and discounted to present value using an appropriate discount rate. The fair value of the non-compete intangibles acquired from GIA were determined by applying the differential cash flow method which compares the present value of cash flows with and without the non-compete agreements in place. The noncontrolling interests were recognized at their acquisition-date fair values of $151 million and $884 million for ION and GIA, respectively. For GIA, the fair value was determined based on the fair value of GIA's common units. The allocation of the fair value of assets acquired and liabilities assumed for the Specialty Networks acquisition was finalized during the nine months ended March 31, 2025, resulting in goodwill of $784 million. There were no significant adjustments to the allocation of the fair value of assets acquired and liabilities assumed for the Specialty Networks acquisition from those disclosed in our fiscal 2024 Form 10-K."]

{"sheet":"Divestitures","index":9,"n_rows":4,"n_cols":2,"rows_kept":4,"merged":[[0,0,1,0]]}
["Divestitures","9 Months Ended"]
[null,"Mar. 31, 2025"]
["Discontinued Operations and Disposal Groups [Abstract]"," "]
["Disposal Groups, Including Discontinued Operations, Disclosure","3. Divestitures On June 5, 2023 we signed a definitive agreement to contribute the Outcomes TM business to TDS, a portfolio company of BlackRock Long Term Private Capital and GTCR, in exchange for a 16 percent equity interest in the combined entity. The transaction closed on July 10, 2023 and we recognized a pre-tax gain of $53 million during the three months ended September 30, 2023, which was included in impairments and (gain)/loss on disposal of assets We determined that the divestiture of the Outcomes TM business did not meet the criteria to be classified as discontinued operations. The Outcomes TM business operated within our former Pharmaceutical segment and its results before the divestiture are reflected within the Pharma segment."]

{"sheet":"Restructuring and Employee Seve","index":10,"n_rows":4,"n_cols":2,"rows_kept":4,"merged":[[0,0,1,0]]}
["Restructuring and Employee Severance","9 Months Ended"]
[null,"Mar. 31, 2025"]
["Restructuring Charges [Abstract]"," "]
["Restructuring and Employee Severance","4. Restructuring and Employee Severance The following tables summarize restructuring and employee severance costs: Three Months Ended March 31, (in millions) 2025 2024 Employee-related $ 22 $ 36 Facility exit and other 6 17 Total restructuring and employee severance $ 28 $ 53 Nine Months Ended March 31, (in millions) 2025 2024 Employee-related $ 41 $ 51 Facility exit and other 20 55 Total restructuring and employee severance $ 61 $ 106 Employee-related costs primarily consist of termination benefits provided to employees who have been involuntarily terminated, duplicate payroll costs, and retention bonuses incurred during transition periods. Facility exit and other costs primarily consist of project consulting fees, accelerated depreciation, professional project management, and costs associated with vacant facilities. Restructuring and employee severance costs during the three and nine months ended March 31, 2025 were primarily related to certain initiatives to rationalize our manufacturing operations and the implementation of certain enterprise-wide cost-savings measures. Restructuring and employee severance costs during the three and nine months ended March 31, 2024 were primarily due to certain projects resulting from the review of our strategy portfolio, capital-allocation framework, and operations, and certain initiatives to rationalize our manufacturing operations. The following table summarizes activity related to liabilities associated with restructuring and employee severance: (in millions) Employee- Facility Exit Total Balance at June 30, 2024 $ 92 $ 5 $ 97 Additions 32 — 32 Payments and other adjustments (42) (5) (47) Balance at March 31, 2025 $ 82 $ — $ 82 "]

{"sheet":"Goodwill and Other Intangible A","index":11,"n_rows":4,"n_cols":2,"rows_kept":4,"merged":[[0,0,1,0]]}
["Goodwill and Other Intangible Assets","9 Months Ended"]
[null,"Mar. 31, 2025"]
["Goodwill and Intangible Assets Disclosure [Abstract]"," "]
["Goodwill and Other Intangible Assets","5. Goodwill and Other Intangible Assets Goodwill The following table summarizes the changes in the carrying amount of goodwill by segment and in total: (in millions) Pharmaceutical and Specialty Solutions Global Medical Products and Distribution Other (1) Total Balance at June 30, 2024 $ 3,555 $ — $ 1,170 $ 4,725 Goodwill acquired, net of purchase price adjustments 4,181 — — 4,181 Balance at March 31, 2025 $ 7,736 $ — $ 1,170 $ 8,906 (1) Comprised of the remaining operating segments, Nuclear and Precision Health Solutions, at-Home Solutions and OptiFreight ® Logistics. The increase in the Pharma segment goodwill is due to the ION and GIA acquisitions that occurred during the nine months ended March 31, 2025. Goodwill recognized in connection with these acquisitions primarily represent the expected benefits from the expected growth from new customers, the assembled workforce of the acquired entities and synergies of integrating these businesses. Substantially all of the goodwill recorded is expected to be nondeductible for income tax purposes. During the nine months ended March 31, 2025, we did not identify any indicators of impairment within our reporting units. We performed interim quantitative goodwill impairment testing for GMPD at September 30, 2023 and March 31, 2024, which resulted in pre-tax goodwill impairment charges of $585 million and $90 million, respectively. GMPD goodwill was fully impaired during the third quarter of fiscal 2024. Other Intangible Assets The following tables summarize other intangible assets by class at: March 31, 2025 (in millions) Gross Accumulated Net Weighted- Average Remaining Amortization Period (Years) Indefinite-life intangibles: Trademarks and patents $ 13 $ — $ 13 N/A Total indefinite-life intangibles 13 — 13 N/A Definite-life intangibles: Customer relationships 3,640 2,574 1,066 11 Trademarks, trade names and patents 896 439 457 8 Customer contracts 235 4 231 16 Developed technology and other 1,027 711 316 7 Non-Competition Agreements 44 19 25 4 Total definite-life intangibles 5,842 3,747 2,095 10 Total other intangible assets $ 5,855 $ 3,747 $ 2,108 N/A June 30, 2024 (in millions) Gross Accumulated Net Indefinite-life intangibles: Trademarks and patents $ 12 $ — $ 12 Total indefinite-life intangibles 12 — 12 Definite-life intangibles: Customer relationships 3,628 2,431 1,197 Trademarks, trade names and patents 561 408 153 Developed technology and other 1,047 684 363 Total definite-life intangibles 5,236 3,523 1,713 Total other intangible assets $ 5,248 $ 3,523 $ 1,725 The increase in definite-life intangibles is due to the acquisitions of ION and GIA. See Note 2 , for additional information on the acquisitions of ION and GIA. Total amortization of intangible assets was $77 million and $64 million for the three months ended March 31, 2025 and 2024, respectively, and $214 million and $191 million for the nine months ended March 31, 2025 and 2024, respectively. Estimated annual amortization of intangible assets for the remainder of fiscal 2025 through 2029 is as follows: $82 million, $308 million, $285 million, $256 million and $249 million."]

{"sheet":"Long-Term Obligations and Other","index":12,"n_rows":4,"n_cols":2,"rows_kept":4,"merged":[[0,0,1,0]]}
["Long-Term Obligations and Other Short-Term Borrowings","9 Months Ended"]
[null,"Mar. 31, 2025"]
["Debt Disclosure [Abstract]"," "]
["Long-Term Obligations and Other Short-Term Borrowings","6. Long-Term Obligations and Other Short-Term Borrowings The following table summarizes long-term obligations and other short-term borrowings at: (in millions) (1) March 31, 2025 June 30, 2024 3.5% Notes due 2024 $ — $ 401 3.75% Notes due 2025 503 507 4.7% Notes due 2026 497 — 3.41% Notes due 2027 1,205 1,191 5.125% Notes due 2029 645 644 5.0% Notes due 2029 744 — 5.45% Notes due 2034 499 491 5.35% Notes due 2034 989 — 4.6% Notes due 2043 322 308 4.5% Notes due 2044 335 330 4.9% Notes due 2045 435 423 4.368% Notes due 2047 565 563 5.75% Notes due 2054 641 — 7.0% Debentures due 2026 124 124 Other Obligations 175 110 Total 7,679 5,092 Less: current portion of long-term obligations and other short-term borrowings 543 434 Long-term obligations, less current portion $ 7,136 $ 4,658 (1) Maturities are presented on a calendar year basis. Maturities of existing long-term obligations and other short-term borrowings for the remainder of fiscal 2025 through fiscal 2029 and thereafter are as follows: $12 million, $548 million, $1.9 billion, $27 million, $663 million and $4.6 billion. Long-Term Debt We had total long-term obligations, including the current portion and other short-term borrowings, of $7.7 billion and $5.1 billion at March 31, 2025 and June 30, 2024, respectively. All the notes represent unsecured obligations of Cardinal Health, Inc. and rank equally in right of payment with all of our existing and future unsecured and unsubordinated indebtedness. Interest is paid pursuant to the terms of the obligations. These notes are effectively subordinated to the liabilities of our subsidiaries, including trade payables of $32.8 billion and $31.8 billion at March 31, 2025 and June 30, 2024, respectively. In November 2024, we issued additional debt, with the aggregate principal amount of $2.9 billion, to fund a portion of the consideration payable in connection with the GIA and ADSG acquisitions and for general purposes. The notes issued are $500 million aggregate principal amount of 4.7% Notes that mature on November 15, 2026, $750 million aggregate principal amount of 5.0% Notes that mature on November 15, 2029, $1.0 billion aggregate principal amount of 5.35% Notes that mature on November 15, 2034, and $650 million aggregate principal amount of 5.75% Notes that mature on November 15, 2054. The proceeds of the notes issued, net of discounts, premiums, and debt issuance costs, were $2.9 billion. During the three months ended December 31, 2024, we repaid the full principal of $400 million of the 3.5% Notes due 2024 at maturity with proceeds from the debt issuance in fiscal 2024, $200 million of which were invested in short-term time deposits and classified as prepaid expenses and other in our condensed consolidated balance sheets at June 30, 2024. As of March 31, 2025, all short-term time deposits related to the debt issuance in fiscal 2024 have matured. If we undergo a change of control, as defined in the notes, and if the notes receive specified ratings below investment grade by each of Standard & Poor's Ratings Services, Moody's Investors Services, and Fitch Ratings, any holder of the notes, excluding the debentures, can require with respect to the notes owned by such holder, or we can offer, to repurchase the notes at 101% of the principal amount plus accrued and unpaid interest. Other Financing Arrangements In addition to cash and equivalents and operating cash flow, other sources of liquidity include a $3.0 billion commercial paper program backed by a $2.0 billion revolving credit facility and a $1.0 billion 364-Day revolving credit facility that expires in October 2025. We also have a $1.0 billion committed receivables sales facility. At March 31, 2025, we had no amounts outstanding under our commercial paper program, revolving credit facilities or our committed receivables sales facility. On December 5, 2024, we entered into a term loan credit agreement that, among other things, provides commitments for a term loan facility in an aggregate amount of up to $1.0 billion. No amounts were borrowed from this agreement as of March 31, 2025. However, on April 1, 2025, we closed on our acquisition of ADSG and borrowed $800 million under this term loan facility. The loan provided under this term loan credit agreement will mature three years from the date of borrowing and allows for prepayment, which may be accelerated pursuant to certain conditions specified in the credit agreement. Interest rates on borrowings will be based on prevailing interest rates, benchmarked based on Term SOFR and subject to our credit ratings. In November 2024, we also obtained a commitment letter from a financial institution for a $2.9 billion unsecured bridge term loan facility that could have been used to complete the acquisition of GIA. We incurred fees related to the facility, which are included in interest expense, net. The unsecured bridge term loan facility was never entered into and we terminated the commitment letter on November 22, 2024."]

{"sheet":"Commitments, Contingent Liabili","index":13,"n_rows":4,"n_cols":2,"rows_kept":4,"merged":[[0,0,1,0]]}
["Commitments, Contingent Liabilities and Litigation","9 Months Ended"]
[null,"Mar. 31, 2025"]
["Commitments and Contingencies Disclosure [Abstract]"," "]
["Commitments, Contingent Liabilities and Litigation",{"$cut":{"chars":17338,"head":"7. Commitments, Contingent Liabilities and Litigation Commitments Generic Sourcing Venture with CVS Health In July 2014, we established Red Oak Sourcing, LLC (\"Red Oak Sourcing\"), a U.S.-based generic pharmaceutical sourcing venture with CVS Health for an initial term of 10 years. Red Oak Sourcing negotiates generic pharmaceutical supply contracts on behalf of its participants. In August 2021, we amended our agreement to extend the term through June 2029. We are required to make quarterly payments to CVS Health for the term of the arrangement. Contingencies New York Opioid Stewardship Act In April 2018, the State of New York passed a budget which included the Opioid Stewardship Act (the \"OSA\"). The OSA created an aggregate $100 million annual assessment on all manufacturers and distributors that was assessed based on each manufacturer or distributor's share of the total morphine milligram equivalents sold or distributed in New York during the applicable calendar year, beginning in 2017. Subsequently, New York passed a new opioid excise tax and limited the OSA to two years (2017 and 2018). We accrue contingencies if it is probable that a liability has been incurred and the amount can be estimated. Since fiscal 2021, we have made certain payments to New York State for our portion of the assessment in 2017 and 2018. However, we, and other distributors, challenged the OSA as unconstitutional. In May 2024, the New York Appellate Division held that the 2017 assessment was unconstitutionally retroactive, directing a refund of assessments paid for calendar year 2017, but upheld the 2018 assessment. Both parties have appealed the decision of the New York Appellate Division to the New York Court of Appeals, the state's highest court, which remanded the case for calculation of interest. The parties subsequently agreed on terms of a potential settlement ending the litigation which could result in a refund of the portion we paid for calendar year 2017. We have not recorded a receivable for this recovery as the settlement remains subject to final approvals. The refund will be recognized upon receipt of the settlement. Legal Proceedings We become involved from time to time in disputes, litigation and regulatory matters. From time to time, we determine that products we distribute, source, manufacture or market do not meet our specifications, regulatory requirements, or published standards. When we or a regulatory agency identify a potential quality or regulatory issue, we investigate and take appropriate corrective action. Such actions have led to product recalls, costs to repair or replace affected products, temporary interruptions in product sales, restrictions on importation, product liability claims and lawsuits and can lead to action by regulators. Even absent an identified regulatory or quality issue or product recall, we can become subject to product liability claims and lawsuits. From time to time, we become aware through employees, internal audits or other parties of possible compliance matters, such as complaints or concerns relating to accounting, internal accounting controls, financial reporting, auditing, or other ethical matters or relating to compliance with laws such as healthcare fraud and abuse, anti-corruption or anti-bribery laws. When we become aware of such possible compliance matters, we investigate internally and take appropriate corrective action. In addition, from time to time, we receive subpoenas or requests for information from various federal or state agencies relating to our business or to the business of a customer, supplier or other industry participants. Internal investigations, subpoenas or requests for information could directly or indirectly lead to the assertion of claims or the commencement of legal proceedings against us or result in sanctions. We have been named from time to time in qui tam actions initiated by private third parties. In such actions, the private parties purport to act on behalf of federal or state governments, allege that false claims have been submitted for payment by the govern"}}]

{"sheet":"Income Taxes","index":14,"n_rows":4,"n_cols":2,"rows_kept":4,"merged":[[0,0,1,0]]}
["Income Taxes","9 Months Ended"]
[null,"Mar. 31, 2025"]
["Income Tax Disclosure [Abstract]"," "]
["Income Taxes","8. Income Taxes Fluctuations in our provision for income taxes as a percentage of pre-tax earnings (“effective tax rate”) are due to changes in international and U.S. state effective tax rates resulting from our business mix and discrete items. Effective Tax Rate During the three and nine months ended March 31, 2025, the effective tax rate was 23.6 percent and 22.8 percent, respectively. During the three and nine months ended March 31, 2024, the effective tax rate was 23.3 percent and 23.4 percent, respectively, and reflects the impact of the tax effect of the goodwill impairment charges recognized during the nine months ended March 31, 2024. Tax Effects of Goodwill Impairment Charges During the nine months ended March 31, 2024, we recognized pre-tax goodwill impairment charges of $675 million. The net tax benefit related to these charges was $56 million for fiscal 2024. Unless an item is considered discrete because it is unusual or infrequent, the tax impact of the item is included in our estimated annual effective tax rate. When items are recognized through our estimated annual effective tax rate, we apply our estimated annual effective tax rate to the earnings before income taxes for the year-to-date period to compute our impact from income taxes for the current quarter and year-to-date period. The tax impacts of discrete items are recognized in their entirety in the period in which they occur. The tax effect of the goodwill impairment charges during the nine months ended March 31, 2024 was included in our estimated annual effective tax rate because it was not considered unusual or infrequent, given that we recorded goodwill impairments in prior fiscal years. The impact of the non-deductible goodwill increased the estimated annual effective tax rate for fiscal 2024. Applying the higher tax rate to the pre-tax income for the nine months ended March 31, 2024 resulted in recognizing an incremental interim tax benefit of approximately $36 million, which impacted the provision for income taxes in the condensed consolidated statements of earnings during the nine months ended March 31, 2024 and prepaid expenses and other assets in the condensed consolidated balance sheet at March 31, 2024. The incremental interim tax benefit reversed in the remainder of fiscal 2024. Unrecognized Tax Benefits We had $890 million and $981 million of unrecognized tax benefits, at March 31, 2025 and June 30, 2024, respectively. The March 31, 2025 and June 30, 2024 balances include $865 million and $882 million of unrecognized tax benefits, respectively, that if recognized, would have an impact on the effective tax rate. At March 31, 2025 and June 30, 2024, we had $64 million and $65 million, respectively, accrued for the payment of interest and penalties related to unrecognized tax benefits, which we recognize in the benefit from income taxes in the condensed consolidated statements of earnings. These balances are gross amounts before any tax benefits and are included in deferred income taxes and other liabilities in the condensed consolidated balance sheets. It is reasonably possible that there could be a change in the amount of unrecognized tax benefits within the next 12 months due to activities of the U.S. Internal Revenue Service (\"IRS\") or other taxing authorities, possible settlement of IRS and other audit issues, reassessment of existing unrecognized tax benefits or the expiration of statutes of limitations. We estimate there will be no material change to unrecognized tax benefits within the next 12 months. Other Tax Matters We file income tax returns in the U.S. federal jurisdiction, various U.S. state jurisdictions, and various foreign jurisdictions. With few exceptions, we are subject to audit by taxing authorities for fiscal years 2015 through the current fiscal year."]

{"sheet":"Fair Value Measurements","index":15,"n_rows":4,"n_cols":2,"rows_kept":4,"merged":[[0,0,1,0]]}
["Fair Value Measurements","9 Months Ended"]
[null,"Mar. 31, 2025"]
["Fair Value Disclosures [Abstract]"," "]
["Fair Value Disclosures","9. Fair Value Measurements Assets and Liabilities Measured on a Recurring Basis The following tables present the fair values for assets and (liabilities) measured on a recurring basis at: March 31, 2025 (in millions) Level 1 Level 2 Level 3 Total Assets: Cash equivalents $ 949 $ — $ — $ 949 Other investments (1) 99 — — 99 Liabilities: Forward contracts (2) — (43) — (43) June 30, 2024 (in millions) Level 1 Level 2 Level 3 Total Assets: Cash equivalents $ 1,442 $ — $ — $ 1,442 Other investments (1) 108 — — 108 Liabilities: Forward contracts (2) — (87) — (87) (1) The other investments balance includes investments in mutual funds, which offset fluctuations in deferred compensation liabilities. These mutual funds invest in the equity securities of companies with both large and small market capitalization and high quality fixed income debt securities. The fair value of these investments is determined using quoted market prices. (2) The fair value of interest rate swaps, foreign currency contracts, and net investment hedges is determined based on the present value of expected future cash flows considering the risks involved, including non-performance risk, and using discount rates appropriate for the respective maturities. Observable Level 2 inputs are used to determine the present value of expected future cash flows. The fair value of these derivative contracts, which are subject to master netting arrangements under certain circumstances, is presented on a gross basis in prepaid expenses and other, other assets, other accrued liabilities, and deferred income taxes and other liabilities within the condensed consolidated balance sheets."]

{"sheet":"Financial Instruments","index":16,"n_rows":4,"n_cols":2,"rows_kept":4,"merged":[[0,0,1,0]]}
["Financial Instruments","9 Months Ended"]
[null,"Mar. 31, 2025"]
["Derivative Instruments and Hedging Activities Disclosure [Abstract]"," "]
["Financial Instruments","10. Financial Instruments We utilize derivative financial instruments to manage exposure to certain risks related to our ongoing operations. The primary risks managed through the use of derivative instruments include interest rate risk, currency exchange risk and commodity price risk. We do not use derivative instruments for trading or speculative purposes. While the majority of our derivative instruments are designated as hedging instruments, we also enter into derivative instruments that are designed to hedge a risk but are not designated as hedging instruments. These derivative instruments are adjusted to current fair value through earnings at the end of each period. We are exposed to counterparty credit risk on all of our derivative instruments. Accordingly, we have established and maintain strict counterparty credit guidelines and only enter into derivative instruments with major financial institutions that are rated investment grade or better. We do not have significant exposure to any one counterparty and we believe the risk of loss is remote. Additionally, we do not require collateral under these agreements. Interest Rate Risk Management We are exposed to the impact of interest rate changes. Our objective is to manage the impact of interest rate changes on cash flows and the market value of our borrowings. We utilize a mix of debt maturities on our fixed-rate debt to manage changes in interest rates. In addition, we enter into interest rate swaps to further manage our exposure to interest rate variations related to our borrowings and to lower our overall borrowing costs. Currency Exchange Risk Management We conduct business in several major international currencies and are subject to risks associated with changing foreign exchange rates. Our objective is to reduce earnings and cash flow volatility associated with foreign exchange rate changes to allow management to focus its attention on business operations. Accordingly, we enter into various contracts that change in value as foreign exchange rates change to protect the value of existing foreign currency assets and liabilities, commitments, and anticipated foreign currency revenue and expenses. Commodity Price Risk Management We are exposed to changes in the price of certain commodities. Our objective is to reduce earnings and cash flow volatility associated with forecasted purchases of these commodities to allow management to focus its attention on business operations. Accordingly, we enter into derivative contracts when possible to manage the price risk associated with certain forecasted purchases. Fair Value Hedges We enter into pay-floating interest rate swaps to hedge the changes in the fair value of fixed-rate debt resulting from fluctuations in interest rates. These contracts are designated and qualify as fair value hedges. Accordingly, the gain or loss recorded on the pay-floating interest rate swaps is directly offset by the change in fair value of the underlying debt. Both the derivative instrument and the underlying debt are adjusted to market value at the end of each period with any resulting gain or loss recorded in interest expense, net in the condensed consolidated statements of earnings. For the three and nine months ended March 31, 2025 and 2024, there were no gains or losses recorded to interest expense as changes in the market value of our derivative instruments offset changes in the market value of the underlying debt. During the nine months ended March 31, 2024, we entered into pay-floating interest rate swaps with total notional amounts of $500 million. These swaps have been designated as fair value hedges of our fixed rate debt and are included in deferred income taxes and other liabilities in our condensed consolidated balance sheets. Cash Flow Hedges We enter into derivative instruments to hedge our exposure to changes in cash flows attributable to interest rate, foreign currency and commodity price fluctuations associated with certain forecasted transactions. These derivative instruments are designated and qualify as cash flow hedges. Accordingly, the gain or loss on the derivative instrument is reported as a component of accumulated other comprehensive loss and reclassified into earnings in the same line item associated with the forecasted transaction and in the same period during which the hedged transaction affects earnings. Pre-tax gains recognized in other comprehensive income/(loss) were $4 million and $1 million for the three months ended March 31, 2025 and 2024, respectively, and $5 million and $2 million for the nine months ended March 31, 2025 and 2024, respectively. Gains and losses recognized in accumulated other comprehensive loss and reclassified into earnings were an immaterial loss and a $2 million gain for the three months ended March 31, 2025 and 2024, respectively, and a $3 million loss and a $4 million gain for the nine months ended March 31, 2025 and 2024, respectively. Losses currently included within accumulated other comprehensive loss associated with our cash flow hedges to be reclassified into net earnings within the next 12 months are $1 million. Net Investment Hedges We hedge the foreign currency risk associated with certain net investment positions in foreign subsidiaries. To accomplish this, we enter into cross-currency swaps that are designated as hedges of net investments. In February 2025, we entered into €100 million ($105 million) cross-currency swaps maturing in February 2027. In February 2025, we terminated the €100 million ($107 million) cross-currency swaps entered into in March 2023 and received net settlement in cash of $2 million, recorded in proceeds from net investment hedge terminations in our condensed consolidated statements of cash flows. In September 2023, we entered into ¥18 billion ($120 million) cross-currency swaps maturing in September 2025 and ¥18 billion ($120 million) cross-currency swaps maturing in June 2027. In June 2024, we terminated the ¥18 billion ($120 million) cross-currency swaps with a maturity date of June 2027. In September 2023, we terminated the ¥38 billion ($300 million) cross-currency swaps entered into in January 2023 and received net settlement in cash of $28 million, recorded in proceeds from net investment hedge terminations in our condensed consolidated statements of cash flows. Cross-currency swaps designated as net investment hedges are marked to market using the current spot exchange rate as of the end of the period, with gains and losses included in the foreign currency translation component of accumulated other comprehensive loss until the sale or substantial liquidation of the underlying net investments. To the extent the cross-currency swaps designated as net investment hedges are not highly effective, changes in carrying value attributable to the change in spot rates are recorded in earnings. Pre-tax gains and losses from net investment hedges recorded in the foreign currency translation component of accumulated other comprehensive income/(loss) were a $16 million loss and a $19 million gain during the three months ended March 31, 2025 and 2024, respectively, and a $11 million loss and a $14 million gain during the nine months ended March 31, 2025 and 2024, respectively. Gains recognized in interest expense, net in the condensed consolidated statements of earnings for the portion of the net investment hedges excluded from the assessment of hedge effectiveness were $3 million during both the three months ended March 31, 2025 and 2024, and $7 million and $10 million during the nine months ended March 31, 2025 and 2024, respectively. Economic (Non-Designated) Hedges We enter into foreign currency contracts to manage our foreign exchange exposure related to sales transactions, intercompany financing transactions and other balance sheet items subject to revaluation that do not meet the requirements for hedge accounting treatment. Accordingly, these derivative instruments are adjusted to current market value at the end of each period through earnings. The gain or loss recorded on these instruments is substantially offset by the remeasurement adjustment on the foreign currency denominated asset or liability. The settlement of the derivative instrument and the remeasurement adjustment on the foreign currency denominated asset or liability are both recorded in other (income)/expense, net. We recorded a $3 million loss and an immaterial gain during the three months ended March 31, 2025 and 2024, respectively, and a $1 million gain and an immaterial loss during the nine months ended March 31, 2025 and 2024, respectively. The principal currencies managed through foreign currency contracts are euro, Canadian dollar, Chinese renminbi, Brazilian real and Indian rupee. Fair Value of Financial Instruments The carrying amounts of cash and equivalents, trade receivables, accounts payable and other accrued liabilities at March 31, 2025 and June 30, 2024 approximate fair value due to their short-term maturities. The following table summarizes the estimated fair value of our long-term obligations and other short-term borrowings compared to the respective carrying amounts at: (in millions) March 31, 2025 June 30, 2024 Estimated fair value $ 7,511 $ 4,891 Carrying amount 7,679 5,092 The fair value of our long-term obligations and other short-term borrowings is estimated based on either the quoted market prices for the same or similar issues or other inputs derived from available market information, which represents a Level 2 measurement."]

{"sheet":"Shareholders' Equity","index":17,"n_rows":4,"n_cols":2,"rows_kept":4,"merged":[[0,0,1,0]]}
["Shareholders' Equity","9 Months Ended"]
[null,"Mar. 31, 2025"]
["Equity [Abstract]"," "]
["Shareholders' Equity","11. Shareholders' Deficit We repurchased $750 million of our common shares, in the aggregate, through share repurchase programs during both the nine months ended March 31, 2025 and 2024. We funded the repurchases with available cash. The common shares repurchased are held in treasury to be used for general corporate purposes. During the three months ended March 31, 2025, we entered into an accelerated share repurchase (\"ASR\") program to repurchase common shares for an aggregate purchase price of $375 million. We received an initial delivery of 2.4 million common shares using a reference price of $125.33. The program concluded on March 11, 2025 at a volume weighted average price per common share of $125.87 resulting in a final delivery of 0.6 million common shares. During the nine months ended March 31, 2025, we paid $15 million for excise taxes related to the completion of prior ASR programs. During the three months ended December 31, 2024, we retired 56 million of common stock shares without par value. During the three months ended September 30, 2024, we entered into an ASR program to repurchase common shares for an aggregate purchase price of $375 million. We received an initial delivery of 2.7 million common shares using a reference price of $109.65. The program concluded on October 30, 2024 at a volume weighted average price per common share of $110.10 resulting in a final delivery of 0.7 million common shares. During the three months ended December 31, 2023, we entered into an ASR program to repurchase common shares for an aggregate purchase price of $250 million. We received an initial delivery of 2.0 million common shares using a reference price of $101.66. The program concluded on December 13, 2023 at a volume weighted average price per common share of $103.67 resulting in a final delivery of 0.4 million common shares. During the three months ended September 30, 2023, we entered into an ASR program to repurchase common shares for an aggregate purchase price of $500 million. We received an initial delivery of 4.4 million common shares using a reference price of $90.57. The program concluded on October 31, 2023 at a volume weighted average price per common share of $88.22 resulting in a final delivery of 1.3 million common shares. Accumulated Other Comprehensive Loss The following tables summarize the changes in the balance of accumulated other comprehensive loss by component and in total: (in millions) Foreign Unrealized Accumulated Other Balance at June 30, 2024 $ (138) $ (29) $ (167) Other comprehensive income/(loss), before reclassifications (13) 3 (10) Amounts reclassified to earnings — 1 1 Total other comprehensive loss attributable to Cardinal Health, Inc., net of tax benefit of $2 million (13) 4 (9) Balance at March 31, 2025 $ (151) $ (25) $ (176) (in millions) Foreign Unrealized Accumulated Other Balance at June 30, 2023 $ (137) $ (14) $ (151) Other comprehensive income/(loss), before reclassifications (4) 1 (3) Amounts reclassified to earnings — (6) (6) Total other comprehensive loss attributable to Cardinal Health, Inc., net of tax expense of $4 million (4) (5) (9) Balance at March 31, 2024 $ (141) $ (19) $ (160)"]

{"sheet":"Earnings Per Share Attributable","index":18,"n_rows":4,"n_cols":2,"rows_kept":4,"merged":[[0,0,1,0]]}
["Earnings Per Share Attributable to Cardinal Health, Inc.","9 Months Ended"]
[null,"Mar. 31, 2025"]
["Earnings Per Share [Abstract]"," "]
["Earnings Per Share [Text Block]","12. Earnings Per Share Attributable to Cardinal Health, Inc. The following tables reconcile the number of common shares used to compute basic and diluted earnings per share attributable to Cardinal Health, Inc. (\"EPS\"): Three Months Ended March 31, (in millions) 2025 2024 Weighted-average common shares–basic 240 243 Effect of dilutive securities: Employee stock options, restricted share units and performance share units 1 2 Weighted-average common shares–diluted 241 245 Nine Months Ended March 31, (in millions) 2025 2024 Weighted-average common shares–basic 242 245 Effect of dilutive securities: Employee stock options, restricted share units and performance share units 1 2 Weighted-average common shares–diluted 243 247 The potentially dilutive employee stock options, restricted share units, and performance share units that were antidilutive were immaterial for both the three and nine months ended March 31, 2025 and 2024."]

{"sheet":"Segment Information","index":19,"n_rows":4,"n_cols":2,"rows_kept":4,"merged":[[0,0,1,0]]}
["Segment Information","9 Months Ended"]
[null,"Mar. 31, 2025"]
["Segment Reporting [Abstract]"," "]
["Segment Information","13. Segment Information We operate under two reportable segments: Pharmaceutical and Specialty Solutions (\"Pharma\") segment and Global Medical Products and Distribution (\"GMPD\") segment. All remaining operating segments that are not significant enough to require separate reportable segment disclosures are included in Other, which is comprised of Nuclear and Precision Health Solutions, at-Home Solutions and OptiFreight ® . The factors for determining the reportable segments include the manner in which management evaluates performance for purposes of allocating resources and assessing performance combined with the nature of the individual business activities. Our Pharmaceutical and Specialty Solutions segment distributes branded and generic pharmaceutical, specialty pharmaceutical and over-the-counter healthcare and consumer products in the United States. This segment also provides services to pharmaceutical manufacturers and healthcare providers for specialty pharmaceutical products; provides pharmacy management services to hospitals and operates a limited number of pharmacies, including pharmacies in community health centers; repackages generic pharmaceuticals and over the counter healthcare products; and includes our managed services organization platforms. Our GMPD segment manufactures, sources and distributes Cardinal Health branded medical, surgical and laboratory products, which are sold in the United States, Canada, Europe, Asia and other markets. In addition to distributing Cardinal Health branded products, this segment also distributes a broad range of medical, surgical, and laboratory products known as national brand products to hospitals, ambulatory surgery centers, clinical laboratories and other healthcare providers in the United States and Canada. The remaining three operating segments included in Other are Nuclear and Precision Health Solutions, at-Home Solutions, and OptiFreight ® Logistics. These operating segments respectively operate nuclear pharmacies and radiopharmaceutical manufacturing facilities, distribute medical products to patients' homes in the United States, and provide supply chain services and solutions to our customers. Revenue The following tables present revenue for the two reportable segments and disaggregated revenue within the remaining operating segments, included in Other, and Corporate: Three Months Ended March 31, (in millions) 2025 2024 Pharmaceutical and Specialty Solutions $ 50,433 $ 50,622 Global Medical Products and Distribution 3,160 3,113 Nuclear and Precision Health Solutions 403 352 at-Home Solutions 817 730 OptiFreight ® Logistics 84 72 Other 1,304 1,154 Total segment revenue 54,897 54,889 Corporate (1) (19) (21) Total revenue $ 54,878 $ 54,868 Nine Months Ended March 31, (in millions) 2025 2024 Pharmaceutical and Specialty Solutions $ 149,272 $ 154,412 Global Medical Products and Distribution 9,437 9,272 Nuclear and Precision Health Solutions 1,148 1,006 at-Home Solutions 2,391 2,136 OptiFreight ® Logistics 234 198 Other 3,773 3,340 Total segment revenue 162,482 167,024 Corporate (1) (63) (64) Total revenue $ 162,419 $ 166,960 (1) Corporate revenue consists of the elimination of inter-segment revenue and other revenue not allocated to the segments. The following tables present revenue by geographic area: Three Months Ended March 31, (in millions) 2025 2024 United States $ 54,498 $ 54,464 International 399 425 Total segment revenue 54,897 54,889 Corporate (1) (19) (21) Total revenue $ 54,878 $ 54,868 Nine Months Ended March 31, (in millions) 2025 2024 United States $ 161,247 $ 165,783 International 1,235 1,241 Total segment revenue 162,482 167,024 Corporate (1) (63) (64) Total revenue $ 162,419 $ 166,960 (1) Corporate revenue consists of the elimination of inter-segment revenue and other revenue not allocated to the segments. Segment Profit We evaluate segment performance based on segment profit, among other measures. Segment profit is segment revenue, less segment cost of products sold, less segment distribution, selling, general and administrative (\"SG&A\") expenses. Segment SG&A expenses include share-based compensation expense as well as allocated corporate technology and shared function expenses, including corporate management, corporate finance, financial and customer care shared services, human resources, information technology and legal and compliance, including certain litigation defense costs. Corporate expenses are allocated to the segments based on headcount, level of benefit provided and other ratable allocation methodologies. The results attributable to noncontrolling interests are recorded within segment profit. We do not allocate the following items to our segments: • last-in first-out, or (\"LIFO\"), inventory charges/(credits); • state opioid assessment related to prior fiscal years; • shareholder cooperation agreement costs; • restructuring and employee severance; • amortization and other acquisition-related costs; • acquisition-related cash and share-based compensation costs; • impairments and (gain)/loss on disposal of assets, net; we recognized a pre-tax goodwill impairment charge of $90 million during the three months ended March 31, 2024 and $675 million during the nine months ended March 31, 2024; • litigation (recoveries)/charges, net; • other (income)/expense, net; • interest expense, net; • loss on early extinguishment of debt; or • provision for/(benefit from) income taxes In addition, certain investment spending, certain portions of enterprise-wide incentive compensation and other spending are not allocated to the segments. Investment spending generally includes the first-year spend for certain projects that require incremental investments in the form of additional operating expenses. Because approval for these projects is dependent on executive management, we retain these expenses at Corporate. Investment spending within Corporate was $15 million and $17 million for the three months ended March 31, 2025 and 2024, respectively, and $42 million and $37 million for the nine months ended March 31, 2025 and 2024, respectively. The following tables present segment profit for the two reportable segments and the remaining operating segments, included in Other, and Corporate: Three Months Ended March 31, (in millions) 2025 2024 Pharmaceutical and Specialty Solutions $ 662 $ 582 Global Medical Products and Distribution 39 22 Other (1) 134 110 Total segment profit 835 714 Corporate (105) (345) Total operating earnings $ 730 $ 369 Nine Months Ended March 31, (in millions) 2025 2024 Pharmaceutical and Specialty Solutions $ 1,723 $ 1,533 Global Medical Products and Distribution 65 45 Other (1) 356 312 Total segment profit 2,144 1,890 Corporate (297) (1,048) Total operating earnings $ 1,847 $ 842 (1) Comprised of the remaining operating segments, Nuclear and Precision Health Solutions, at-Home Solutions, and OptiFreight ® Logistics. Segment Assets The following table presents total assets for the two reportable segments and the remaining operating segments, included in Other, and Corporate: (in millions) March 31, June 30, Pharmaceutical and Specialty Solutions $ 35,734 $ 29,149 Global Medical Products and Distribution 7,201 7,047 Other (1) 2,726 2,606 Corporate 4,210 6,319 Total assets $ 49,871 $ 45,121 "]

{"sheet":"Share-Based Compensation","index":20,"n_rows":4,"n_cols":2,"rows_kept":4,"merged":[[0,0,1,0]]}
["Share-Based Compensation","9 Months Ended"]
[null,"Mar. 31, 2025"]
["Share-Based Payment Arrangement [Abstract]"," "]
["Share-Based Compensation","14. Share-Based Compensation We maintain Cardinal Health Inc. corporate stock incentive plans (collectively, the “Plans”) for the benefit of certain of our officers, directors and employees. As of March 31, 2025, we have 15 million shares authorized for issuance under the Plans. Upon vesting these units convert to common shares without restrictions or future service requirements. The following tables provide total share-based compensation expense by type of award: Three Months Ended March 31, (in millions) 2025 2024 Restricted share unit expense $ 18 $ 20 Performance share unit expense 14 11 Total share-based compensation $ 32 $ 31 Nine Months Ended March 31, (in millions) 2025 2024 Restricted share unit expense $ 54 $ 58 Performance share unit expense 37 30 Total share-based compensation $ 91 $ 88 The total tax benefit related to share-based compensation was $4 million for both the three months ended March 31, 2025 and 2024, and $11 million and $12 million for the nine months ended March 31, 2025 and 2024, respectively. Share-based compensation expense is included in selling, general and administrative expenses in the condensed consolidated statements of earnings. Our consolidated statements of cash flows present our share-based compensation expense as a reconciling adjustment between net income and net cash provided by operating activities for all periods presented. Restricted Share Units Restricted share units granted under the Plans generally vest in equal annual installments over three years. Restricted share units accrue cash dividend equivalents that are payable upon vesting of the awards. The following table summarizes all transactions related to restricted share units under the Plans: (in millions, except per share amounts) Restricted Share Units Weighted-Average Nonvested at June 30, 2024 1.7 $ 70.98 Granted 0.7 108.20 Vested (0.9) 71.74 Canceled and forfeited (0.1) 93.05 Nonvested at March 31, 2025 1.4 $ 85.45 The total fair value of units vested during the three months ended March 31, 2025 and 2024 were $3 million and $4 million, respectively. The total fair value of units vested during the nine months ended March 31, 2025 and 2024, were $67 million and $66 million, respectively. At March 31, 2025, the total pre-tax compensation cost, net of estimated forfeitures, related to nonvested restricted share units not yet recognized was $79 million, which is expected to be recognized over a weighted-average period of two years. Performance Share Units Performance share units vest over a three-year performance period based on achievement of specific performance goals. Based on the extent to which the targets are achieved and our total shareholder return relative to the S&P 500 Health Care Index, vested shares may range from zero to 240 percent of the target award amount. Performance share units accrue cash dividend equivalents that are payable upon vesting of the awards. The following table summarizes all transactions related to performance share units under the Plans (based on target award amounts): (in millions, except per share amounts) Performance Weighted-Average Nonvested at June 30, 2024 1.3 $ 97.03 Granted 0.5 113.88 Vested (0.3) 108.79 Canceled and forfeited — — Nonvested at March 31, 2025 1.5 $ 99.53 No performance share units vested during the three months ended March 31, 2025 and 2024. The total fair value of units vested during the nine months ended March 31, 2025 and 2024, were $41 million and $24 million, respectively. At March 31, 2025, the total pre-tax compensation cost, net of estimated forfeitures, related to nonvested performance share units not yet recognized was $53 million, which is expected to be recognized over a weighted-average period of two years if performance goals are achieved. GIA Share-Based Compensation GIA, a majority-owned subsidiary of Cardinal Health, maintains standalone share-based compensation plans. The fair value was estimated using the implied enterprise value based on the purchase price paid for the 73 percent ownership interest. Share-based compensation expense associated with these awards was $17 million for the three and nine months ended March 31, 2025, of which $16 million is included in acquisition-related cash and share-based compensation costs and $1 million is included in selling, general and administrative expenses in the condensed consolidated statements of earnings In connection with the acquisition of physician practices, GIA issues common units in GIA (collectively the “Units”), to physicians. The Units contain forfeiture provisions ranging from 36 to 60 months. These forfeiture provisions provide that the physicians forfeit all or a portion of the Units should they leave GIA, except in certain limited situations, effectively requiring the physicians to stay employed with the physician practice managed by GIA in order to retain the Units. As such, the fair value of the nonvested Units at the date of issuance is treated as equity compensation and recognized over the required service period. The Units were initially recognized by Cardinal Health as noncontrolling interests on the acquisition date at the fair value of the acquired shares in the amount of $168 million. As the Units vest, an increase to the carrying amount of the noncontrolling interests is recorded to reflect the change in ownership interest in GIA. The following table summarizes the fair market value of GIA Units as of March 31, 2025: (in millions, except per share amounts) GIA Share Units Weighted-Average Nonvested at January 30, 2025 115 $ 1.46 Granted 16 1.46 Vested (12) 1.46 Canceled and forfeited — — Nonvested at March 31, 2025 119 $ 1.46 Vested at March 31, 2025 618 $ 1.46 The total fair value of units vested during the three and nine months ended March 31, 2025, was $17 million. At March 31, 2025, the total pre-tax compensation cost, net of estimated forfeitures, related to nonvested Units not yet recognized was $174 million, which is expected to be recognized over a weighted-average period of approximately three years."]

{"sheet":"Pay vs Performance Disclosure","index":21,"n_rows":4,"n_cols":5,"rows_kept":4,"merged":[[0,0,1,0],[0,1,0,2],[0,3,0,4]]}
["Pay vs Performance Disclosure - USD ($) $ in Millions","3 Months Ended",null,"9 Months Ended"]
[null,"Mar. 31, 2025","Mar. 31, 2024","Mar. 31, 2025","Mar. 31, 2024"]
["Pay vs Performance Disclosure"," "," "," "," "]
["Net Income (Loss) Attributable to Parent",{"v":506,"d":"$ 506"},{"v":261,"d":"$ 261"},{"v":1322,"d":"$ 1,322"},{"v":617,"d":"$ 617"}]

{"sheet":"Insider Trading Arrangements","index":22,"n_rows":7,"n_cols":2,"rows_kept":7,"merged":[[0,0,1,0]]}
["Insider Trading Arrangements","3 Months Ended"]
[null,"Mar. 31, 2025"]
["Trading Arrangements, by Individual"," "]
["Rule 10b5-1 Arrangement Adopted","false"]
["Non-Rule 10b5-1 Arrangement Adopted","false"]
["Rule 10b5-1 Arrangement Terminated","false"]
["Non-Rule 10b5-1 Arrangement Terminated","false"]

{"sheet":"Basis of Presentation and Sum_2","index":23,"n_rows":9,"n_cols":2,"rows_kept":9,"merged":[[0,0,1,0]]}
["Basis of Presentation and Summary of Significant Accounting Policies (Policies)","9 Months Ended"]
[null,"Mar. 31, 2025"]
["Accounting Policies [Abstract]"," "]
["Basis of Presentation","Basis of Presentation Our condensed consolidated financial statements include the accounts of all majority-owned or consolidated subsidiaries, and all significant intercompany transactions and amounts have been eliminated. The results of businesses acquired or disposed of are included in the condensed consolidated financial statements from the date of the acquisition or up to the date of disposal, respectively. We report our financial results in two reportable segments: Pharmaceutical and Specialty Solutions (\"Pharma\") segment and Global Medical Products and Distribution (\"GMPD\") segment. All remaining operating segments that are not significant enough to require separate reportable segment disclosures are included in Other, which is comprised of Nuclear and Precision Health Solutions, at-Home Solutions, and OptiFreight ® Logistics. References to \"we,\" \"our,\" and similar pronouns in this Quarterly Report on Form 10-Q for the quarter ended March 31, 2025 (this \"Form 10-Q\") are to Cardinal Health, Inc. and its majority-owned or consolidated subsidiaries unless the context requires otherwise. Our fiscal year ends on June 30. References to fiscal 2025 and 2024 in these condensed consolidated financial statements are to the fiscal years ending or ended June 30, 2025 and June 30, 2024, respectively. Our condensed consolidated financial statements have been prepared in accordance with the U.S. Securities and Exchange Commission (\"SEC\") instructions to Quarterly Reports on Form 10-Q and include the information and disclosures required by accounting principles generally accepted in the United States (\"GAAP\") for interim financial reporting. The preparation of financial statements in conformity with GAAP requires us to make estimates, judgments and assumptions that affect amounts reported in the condensed consolidated financial statements and accompanying notes. Actual amounts may differ from these estimated amounts. In our opinion, all adjustments necessary for a fair presentation of the condensed consolidated financial statements have been included. Except as disclosed elsewhere in this Form 10-Q, all such adjustments are of a normal and recurring nature. In addition, financial results presented for this fiscal 2025 interim period are not necessarily indicative of the results that may be expected for the full fiscal year ending June 30, 2025. These condensed consolidated financial statements are unaudited and, accordingly, should be read in conjunction with the audited consolidated financial statements and related notes contained in our Annual Report on Form 10-K for the fiscal year ended June 30, 2024 (our \"2024 Form 10-K\")."]
["Comparability of Prior Year Financial Data, Policy","Revision of Prior Period Consolidated Financial Statements As previously disclosed in the 2024 Form 10-K, we revised our prior period financial statements to correct for an accounting error related to the at-Home Solutions operating segment that was not material, individually or in the aggregate, to our previously issued Consolidated Financial Statements, as well as other unrelated immaterial errors. The appropriate revisions to our historical condensed consolidated financial statements and the notes thereto are reflected herein. See Note 1 and Note 16 to the \"Consolidated Financial Statements\" in the 2024 Form 10-K for additional information."]
["Major Customers","Major Customers On April 22, 2024, we announced that our pharmaceutical distribution contracts with OptumRx, which expired at the end of June 2024, would not be renewed. Sales to OptumRx generated 17 percent of our consolidated revenue in fiscal 2024."]
["Recent Financial Accounting Standards","Recently Issued Financial Accounting Standards and Disclosure Rules Not Yet Adopted We assess the adoption impacts of recently issued accounting standards by the Financial Accounting Standards Board (\"FASB\") on our condensed consolidated financial statements as well as material updates to previous assessments, if any, from our fiscal 2024 Form 10-K. Segment Reporting In November 2023, the FASB issued Accounting Standards Update (\"ASU\") 2023-07 Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which enhances reportable segment disclosure requirements, primarily through disclosures of significant segment expenses. This guidance will be effective for us in our fiscal 2025 Form 10-K and the guidance must be applied retrospectively to all prior periods presented. We have evaluated the impact of adoption of this guidance on our disclosures and this will be reflected in our fiscal 2025 Form 10-K. Income Tax Disclosure In December 2023, the FASB issued ASU 2023-09 Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which enhances income tax disclosures primarily related to the rate reconciliation and income taxes paid information. This guidance also includes certain other amendments to improve the effectiveness of income tax disclosures. This guidance will be effective for us in fiscal 2026 Form 10-K and should be applied on a prospective basis, with retrospective application permitted. We are currently evaluating the impact of adoption of this guidance on our disclosures. Disaggregation of Income Statement Expenses In November 2024, the FASB issued ASU 2024-03 Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40), which requires disaggregated disclosures of certain categories of expenses which are included in any relevant income statement expense caption on an annual and interim basis. Additionally, the guidance requires the disclosure of total selling expenses and, in annual reporting periods, an entity's definition of selling expenses. This guidance will be effective for us in fiscal 2028 Form 10-K and should be applied on a prospective basis, with retrospective application permitted. We are currently evaluating the impact of adoption of this guidance on our disclosures. Recently Adopted Financial Accounting Standards There were no new material accounting standards adopted during the nine months ended March 31, 2025."]
["Consolidation, Variable Interest Entity, Policy","Variable Interest Entities We evaluate our ownership, contractual, and other interests in entities to determine if they are a variable interest entity (“VIE”), if we have a variable interest in those entities, and the nature and extent of those interests. These evaluations may involve management judgment and the use of estimates and assumptions based on available historical information, among other factors. Based on our evaluations, if we determine we are the primary beneficiary of such VIEs, we consolidate such entities into our financial statements. Consolidated Variable Interest Entities We consolidate a VIE when we have the power to direct the activities that most significantly impact the VIE’s economic performance and the obligation to absorb losses or the right to receive benefits of the VIE and, as a result, are considered the primary beneficiary of the VIE. On January 1, 2020, GI Alliance (\"GIA\") entered into a management services arrangement with Texas Digestive Disease Consultants, PLLC (“TDDC”) that authorized GIA to perform certain management services in the manner that it deemed reasonably appropriate to meet the day-to-day business needs of TDDC. In exchange for the management services provided, GIA is entitled to receive an annual management fee equal to a percentage of TDDC’s net operating income. The agreement has a 15 year term with two successive 5 year terms set to renew automatically. Based on these determinations, we concluded that TDDC is a VIE and that GIA is the primary beneficiary."]
["Consolidation, Subsidiaries or Other Investments, Consolidated Entities, Policy","Noncontrolling Interests Noncontrolling interests represent the portion of net earnings, comprehensive income and net assets that is not attributable to Cardinal Health. Noncontrolling interests as of March 31, 2025 primarily represents third-party equity interests in GIA and ION. The net earnings attributable to noncontrolling interests in GIA contain certain call and put rights, however, the exercise of these options is fully within the control of Cardinal Health. and the associated noncontrolling interest has therefore been determined to be nonredeemable and classified within permanent equity. The fair value was estimated using the implied enterprise value based on the purchase price paid for the controlling interest. See Note 2 , for additional information on the acquisition of GIA."]

{"sheet":"Business Combinations, Asset Ac","index":24,"n_rows":4,"n_cols":2,"rows_kept":4,"merged":[[0,0,1,0]]}
["Business Combinations, Asset Acquisitions, and Joint Venture Formation (Tables)","9 Months Ended"]
[null,"Mar. 31, 2025"]
["Business Combination, Asset Acquisition, Transaction between Entities under Common Control, and Joint Venture Formation [Abstract]"," "]
["Business Combination, Recognized Asset Acquired and Liability Assumed","The following table summarizes the estimated fair values of the assets acquired and liabilities assumed as of the acquisition date for ION and GIA: (in millions) ION GIA Identifiable intangible assets: Customer contracts (1) $ 235 $ — Trademarks (2) 78 256 Non-competition agreements (3) — 24 Total identifiable intangible assets acquired 313 280 Identifiable net assets/(liabilities): Cash and equivalents 8 76 Trade receivables, net 59 195 Inventories 4 21 Prepaid expenses and other 5 13 Property and equipment, net 32 67 Other assets 45 287 Accounts payable (10) (89) Current portion of long-term obligations and other short-term borrowings (3) (1) Other accrued liabilities (38) (171) Long-term obligations, less current portion (14) (15) Deferred income taxes and other liabilities (88) (209) Total identifiable net assets/(liabilities) acquired 313 454 Noncontrolling interest (151) (884) Goodwill 908 3,241 Total net assets acquired $ 1,070 $ 2,811 (1) The weighted-average useful life of customer contracts is 20 years. (2) The weighted-average useful life of trademarks is 10 years. (3) The weighted-average useful life of non-competition agreements is 4 years."]

{"sheet":"Restructuring and Employee Se_2","index":25,"n_rows":5,"n_cols":2,"rows_kept":5,"merged":[[0,0,1,0]]}
["Restructuring and Employee Severance (Tables)","9 Months Ended"]
[null,"Mar. 31, 2025"]
["Restructuring Charges [Abstract]"," "]
["Summary of Restructuring and Employee Severance","The following tables summarize restructuring and employee severance costs: Three Months Ended March 31, (in millions) 2025 2024 Employee-related $ 22 $ 36 Facility exit and other 6 17 Total restructuring and employee severance $ 28 $ 53 Nine Months Ended March 31, (in millions) 2025 2024 Employee-related $ 41 $ 51 Facility exit and other 20 55 Total restructuring and employee severance $ 61 $ 106 "]
["Schedule of Activity Related to Liabilities Associated with Restructuring and Employee Severance","The following table summarizes activity related to liabilities associated with restructuring and employee severance: (in millions) Employee- Facility Exit Total Balance at June 30, 2024 $ 92 $ 5 $ 97 Additions 32 — 32 Payments and other adjustments (42) (5) (47) Balance at March 31, 2025 $ 82 $ — $ 82 "]

{"sheet":"Goodwill and Other Intangible_2","index":26,"n_rows":5,"n_cols":2,"rows_kept":5,"merged":[[0,0,1,0]]}
["Goodwill and Other Intangible Assets (Tables)","9 Months Ended"]
[null,"Mar. 31, 2025"]
["Goodwill and Intangible Assets Disclosure [Abstract]"," "]
["Schedule of Goodwill by Reportable Segment","The following table summarizes the changes in the carrying amount of goodwill by segment and in total: (in millions) Pharmaceutical and Specialty Solutions Global Medical Products and Distribution Other (1) Total Balance at June 30, 2024 $ 3,555 $ — $ 1,170 $ 4,725 Goodwill acquired, net of purchase price adjustments 4,181 — — 4,181 Balance at March 31, 2025 $ 7,736 $ — $ 1,170 $ 8,906 (1) Comprised of the remaining operating segments, Nuclear and Precision Health Solutions, at-Home Solutions and OptiFreight ® Logistics. The increase in the Pharma segment goodwill is due to the ION and GIA acquisitions that occurred during the nine months ended March 31, 2025. Goodwill recognized in connection with these acquisitions primarily represent the expected benefits from the expected growth from new customers, the assembled workforce of the acquired entities and synergies of integrating these businesses. Substantially all of the goodwill recorded is expected to be nondeductible for income tax purposes. During the nine months ended March 31, 2025, we did not identify any indicators of impairment within our reporting units. We performed interim quantitative goodwill impairment testing for GMPD at September 30, 2023 and March 31, 2024, which resulted in pre-tax goodwill impairment charges of $585 million and $90 million, respectively. GMPD goodwill was fully impaired during the third quarter of fiscal 2024."]
["Schedule of Finite-Lived Intangible Assets","The following tables summarize other intangible assets by class at: March 31, 2025 (in millions) Gross Accumulated Net Weighted- Average Remaining Amortization Period (Years) Indefinite-life intangibles: Trademarks and patents $ 13 $ — $ 13 N/A Total indefinite-life intangibles 13 — 13 N/A Definite-life intangibles: Customer relationships 3,640 2,574 1,066 11 Trademarks, trade names and patents 896 439 457 8 Customer contracts 235 4 231 16 Developed technology and other 1,027 711 316 7 Non-Competition Agreements 44 19 25 4 Total definite-life intangibles 5,842 3,747 2,095 10 Total other intangible assets $ 5,855 $ 3,747 $ 2,108 N/A June 30, 2024 (in millions) Gross Accumulated Net Indefinite-life intangibles: Trademarks and patents $ 12 $ — $ 12 Total indefinite-life intangibles 12 — 12 Definite-life intangibles: Customer relationships 3,628 2,431 1,197 Trademarks, trade names and patents 561 408 153 Developed technology and other 1,047 684 363 Total definite-life intangibles 5,236 3,523 1,713 Total other intangible assets $ 5,248 $ 3,523 $ 1,725 "]

{"sheet":"Long-Term Obligations and Oth_2","index":27,"n_rows":4,"n_cols":2,"rows_kept":4,"merged":[[0,0,1,0]]}
["Long-Term Obligations and Other Short-Term Borrowings (Tables)","9 Months Ended"]
[null,"Mar. 31, 2025"]
["Debt Disclosure [Abstract]"," "]
["Schedule of Debt [Table Text Block]","The following table summarizes long-term obligations and other short-term borrowings at: (in millions) (1) March 31, 2025 June 30, 2024 3.5% Notes due 2024 $ — $ 401 3.75% Notes due 2025 503 507 4.7% Notes due 2026 497 — 3.41% Notes due 2027 1,205 1,191 5.125% Notes due 2029 645 644 5.0% Notes due 2029 744 — 5.45% Notes due 2034 499 491 5.35% Notes due 2034 989 — 4.6% Notes due 2043 322 308 4.5% Notes due 2044 335 330 4.9% Notes due 2045 435 423 4.368% Notes due 2047 565 563 5.75% Notes due 2054 641 — 7.0% Debentures due 2026 124 124 Other Obligations 175 110 Total 7,679 5,092 Less: current portion of long-term obligations and other short-term borrowings 543 434 Long-term obligations, less current portion $ 7,136 $ 4,658 "]

{"sheet":"Fair Value Measurements (Tables","index":28,"n_rows":4,"n_cols":2,"rows_kept":4,"merged":[[0,0,1,0]]}
["Fair Value Measurements (Tables)","9 Months Ended"]
[null,"Mar. 31, 2025"]
["Fair Value Disclosures [Abstract]"," "]
["Fair Value, Assets and Liabilities Measured on Recurring Basis","The following tables present the fair values for assets and (liabilities) measured on a recurring basis at: March 31, 2025 (in millions) Level 1 Level 2 Level 3 Total Assets: Cash equivalents $ 949 $ — $ — $ 949 Other investments (1) 99 — — 99 Liabilities: Forward contracts (2) — (43) — (43) June 30, 2024 (in millions) Level 1 Level 2 Level 3 Total Assets: Cash equivalents $ 1,442 $ — $ — $ 1,442 Other investments (1) 108 — — 108 Liabilities: Forward contracts (2) — (87) — (87) (1) The other investments balance includes investments in mutual funds, which offset fluctuations in deferred compensation liabilities. These mutual funds invest in the equity securities of companies with both large and small market capitalization and high quality fixed income debt securities. The fair value of these investments is determined using quoted market prices. (2) The fair value of interest rate swaps, foreign currency contracts, and net investment hedges is determined based on the present value of expected future cash flows considering the risks involved, including non-performance risk, and using discount rates appropriate for the respective maturities. Observable Level 2 inputs are used to determine the present value of expected future cash flows. The fair value of these derivative contracts, which are subject to master netting arrangements under certain circumstances, is presented on a gross basis in prepaid expenses and other, other assets, other accrued liabilities, and deferred income taxes and other liabilities within the condensed consolidated balance sheets."]

{"sheet":"Financial Instruments (Tables)","index":29,"n_rows":4,"n_cols":2,"rows_kept":4,"merged":[[0,0,1,0]]}
["Financial Instruments (Tables)","9 Months Ended"]
[null,"Mar. 31, 2025"]
["Derivative Instruments and Hedging Activities Disclosure [Abstract]"," "]
["Schedule of Estimated Fair Value of Long-term Obligations and Other Short-term Borrowings Compared to the Respective Carrying Amount","The following table summarizes the estimated fair value of our long-term obligations and other short-term borrowings compared to the respective carrying amounts at: (in millions) March 31, 2025 June 30, 2024 Estimated fair value $ 7,511 $ 4,891 Carrying amount 7,679 5,092 "]

{"sheet":"Shareholders' Equity (Tables)","index":30,"n_rows":4,"n_cols":2,"rows_kept":4,"merged":[[0,0,1,0]]}
["Shareholders' Equity (Tables)","9 Months Ended"]
[null,"Mar. 31, 2025"]
["Equity [Abstract]"," "]
["Schedule of Changes in the Balance of Accumulated Other Comprehensive Loss by Component and in Total","The following tables summarize the changes in the balance of accumulated other comprehensive loss by component and in total: (in millions) Foreign Unrealized Accumulated Other Balance at June 30, 2024 $ (138) $ (29) $ (167) Other comprehensive income/(loss), before reclassifications (13) 3 (10) Amounts reclassified to earnings — 1 1 Total other comprehensive loss attributable to Cardinal Health, Inc., net of tax benefit of $2 million (13) 4 (9) Balance at March 31, 2025 $ (151) $ (25) $ (176) (in millions) Foreign Unrealized Accumulated Other Balance at June 30, 2023 $ (137) $ (14) $ (151) Other comprehensive income/(loss), before reclassifications (4) 1 (3) Amounts reclassified to earnings — (6) (6) Total other comprehensive loss attributable to Cardinal Health, Inc., net of tax expense of $4 million (4) (5) (9) Balance at March 31, 2024 $ (141) $ (19) $ (160)"]

{"sheet":"Earnings Per Share Attributab_2","index":31,"n_rows":4,"n_cols":2,"rows_kept":4,"merged":[[0,0,1,0]]}
["Earnings Per Share Attributable to Cardinal Health, Inc. (Tables)","9 Months Ended"]
[null,"Mar. 31, 2025"]
["Earnings Per Share [Abstract]"," "]
["Reconciliation of Common Shares Used to Compute Basic and Diluted Earnings Per Share","The following tables reconcile the number of common shares used to compute basic and diluted earnings per share attributable to Cardinal Health, Inc. (\"EPS\"): Three Months Ended March 31, (in millions) 2025 2024 Weighted-average common shares–basic 240 243 Effect of dilutive securities: Employee stock options, restricted share units and performance share units 1 2 Weighted-average common shares–diluted 241 245 Nine Months Ended March 31, (in millions) 2025 2024 Weighted-average common shares–basic 242 245 Effect of dilutive securities: Employee stock options, restricted share units and performance share units 1 2 Weighted-average common shares–diluted 243 247 "]

{"sheet":"Segment Information (Tables)","index":32,"n_rows":7,"n_cols":2,"rows_kept":7,"merged":[[0,0,1,0]]}
["Segment Information (Tables)","9 Months Ended"]
[null,"Mar. 31, 2025"]
["Segment Reporting [Abstract]"," "]
["Disaggregation of Revenue [Table Text Block]","The following tables present revenue for the two reportable segments and disaggregated revenue within the remaining operating segments, included in Other, and Corporate: Three Months Ended March 31, (in millions) 2025 2024 Pharmaceutical and Specialty Solutions $ 50,433 $ 50,622 Global Medical Products and Distribution 3,160 3,113 Nuclear and Precision Health Solutions 403 352 at-Home Solutions 817 730 OptiFreight ® Logistics 84 72 Other 1,304 1,154 Total segment revenue 54,897 54,889 Corporate (1) (19) (21) Total revenue $ 54,878 $ 54,868 Nine Months Ended March 31, (in millions) 2025 2024 Pharmaceutical and Specialty Solutions $ 149,272 $ 154,412 Global Medical Products and Distribution 9,437 9,272 Nuclear and Precision Health Solutions 1,148 1,006 at-Home Solutions 2,391 2,136 OptiFreight ® Logistics 234 198 Other 3,773 3,340 Total segment revenue 162,482 167,024 Corporate (1) (63) (64) Total revenue $ 162,419 $ 166,960 (1) Corporate revenue consists of the elimination of inter-segment revenue and other revenue not allocated to the segments."]
["Revenue from External Customers by Geographic Areas [Table Text Block]","The following tables present revenue by geographic area: Three Months Ended March 31, (in millions) 2025 2024 United States $ 54,498 $ 54,464 International 399 425 Total segment revenue 54,897 54,889 Corporate (1) (19) (21) Total revenue $ 54,878 $ 54,868 Nine Months Ended March 31, (in millions) 2025 2024 United States $ 161,247 $ 165,783 International 1,235 1,241 Total segment revenue 162,482 167,024 Corporate (1) (63) (64) Total revenue $ 162,419 $ 166,960 (1) Corporate revenue consists of the elimination of inter-segment revenue and other revenue not allocated to the segments."]
["Segment Profit by Reportable Segment","The following tables present segment profit for the two reportable segments and the remaining operating segments, included in Other, and Corporate: Three Months Ended March 31, (in millions) 2025 2024 Pharmaceutical and Specialty Solutions $ 662 $ 582 Global Medical Products and Distribution 39 22 Other (1) 134 110 Total segment profit 835 714 Corporate (105) (345) Total operating earnings $ 730 $ 369 Nine Months Ended March 31, (in millions) 2025 2024 Pharmaceutical and Specialty Solutions $ 1,723 $ 1,533 Global Medical Products and Distribution 65 45 Other (1) 356 312 Total segment profit 2,144 1,890 Corporate (297) (1,048) Total operating earnings $ 1,847 $ 842 (1) Comprised of the remaining operating segments, Nuclear and Precision Health Solutions, at-Home Solutions, and OptiFreight ® Logistics."]
["Assets by Reportable Segment","The following table presents total assets for the two reportable segments and the remaining operating segments, included in Other, and Corporate: (in millions) March 31, June 30, Pharmaceutical and Specialty Solutions $ 35,734 $ 29,149 Global Medical Products and Distribution 7,201 7,047 Other (1) 2,726 2,606 Corporate 4,210 6,319 Total assets $ 49,871 $ 45,121 (1) Comprised of the remaining operating segments, Nuclear and Precision Health Solutions, at-Home Solutions, and OptiFreight ® Logistics."]

{"sheet":"Share-Based Compensation (Table","index":33,"n_rows":7,"n_cols":2,"rows_kept":7,"merged":[[0,0,1,0]]}
["Share-Based Compensation (Tables)","9 Months Ended"]
[null,"Mar. 31, 2025"]
["Share-Based Payment Arrangement [Abstract]"," "]
["Schedule of Total Share-based Compensation Expense by Type of Award","The following tables provide total share-based compensation expense by type of award: Three Months Ended March 31, (in millions) 2025 2024 Restricted share unit expense $ 18 $ 20 Performance share unit expense 14 11 Total share-based compensation $ 32 $ 31 Nine Months Ended March 31, (in millions) 2025 2024 Restricted share unit expense $ 54 $ 58 Performance share unit expense 37 30 Total share-based compensation $ 91 $ 88 "]
["Schedule of Transactions Related to Restricted Share Units Under the Plans","The following table summarizes all transactions related to restricted share units under the Plans: (in millions, except per share amounts) Restricted Share Units Weighted-Average Nonvested at June 30, 2024 1.7 $ 70.98 Granted 0.7 108.20 Vested (0.9) 71.74 Canceled and forfeited (0.1) 93.05 Nonvested at March 31, 2025 1.4 $ 85.45 "]
["Schedule of Transactions Related to Performance Share Units Under the Plans","The following table summarizes all transactions related to performance share units under the Plans (based on target award amounts): (in millions, except per share amounts) Performance Weighted-Average Nonvested at June 30, 2024 1.3 $ 97.03 Granted 0.5 113.88 Vested (0.3) 108.79 Canceled and forfeited — — Nonvested at March 31, 2025 1.5 $ 99.53 "]
["Schedule of Transactions Related to GIA Units","The following table summarizes the fair market value of GIA Units as of March 31, 2025: (in millions, except per share amounts) GIA Share Units Weighted-Average Nonvested at January 30, 2025 115 $ 1.46 Granted 16 1.46 Vested (12) 1.46 Canceled and forfeited — — Nonvested at March 31, 2025 119 $ 1.46 Vested at March 31, 2025 618 $ 1.46 "]

{"sheet":"Basis of Presentation and Sum_3","index":34,"n_rows":12,"n_cols":4,"rows_kept":12,"merged":[[0,0,1,0]]}
["Basis of Presentation and Summary of Significant Accounting Policies (Narrative, Recent Financial Accounting Standards) (Details) - USD ($) $ in Millions","3 Months Ended","9 Months Ended"]
[null,"Sep. 30, 2024","Mar. 31, 2025","Jun. 30, 2024"]
["Concentration Risk [Line Items]"," "," "," "]
["Total assets"," ",{"v":49871,"d":"$ 49,871"},{"v":45121,"d":"$ 45,121"}]
["Consolidation, Variable Interest Entity, Policy"," ","Variable Interest Entities We evaluate our ownership, contractual, and other interests in entities to determine if they are a variable interest entity (“VIE”), if we have a variable interest in those entities, and the nature and extent of those interests. These evaluations may involve management judgment and the use of estimates and assumptions based on available historical information, among other factors. Based on our evaluations, if we determine we are the primary beneficiary of such VIEs, we consolidate such entities into our financial statements. Consolidated Variable Interest Entities We consolidate a VIE when we have the power to direct the activities that most significantly impact the VIE’s economic performance and the obligation to absorb losses or the right to receive benefits of the VIE and, as a result, are considered the primary beneficiary of the VIE. On January 1, 2020, GI Alliance (\"GIA\") entered into a management services arrangement with Texas Digestive Disease Consultants, PLLC (“TDDC”) that authorized GIA to perform certain management services in the manner that it deemed reasonably appropriate to meet the day-to-day business needs of TDDC. In exchange for the management services provided, GIA is entitled to receive an annual management fee equal to a percentage of TDDC’s net operating income. The agreement has a 15 year term with two successive 5 year terms set to renew automatically. Based on these determinations, we concluded that TDDC is a VIE and that GIA is the primary beneficiary."," "]
["Variable Interest Entity, Primary Beneficiary"," "," "," "]
["Concentration Risk [Line Items]"," "," "," "]
["Total assets"," ",{"v":524,"d":"$ 524"}," "]
["Liabilities"," ",{"v":249,"d":"$ 249"}," "]
["OptumRx | Revenue Benchmark | Customer Concentration Risk | Pharmaceutical and Specialty Solutions"," "," "," "]
["Concentration Risk [Line Items]"," "," "," "]
["Concentration Risk, Percentage",{"v":0.17,"d":"17%"}," "," "]

{"sheet":"Business Combinations and Ass_2","index":35,"n_rows":91,"n_cols":9,"rows_kept":91,"merged":[[0,0,1,0],[0,1,0,2],[0,3,0,4]]}
["Business Combinations and Asset Acquisitions (Details) - USD ($) $ in Millions","3 Months Ended",null,"9 Months Ended"]
[null,"Mar. 31, 2025","Mar. 31, 2024","Mar. 31, 2025","Mar. 31, 2024","Jan. 30, 2025","Dec. 02, 2024","Jun. 30, 2024","Mar. 18, 2024"]
["Business Combination [Line Items]"," "," "," "," "," "," "," "," "]
["Net Intangible",{"v":2095,"d":"$ 2,095"}," ",{"v":2095,"d":"$ 2,095"}," "," "," ",{"v":1713,"d":"$ 1,713"}," "]
["Goodwill",{"v":8906,"d":"$ 8,906"}," ",{"v":8906,"d":"$ 8,906"}," "," "," ",{"v":4725,"d":"$ 4,725"}," "]
["Weighted- Average Remaining Amortization Period (Years)","10 years"," ","10 years"," "," "," "," "," "]
["ION"," "," "," "," "," "," "," "," "]
["Business Combination [Line Items]"," "," "," "," "," "," "," "," "]
["Payments to Acquire Businesses, Gross",{"v":1100,"d":"$ 1,100"}," "," "," "," "," "," "," "]
["Business Combination, Recognized Asset Acquired, Identifiable Intangible Asset, Finite-Lived"," "," "," "," "," ",{"v":313,"d":"$ 313"}," "," "]
["Business Combination, Recognized Asset Acquired, Cash and Cash Equivalent"," "," "," "," "," ",{"v":8,"d":"8 "}," "," "]
["Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities"," "," "," "," "," ",{"v":-3,"d":"(3)"}," "," "]
["Business Combination, Recognized Asset Acquired, Receivable, Current"," "," "," "," "," ",{"v":59,"d":"59 "}," "," "]
["Business Combination, Recognized Asset Acquired, Inventory, Current"," "," "," "," "," ",{"v":4,"d":"4 "}," "," "]
["Business Combination, Recognized Asset Acquired, Prepaid Expense and Other Asset, Current"," "," "," "," "," ",{"v":5,"d":"5 "}," "," "]
["Business Combination, Recognized Asset Acquired, Property, Plant, and Equipment"," "," "," "," "," ",{"v":32,"d":"32 "}," "," "]
["Business Combination, Recognized Asset Acquired, Other Asset, Noncurrent"," "," "," "," "," ",{"v":45,"d":"45 "}," "," "]
["Business Combination, Recognized Liability Assumed, Accounts Payable, Current"," "," "," "," "," ",{"v":-10,"d":"(10)"}," "," "]
["Business Combination, Recognized Liability Assumed, Other Liability, Current"," "," "," "," "," ",{"v":-38,"d":"(38)"}," "," "]
["Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities"," "," "," "," "," ",{"v":-14,"d":"(14)"}," "," "]
["Business Combination, Recognized Liability Assumed, Other Liability, Noncurrent"," "," "," "," "," ",{"v":-88,"d":"(88)"}," "," "]
["Business Combination, Recognized Asset Acquired to Liability Assumed, Excess (Less)"," "," "," "," "," ",{"v":313,"d":"313 "}," "," "]
["Business Combination, Acquisition of Less than 100 Percent, Noncontrolling Interest, Fair Value"," "," "," "," "," ",{"v":-151,"d":"(151)"}," "," "]
["Goodwill"," "," "," "," "," ",{"v":908,"d":"908 "}," "," "]
["Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net"," "," "," "," "," ",{"v":1070,"d":"1,070 "}," "," "]
["Business Combination, Acquisition-Related Cost, Expense",{"v":6,"d":"$ 6"}," ",{"v":25,"d":"$ 25"}," "," "," "," "," "]
["ION | Measurement Input, Discount Rate | Valuation Technique, Discounted Cash Flow"," "," "," "," "," "," "," "," "]
["Business Combination [Line Items]"," "," "," "," "," "," "," "," "]
["Intangible Assets Measurement Input",{"v":0.095,"d":"9.50%"}," "," "," "," "," "," "," "]
["Specialty Networks"," "," "," "," "," "," "," "," "]
["Business Combination [Line Items]"," "," "," "," "," "," "," "," "]
["Payments to Acquire Businesses, Gross"," ",{"v":1200,"d":"$ 1,200"}," "," "," "," "," "," "]
["Goodwill"," "," "," "," "," "," "," ",{"v":784,"d":"$ 784"}]
["Business Combination, Acquisition-Related Cost, Expense",{"v":2,"d":"$ 2"},{"v":15,"d":"$ 15"},{"v":6,"d":"6 "},{"v":15,"d":"$ 15"}," "," "," "," "]
["ADSG [Member]"," "," "," "," "," "," "," "," "]
["Business Combination [Line Items]"," "," "," "," "," "," "," "," "]
["Business Combination, Price of Acquisition, Expected",{"v":1100,"d":"1,100 "}," "," "," "," "," "," "," "]
["GIA [Member]"," "," "," "," "," "," "," "," "]
["Business Combination [Line Items]"," "," "," "," "," "," "," "," "]
["Business Combination, Recognized Asset Acquired, Identifiable Intangible Asset, Finite-Lived"," "," "," "," ",{"v":280,"d":"$ 280"}," "," "," "]
["Business Combination, Recognized Asset Acquired, Cash and Cash Equivalent"," "," "," "," ",{"v":76,"d":"76 "}," "," "," "]
["Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities"," "," "," "," ",{"v":-1,"d":"(1)"}," "," "," "]
["Business Combination, Recognized Asset Acquired, Receivable, Current"," "," "," "," ",{"v":195,"d":"195 "}," "," "," "]
["Business Combination, Recognized Asset Acquired, Inventory, Current"," "," "," "," ",{"v":21,"d":"21 "}," "," "," "]
["Business Combination, Recognized Asset Acquired, Prepaid Expense and Other Asset, Current"," "," "," "," ",{"v":13,"d":"13 "}," "," "," "]
["Business Combination, Recognized Asset Acquired, Property, Plant, and Equipment"," "," "," "," ",{"v":67,"d":"67 "}," "," "," "]
["Business Combination, Recognized Asset Acquired, Other Asset, Noncurrent"," "," "," "," ",{"v":287,"d":"287 "}," "," "," "]
["Business Combination, Recognized Liability Assumed, Accounts Payable, Current"," "," "," "," ",{"v":-89,"d":"(89)"}," "," "," "]
["Business Combination, Recognized Liability Assumed, Other Liability, Current"," "," "," "," ",{"v":-171,"d":"(171)"}," "," "," "]
["Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities"," "," "," "," ",{"v":-15,"d":"(15)"}," "," "," "]
["Business Combination, Recognized Liability Assumed, Other Liability, Noncurrent"," "," "," "," ",{"v":-209,"d":"(209)"}," "," "," "]
["Business Combination, Recognized Asset Acquired to Liability Assumed, Excess (Less)"," "," "," "," ",{"v":454,"d":"454 "}," "," "," "]
["Business Combination, Acquisition of Less than 100 Percent, Noncontrolling Interest, Fair Value"," "," "," "," ",{"v":-884,"d":"(884)"}," "," "," "]
["Goodwill"," "," "," "," ",{"v":3241,"d":"3,241 "}," "," "," "]
["Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net"," "," "," "," ",{"v":2811,"d":"$ 2,811"}," "," "," "]
["Business Combination, Acquisition-Related Cost, Expense",{"v":59,"d":"59 "}," ",{"v":69,"d":"69 "}," "," "," "," "," "]
["Business Combination, Price of Acquisition, Expected",{"v":2800,"d":"$ 2,800"}," "," "," "," "," "," "," "]
["Business Combination, Voting Equity Interest Acquired, Percentage"," "," "," "," ",{"v":0.73,"d":"73%"}," "," "," "]
["GIA [Member] | Measurement Input, Discount Rate | Valuation Technique, Discounted Cash Flow"," "," "," "," "," "," "," "," "]
["Business Combination [Line Items]"," "," "," "," "," "," "," "," "]
["Intangible Assets Measurement Input",{"v":0.1,"d":"10%"}," "," "," "," "," "," "," "]
["Customer Contracts"," "," "," "," "," "," "," "," "]
["Business Combination [Line Items]"," "," "," "," "," "," "," "," "]
["Net Intangible",{"v":231,"d":"$ 231"}," ",{"v":231,"d":"$ 231"}," "," "," "," "," "]
["Weighted- Average Remaining Amortization Period (Years)","16 years"," ","16 years"," "," "," "," "," "]
["Customer Contracts | ION"," "," "," "," "," "," "," "," "]
["Business Combination [Line Items]"," "," "," "," "," "," "," "," "]
["Net Intangible"," "," "," "," "," ",{"v":235,"d":"$ 235"}," "," "]
["Weighted- Average Remaining Amortization Period (Years)"," "," "," "," "," ","20 years"," "," "]
["Customer Contracts | GIA [Member]"," "," "," "," "," "," "," "," "]
["Business Combination [Line Items]"," "," "," "," "," "," "," "," "]
["Net Intangible"," "," "," "," ",{"v":0,"d":"$ 0"}," "," "," "]
["Trademarks and Trade Names | ION"," "," "," "," "," "," "," "," "]
["Business Combination [Line Items]"," "," "," "," "," "," "," "," "]
["Net Intangible"," "," "," "," "," ",{"v":78,"d":"$ 78"}," "," "]
["Weighted- Average Remaining Amortization Period (Years)"," "," "," "," "," ","10 years"," "," "]
["Trademarks and Trade Names | GIA [Member]"," "," "," "," "," "," "," "," "]
["Business Combination [Line Items]"," "," "," "," "," "," "," "," "]
["Net Intangible"," "," "," "," ",{"v":256,"d":"$ 256"}," "," "," "]
["Weighted- Average Remaining Amortization Period (Years)"," "," "," "," ","10 years"," "," "," "]
["Noncompete Agreements"," "," "," "," "," "," "," "," "]
["Business Combination [Line Items]"," "," "," "," "," "," "," "," "]
["Net Intangible",{"v":25,"d":"$ 25"}," ",{"v":25,"d":"$ 25"}," "," "," "," "," "]
["Weighted- Average Remaining Amortization Period (Years)","4 years"," ","4 years"," "," "," "," "," "]
["Noncompete Agreements | ION"," "," "," "," "," "," "," "," "]
["Business Combination [Line Items]"," "," "," "," "," "," "," "," "]
["Net Intangible"," "," "," "," "," ",{"v":0,"d":"$ 0"}," "," "]
["Noncompete Agreements | GIA [Member]"," "," "," "," "," "," "," "," "]
["Business Combination [Line Items]"," "," "," "," "," "," "," "," "]
["Net Intangible"," "," "," "," ",{"v":24,"d":"$ 24"}," "," "," "]
["Weighted- Average Remaining Amortization Period (Years)"," "," "," "," ","4 years"," "," "," "]

{"sheet":"Discontinued Operations and Dis","index":36,"n_rows":10,"n_cols":4,"rows_kept":10,"merged":[[0,0,1,0]]}
["Discontinued Operations and Disposal Groups (Details) - USD ($) $ in Millions","3 Months Ended","9 Months Ended"]
[null,"Dec. 31, 2023","Mar. 31, 2024","Mar. 31, 2025"]
["Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]"," "," "," "]
["Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal, Statement of Income or Comprehensive Income [Extensible Enumeration]","Gain (Loss) on Sale of Assets and Asset Impairment Charges"," "," "]
["Outcomes Divestiture [Member]"," "," "," "]
["Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]"," "," "," "]
["Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal"," ",{"v":53,"d":"$ 53"}," "]
["Transaction Data System Investment"," "," "," "]
["Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]"," "," "," "]
["Equity Method Investment, Ownership Percentage"," "," ",{"v":0.16,"d":"16%"}]

{"sheet":"Restructuring and Employee Se_3","index":37,"n_rows":6,"n_cols":5,"rows_kept":6,"merged":[[0,0,1,0],[0,1,0,2],[0,3,0,4]]}
["Restructuring and Employee Severance (Activity Related to Restructuring and Employee Severance Costs) (Details) - USD ($) $ in Millions","3 Months Ended",null,"9 Months Ended"]
[null,"Mar. 31, 2025","Mar. 31, 2024","Mar. 31, 2025","Mar. 31, 2024"]
["Restructuring Charges [Abstract]"," "," "," "," "]
["Employee-related costs",{"v":22,"d":"$ 22"},{"v":36,"d":"$ 36"},{"v":41,"d":"$ 41"},{"v":51,"d":"$ 51"}]
["Facility Exit and Other Costs",{"v":6,"d":"6 "},{"v":17,"d":"17 "},{"v":20,"d":"20 "},{"v":55,"d":"55 "}]
["Total restructuring and employee severance",{"v":28,"d":"$ 28"},{"v":53,"d":"$ 53"},{"v":61,"d":"$ 61"},{"v":106,"d":"$ 106"}]

{"sheet":"Restructuring and Employee Se_4","index":38,"n_rows":19,"n_cols":2,"rows_kept":19,"merged":[[0,0,1,0]]}
["Restructuring and Employee Severance (Liabilities Associated with Restructuring and Employee Severance Activities) (Details) $ in Millions","9 Months Ended"]
[null,"Mar. 31, 2025 USD ($)"]
["Restructuring Reserve [Roll Forward]"," "]
["Beginning Balance",{"v":97,"d":"$ 97"}]
["Additions",{"v":32,"d":"32 "}]
["Payments and other adjustments",{"v":-47,"d":"(47)"}]
["Ending Balance",{"v":82,"d":"82 "}]
["Employee- Related Costs"," "]
["Restructuring Reserve [Roll Forward]"," "]
["Beginning Balance",{"v":92,"d":"92 "}]
["Additions",{"v":32,"d":"32 "}]
["Payments and other adjustments",{"v":-42,"d":"(42)"}]
["Ending Balance",{"v":82,"d":"82 "}]
["Facility Exit and Other Costs"," "]
["Restructuring Reserve [Roll Forward]"," "]
["Beginning Balance",{"v":5,"d":"5 "}]
["Additions",{"v":0,"d":"0 "}]
["Payments and other adjustments",{"v":-5,"d":"(5)"}]
["Ending Balance",{"v":0,"d":"$ 0"}]

{"sheet":"Restructuring and Employee Se_5","index":39,"n_rows":5,"n_cols":5,"rows_kept":5,"merged":[[0,0,1,0],[0,1,0,2],[0,3,0,4]]}
["Restructuring and Employee Severance Narative (Details) - USD ($) $ in Millions","3 Months Ended",null,"9 Months Ended"]
[null,"Mar. 31, 2025","Mar. 31, 2024","Mar. 31, 2025","Mar. 31, 2024"]
["Restructuring Cost and Reserve [Line Items]"," "," "," "," "]
["Employee-related costs",{"v":22,"d":"$ 22"},{"v":36,"d":"$ 36"},{"v":41,"d":"$ 41"},{"v":51,"d":"$ 51"}]
["Facility Exit and Other Costs",{"v":6,"d":"$ 6"},{"v":17,"d":"$ 17"},{"v":20,"d":"$ 20"},{"v":55,"d":"$ 55"}]

{"sheet":"Goodwill and Other Intangible_3","index":40,"n_rows":22,"n_cols":5,"rows_kept":22,"merged":[[0,0,1,0],[0,1,0,2],[0,3,0,4]]}
["Goodwill and Other Intangible Assets (Schedule of Goodwill by Reportable Segment) (Details) - USD ($) $ in Millions","3 Months Ended",null,"9 Months Ended"]
[null,"Mar. 31, 2024","Sep. 30, 2023","Mar. 31, 2025","Mar. 31, 2024"]
["Goodwill [Roll Forward]"," "," "," "," "]
["Beginning balance"," "," ",{"v":4725,"d":"$ 4,725"}," "]
["Goodwill acquired, net of purchase price adjustments"," "," ",{"v":4181,"d":"4,181 "}," "]
["Ending balance"," "," ",{"v":8906,"d":"8,906 "}," "]
["Pharmaceutical and Specialty Solutions"," "," "," "," "]
["Goodwill [Roll Forward]"," "," "," "," "]
["Beginning balance"," "," ",{"v":3555,"d":"3,555 "}," "]
["Goodwill acquired, net of purchase price adjustments"," "," ",{"v":4181,"d":"4,181 "}," "]
["Ending balance"," "," ",{"v":7736,"d":"7,736 "}," "]
["Global Medical Products and Distribution"," "," "," "," "]
["Goodwill [Roll Forward]"," "," "," "," "]
["Beginning balance"," "," ",{"v":0,"d":"0 "}," "]
["Goodwill acquired, net of purchase price adjustments"," "," ",{"v":0,"d":"0 "}," "]
["Ending balance"," "," ",{"v":0,"d":"0 "}," "]
["Goodwill impairment",{"v":90,"d":"$ 90"},{"v":585,"d":"$ 585"}," ",{"v":675,"d":"$ 675"}]
["Other Segments"," "," "," "," "]
["Goodwill [Roll Forward]"," "," "," "," "]
["Beginning balance"," "," ",{"v":1170,"d":"1,170 "}," "]
["Goodwill acquired, net of purchase price adjustments"," "," ",{"v":0,"d":"0 "}," "]
["Ending balance"," "," ",{"v":1170,"d":"$ 1,170"}," "]

{"sheet":"Goodwill and Other Intangible_4","index":41,"n_rows":43,"n_cols":3,"rows_kept":43}
["Goodwill and Other Intangible Assets (Schedule of Intangible Assets) (Details) - USD ($) $ in Millions","Mar. 31, 2025","Jun. 30, 2024"]
["Indefinite-lived Intangible Assets [Line Items]"," "," "]
["Net Intangible",{"v":13,"d":"$ 13"},{"v":12,"d":"$ 12"}]
["Finite-Lived Intangible Assets [Line Items]"," "," "]
["Gross Intangible",{"v":5842,"d":"5,842 "},{"v":5236,"d":"5,236 "}]
["Accumulated Amortization",{"v":3747,"d":"3,747 "},{"v":3523,"d":"3,523 "}]
["Net Intangible",{"v":2095,"d":"$ 2,095"},{"v":1713,"d":"1,713 "}]
["Weighted- Average Remaining Amortization Period (Years)","10 years"," "]
["Gross Intangible, Total other intangible assets",{"v":5855,"d":"$ 5,855"},{"v":5248,"d":"5,248 "}]
["Net Intangible, Total other intangible assets",{"v":2108,"d":"2,108 "},{"v":1725,"d":"1,725 "}]
["Trademarks and patents"," "," "]
["Indefinite-lived Intangible Assets [Line Items]"," "," "]
["Net Intangible",{"v":13,"d":"13 "},{"v":12,"d":"12 "}]
["Customer relationships"," "," "]
["Finite-Lived Intangible Assets [Line Items]"," "," "]
["Gross Intangible",{"v":3640,"d":"3,640 "},{"v":3628,"d":"3,628 "}]
["Accumulated Amortization",{"v":2574,"d":"2,574 "},{"v":2431,"d":"2,431 "}]
["Net Intangible",{"v":1066,"d":"$ 1,066"},{"v":1197,"d":"1,197 "}]
["Weighted- Average Remaining Amortization Period (Years)","11 years"," "]
["Trademarks, trade names and patents"," "," "]
["Finite-Lived Intangible Assets [Line Items]"," "," "]
["Gross Intangible",{"v":896,"d":"$ 896"},{"v":561,"d":"561 "}]
["Accumulated Amortization",{"v":439,"d":"439 "},{"v":408,"d":"408 "}]
["Net Intangible",{"v":457,"d":"$ 457"},{"v":153,"d":"153 "}]
["Weighted- Average Remaining Amortization Period (Years)","8 years"," "]
["Developed technology and other"," "," "]
["Finite-Lived Intangible Assets [Line Items]"," "," "]
["Gross Intangible",{"v":1027,"d":"$ 1,027"},{"v":1047,"d":"1,047 "}]
["Accumulated Amortization",{"v":711,"d":"711 "},{"v":684,"d":"684 "}]
["Net Intangible",{"v":316,"d":"$ 316"},{"v":363,"d":"$ 363"}]
["Weighted- Average Remaining Amortization Period (Years)","7 years"," "]
["Customer Contracts"," "," "]
["Finite-Lived Intangible Assets [Line Items]"," "," "]
["Gross Intangible",{"v":235,"d":"$ 235"}," "]
["Accumulated Amortization",{"v":4,"d":"4 "}," "]
["Net Intangible",{"v":231,"d":"$ 231"}," "]
["Weighted- Average Remaining Amortization Period (Years)","16 years"," "]
["Noncompete Agreements"," "," "]
["Finite-Lived Intangible Assets [Line Items]"," "," "]
["Gross Intangible",{"v":44,"d":"$ 44"}," "]
["Accumulated Amortization",{"v":19,"d":"19 "}," "]
["Net Intangible",{"v":25,"d":"$ 25"}," "]
["Weighted- Average Remaining Amortization Period (Years)","4 years"," "]

{"sheet":"Goodwill and Other Intangible_5","index":42,"n_rows":15,"n_cols":7,"rows_kept":15,"merged":[[0,0,1,0],[0,1,0,3],[0,4,0,5]]}
["Goodwill and Other Intangible Assets (Narrative) (Details) - USD ($) $ in Millions","3 Months Ended",null,null,"9 Months Ended"]
[null,"Mar. 31, 2025","Mar. 31, 2024","Sep. 30, 2023","Mar. 31, 2025","Mar. 31, 2024","Jun. 30, 2024"]
["Goodwill and Intangible Assets Disclosure [Abstract]"," "," "," "," "," "," "]
["Amortization of intangible assets",{"v":77,"d":"$ 77"},{"v":64,"d":"$ 64"}," ",{"v":214,"d":"$ 214"},{"v":191,"d":"$ 191"}," "]
["Estimated annual amortization of intangible assets - Remainder of Fiscal Year",{"v":82,"d":"82 "}," "," ",{"v":82,"d":"82 "}," "," "]
["Estimated annual amortization of intangible assets - Year One",{"v":308,"d":"308 "}," "," ",{"v":308,"d":"308 "}," "," "]
["Estimated annual amortization of intangible assets - Year Two",{"v":285,"d":"285 "}," "," ",{"v":285,"d":"285 "}," "," "]
["Estimated annual amortization of intangible assets - Year Three",{"v":256,"d":"256 "}," "," ",{"v":256,"d":"256 "}," "," "]
["Estimated annual amortization of intangible assets - Year Four",{"v":249,"d":"249 "}," "," ",{"v":249,"d":"249 "}," "," "]
["Goodwill [Line Items]"," "," "," "," "," "," "]
["Goodwill",{"v":8906,"d":"8,906 "}," "," ",{"v":8906,"d":"8,906 "}," ",{"v":4725,"d":"$ 4,725"}]
["Global Medical Products and Distribution"," "," "," "," "," "," "]
["Goodwill [Line Items]"," "," "," "," "," "," "]
["Goodwill",{"v":0,"d":"$ 0"}," "," ",{"v":0,"d":"$ 0"}," ",{"v":0,"d":"$ 0"}]
["Goodwill impairment"," ",{"v":90,"d":"$ 90"},{"v":585,"d":"$ 585"}," ",{"v":675,"d":"$ 675"}," "]

{"sheet":"Long-Term Obligations and Oth_3","index":43,"n_rows":98,"n_cols":11,"rows_kept":98,"merged":[[0,0,1,0],[0,2,0,3],[0,6,0,7]]}
["Long-Term Obligations and Other Short-Term Borrowings (Details) € in Millions, ¥ in Millions, $ in Millions","3 Months Ended","9 Months Ended",null,"12 Months Ended"]
[null,"Mar. 31, 2025 USD ($)","Mar. 31, 2025 USD ($)","Mar. 31, 2024 USD ($)","Dec. 04, 2025","Apr. 01, 2025 USD ($)","Mar. 31, 2025 EUR (€)","Mar. 31, 2025 JPY (¥)","Nov. 22, 2024 USD ($)","Nov. 11, 2024 USD ($)","Jun. 30, 2024 USD ($)"]
["Debt Instrument [Line Items]"," "," "," "," "," "," "," "," "," "," "]
["Other Borrowings",{"v":175,"d":"$ 175"},{"v":175,"d":"$ 175"}," "," "," "," "," "," "," ",{"v":110,"d":"$ 110"}]
["Debt and Lease Obligation",{"v":7679,"d":"7,679 "},{"v":7679,"d":"7,679 "}," "," "," "," "," "," "," ",{"v":5092,"d":"5,092 "}]
["Current portion of long-term obligations and other short-term borrowings",{"v":543,"d":"543 "},{"v":543,"d":"543 "}," "," "," "," "," "," "," ",{"v":434,"d":"434 "}]
["Long-term obligations, less current portion",{"v":7136,"d":"7,136 "},{"v":7136,"d":"7,136 "}," "," "," "," "," "," "," ",{"v":4658,"d":"4,658 "}]
["Long-Term Debt, Maturity, Year One",{"v":12,"d":"12 "},{"v":12,"d":"12 "}," "," "," "," "," "," "," "," "]
["Long-Term Debt, Maturity, Year Two",{"v":548,"d":"548 "},{"v":548,"d":"548 "}," "," "," "," "," "," "," "," "]
["Long-Term Debt, Maturity, Year Three",{"v":1900,"d":"1,900 "},{"v":1900,"d":"1,900 "}," "," "," "," "," "," "," "," "]
["Long-Term Debt, Maturity, Year Four",{"v":27,"d":"27 "},{"v":27,"d":"27 "}," "," "," "," "," "," "," "," "]
["Long-Term Debt, Maturity, Year Five",{"v":663,"d":"663 "},{"v":663,"d":"663 "}," "," "," "," "," "," "," "," "]
["Long-Term Debt, Maturity, after Year Five",{"v":4600,"d":"4,600 "},{"v":4600,"d":"4,600 "}," "," "," "," "," "," "," "," "]
["Total Long-Term and Short-Term Obligations",{"v":7700,"d":"7,700 "},{"v":7700,"d":"7,700 "}," "," "," "," "," "," "," ",{"v":5100,"d":"5,100 "}]
["Accounts Payable",{"v":32800,"d":"32,800 "},{"v":32800,"d":"32,800 "}," "," "," "," "," "," "," ",{"v":31800,"d":"31,800 "}]
["Debt Instrument, Issued, Principal"," ",{"v":2900,"d":"2,900 "}," "," "," "," "," "," "," "," "]
["Proceeds from Issuance of Long-Term Debt"," ",{"v":2900,"d":"2,900 "}," "," "," "," "," "," "," "," "]
["Proceeds from short-term investment in time deposit"," ",{"v":200,"d":"200 "},{"v":0,"d":"$ 0"}," "," "," "," "," "," "," "]
["September 2025 | Currency Swap [Member] | Net Investment Hedging [Member] | Designated as Hedging Instrument"," "," "," "," "," "," "," "," "," "," "]
["Debt Instrument [Line Items]"," "," "," "," "," "," "," "," "," "," "]
["Derivative, Notional Amount",{"v":120,"d":"120 "},{"v":120,"d":"120 "}," "," "," "," ",{"v":18000,"d":"¥ 18,000"}," "," "," "]
["February 2027 | Currency Swap [Member] | Net Investment Hedging [Member] | Designated as Hedging Instrument"," "," "," "," "," "," "," "," "," "," "]
["Debt Instrument [Line Items]"," "," "," "," "," "," "," "," "," "," "]
["Derivative, Notional Amount",{"v":105,"d":"105 "},{"v":105,"d":"105 "}," "," "," ",{"v":100,"d":"€ 100"}," "," "," "," "]
["Commercial Paper [Member]"," "," "," "," "," "," "," "," "," "," "]
["Debt Instrument [Line Items]"," "," "," "," "," "," "," "," "," "," "]
["Line of Credit Facility, Maximum Borrowing Capacity",{"v":3000,"d":"3,000 "},{"v":3000,"d":"3,000 "}," "," "," "," "," "," "," "," "]
["Revolving Credit Facility [Member] | Backstop Credit Facility"," "," "," "," "," "," "," "," "," "," "]
["Debt Instrument [Line Items]"," "," "," "," "," "," "," "," "," "," "]
["Line of Credit Facility, Maximum Borrowing Capacity",{"v":2000,"d":"2,000 "},{"v":2000,"d":"2,000 "}," "," "," "," "," "," "," "," "]
["Short Term Credit Facilities Member"," "," "," "," "," "," "," "," "," "," "]
["Debt Instrument [Line Items]"," "," "," "," "," "," "," "," "," "," "]
["Other Short-term Borrowings",{"v":0,"d":"0 "},{"v":0,"d":"0 "}," "," "," "," "," "," "," "," "]
["Committed Receivables Sales Facility Program [Member]"," "," "," "," "," "," "," "," "," "," "]
["Debt Instrument [Line Items]"," "," "," "," "," "," "," "," "," "," "]
["Line of Credit Facility, Maximum Borrowing Capacity",{"v":1000,"d":"1,000 "},{"v":1000,"d":"1,000 "}," "," "," "," "," "," "," "," "]
["Credit Agreement"," "," "," "," "," "," "," "," "," "," "]
["Debt Instrument [Line Items]"," "," "," "," "," "," "," "," "," "," "]
["Line of Credit Facility, Maximum Borrowing Capacity",{"v":1000,"d":"1,000 "},{"v":1000,"d":"1,000 "}," "," "," "," "," "," "," "," "]
["Credit Agreement | Subsequent Event"," "," "," "," "," "," "," "," "," "," "]
["Debt Instrument [Line Items]"," "," "," "," "," "," "," "," "," "," "]
["Long-Term Line of Credit"," "," "," "," ",{"v":800,"d":"$ 800"}," "," "," "," "," "]
["364-Dad Revolving Credit Facility | Backstop Credit Facility"," "," "," "," "," "," "," "," "," "," "]
["Debt Instrument [Line Items]"," "," "," "," "," "," "," "," "," "," "]
["Line of Credit Facility, Maximum Borrowing Capacity",{"v":1000,"d":"1,000 "},{"v":1000,"d":"1,000 "}," "," "," "," "," "," "," "," "]
["364-Dad Revolving Credit Facility | Backstop Credit Facility | Forecast [Member]"," "," "," "," "," "," "," "," "," "," "]
["Debt Instrument [Line Items]"," "," "," "," "," "," "," "," "," "," "]
["Debt Instrument, Term"," "," "," ","364 days"," "," "," "," "," "," "]
["Bridge Loan"," "," "," "," "," "," "," "," "," "," "]
["Debt Instrument [Line Items]"," "," "," "," "," "," "," "," "," "," "]
["Line of Credit Facility, Maximum Borrowing Capacity"," "," "," "," "," "," "," ",{"v":0,"d":"$ 0"},{"v":2900,"d":"$ 2,900"}," "]
["3.5% Notes due 2024"," "," "," "," "," "," "," "," "," "," "]
["Debt Instrument [Line Items]"," "," "," "," "," "," "," "," "," "," "]
["Notes Payable",{"v":0,"d":"0 "},{"v":0,"d":"0 "}," "," "," "," "," "," "," ",{"v":401,"d":"401 "}]
["Repayments of Debt",{"v":400,"d":"400 "}," "," "," "," "," "," "," "," "," "]
["3.75% Notes due 2025"," "," "," "," "," "," "," "," "," "," "]
["Debt Instrument [Line Items]"," "," "," "," "," "," "," "," "," "," "]
["Notes Payable",{"v":503,"d":"503 "},{"v":503,"d":"503 "}," "," "," "," "," "," "," ",{"v":507,"d":"507 "}]
["3.41% Notes due 2027"," "," "," "," "," "," "," "," "," "," "]
["Debt Instrument [Line Items]"," "," "," "," "," "," "," "," "," "," "]
["Notes Payable",{"v":1205,"d":"1,205 "},{"v":1205,"d":"1,205 "}," "," "," "," "," "," "," ",{"v":1191,"d":"1,191 "}]
["5.125% Notes due 2029"," "," "," "," "," "," "," "," "," "," "]
["Debt Instrument [Line Items]"," "," "," "," "," "," "," "," "," "," "]
["Notes Payable",{"v":645,"d":"645 "},{"v":645,"d":"645 "}," "," "," "," "," "," "," ",{"v":644,"d":"644 "}]
["5.45% Notes due 2034"," "," "," "," "," "," "," "," "," "," "]
["Debt Instrument [Line Items]"," "," "," "," "," "," "," "," "," "," "]
["Notes Payable",{"v":499,"d":"499 "},{"v":499,"d":"499 "}," "," "," "," "," "," "," ",{"v":491,"d":"491 "}]
["4.6% Notes due 2043"," "," "," "," "," "," "," "," "," "," "]
["Debt Instrument [Line Items]"," "," "," "," "," "," "," "," "," "," "]
["Notes Payable",{"v":322,"d":"322 "},{"v":322,"d":"322 "}," "," "," "," "," "," "," ",{"v":308,"d":"308 "}]
["4.5% Notes due 2044"," "," "," "," "," "," "," "," "," "," "]
["Debt Instrument [Line Items]"," "," "," "," "," "," "," "," "," "," "]
["Notes Payable",{"v":335,"d":"335 "},{"v":335,"d":"335 "}," "," "," "," "," "," "," ",{"v":330,"d":"330 "}]
["4.9% Notes due 2045"," "," "," "," "," "," "," "," "," "," "]
["Debt Instrument [Line Items]"," "," "," "," "," "," "," "," "," "," "]
["Notes Payable",{"v":435,"d":"435 "},{"v":435,"d":"435 "}," "," "," "," "," "," "," ",{"v":423,"d":"423 "}]
["4.368% Notes due 2047"," "," "," "," "," "," "," "," "," "," "]
["Debt Instrument [Line Items]"," "," "," "," "," "," "," "," "," "," "]
["Notes Payable",{"v":565,"d":"565 "},{"v":565,"d":"565 "}," "," "," "," "," "," "," ",{"v":563,"d":"563 "}]
["7.0% Debentures due fiscal 2027"," "," "," "," "," "," "," "," "," "," "]
["Debt Instrument [Line Items]"," "," "," "," "," "," "," "," "," "," "]
["Notes Payable",{"v":124,"d":"124 "},{"v":124,"d":"124 "}," "," "," "," "," "," "," ",{"v":124,"d":"124 "}]
["5.0% Notes due 2029"," "," "," "," "," "," "," "," "," "," "]
["Debt Instrument [Line Items]"," "," "," "," "," "," "," "," "," "," "]
["Notes Payable",{"v":744,"d":"744 "},{"v":744,"d":"744 "}," "," "," "," "," "," "," ",{"v":0,"d":"0 "}]
["Debt Instrument, Issued, Principal"," ",{"v":750,"d":"750 "}," "," "," "," "," "," "," "," "]
["5.35% Notes due 2034"," "," "," "," "," "," "," "," "," "," "]
["Debt Instrument [Line Items]"," "," "," "," "," "," "," "," "," "," "]
["Notes Payable",{"v":989,"d":"989 "},{"v":989,"d":"989 "}," "," "," "," "," "," "," ",{"v":0,"d":"0 "}]
["Debt Instrument, Issued, Principal"," ",{"v":1000,"d":"1,000 "}," "," "," "," "," "," "," "," "]
["5.75% Notes due 2054"," "," "," "," "," "," "," "," "," "," "]
["Debt Instrument [Line Items]"," "," "," "," "," "," "," "," "," "," "]
["Notes Payable",{"v":641,"d":"641 "},{"v":641,"d":"641 "}," "," "," "," "," "," "," ",{"v":0,"d":"0 "}]
["Debt Instrument, Issued, Principal"," ",{"v":650,"d":"650 "}," "," "," "," "," "," "," "," "]
["4.7% Notes due 2026"," "," "," "," "," "," "," "," "," "," "]
["Debt Instrument [Line Items]"," "," "," "," "," "," "," "," "," "," "]
["Notes Payable",{"v":497,"d":"$ 497"},{"v":497,"d":"497 "}," "," "," "," "," "," "," ",{"v":0,"d":"$ 0"}]
["Debt Instrument, Issued, Principal"," ",{"v":500,"d":"$ 500"}," "," "," "," "," "," "," "," "]

{"sheet":"Commitments, Contingent Liabi_2","index":44,"n_rows":61,"n_cols":18,"rows_kept":61,"merged":[[0,0,1,0],[0,3,0,5],[0,7,0,8]]}
["Commitments, Contingent Liabilities and Litigation (Details) $ in Millions",null,null,"3 Months Ended",null,null,"5 Months Ended","9 Months Ended",null,"12 Months Ended","40 Months Ended","176 Months Ended"]
[null,"Apr. 30, 2023 USD ($) lawsuit","Jul. 31, 2014","Mar. 31, 2025 USD ($) states numberOfUSTerritories","Mar. 31, 2024 USD ($)","Sep. 30, 2022 USD ($)","Sep. 30, 2023 USD ($)","Mar. 31, 2025 USD ($) states numberOfUSTerritories","Mar. 31, 2024 USD ($)","Jun. 30, 2024 USD ($)","Oct. 31, 2024 USD ($)","Dec. 31, 2038 USD ($)","Apr. 29, 2025 lawsuit","Aug. 31, 2024 USD ($)","Nov. 30, 2023 USD ($)","Oct. 31, 2022 USD ($)","Jul. 31, 2022 USD ($)","Apr. 30, 2018 USD ($)"]
["Loss Contingencies [Line Items]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Income from Settlements of Class Action Lawsuits"," "," ",{"v":106,"d":"$ 106"},{"v":6,"d":"$ 6"}," "," ",{"v":165,"d":"$ 165"},{"v":77,"d":"$ 77"}," "," "," "," "," "," "," "," "," "]
["Product Liability Lawsuits | IVC April 2023 Agreement"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Loss Contingencies [Line Items]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Loss Contingency, Claims Settled, Number | lawsuit",{"v":4375,"d":"4,375 "}," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Product Liability Lawsuits | Minimum"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Loss Contingencies [Line Items]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Loss Contingency Accrual"," "," ",{"v":85,"d":"85 "}," "," "," ",{"v":85,"d":"85 "}," "," "," "," "," "," "," "," "," "," "]
["Total Opioid Litigation [Member]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Loss Contingencies [Line Items]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Estimated Litigation Liability"," "," ",{"v":4900,"d":"4,900 "}," "," "," ",{"v":4900,"d":"4,900 "}," "," "," "," "," "," "," "," "," "," "]
["Estimated Litigation Liability, Current"," "," ",{"v":636,"d":"$ 636"}," "," "," ",{"v":636,"d":"$ 636"}," "," "," "," "," "," "," "," "," "," "]
["Litigation Settlement, Loss"," "," "," "," "," "," "," "," ",{"v":340,"d":"$ 340"}," "," "," "," "," "," "," "," "]
["Income As A Result Of Prepayments"," "," "," "," "," "," "," "," ",{"v":105,"d":"105 "}," "," "," "," "," "," "," "," "]
["Loss Contingency Accrual, Period Increase (Decrease)"," "," "," "," "," "," "," "," ",{"v":344,"d":"344 "}," "," "," "," "," "," "," "," "]
["New York Opioid Stewardship Act [Member]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Loss Contingencies [Line Items]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Aggregate Annual Assessment"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," ",{"v":100,"d":"$ 100"}]
["Opioid Lawsuits [Member]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Loss Contingencies [Line Items]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Settling States | states"," "," ",{"v":48,"d":"48 "}," "," "," ",{"v":48,"d":"48 "}," "," "," "," "," "," "," "," "," "," "]
["Settling U.S Territories | numberOfUSTerritories"," "," ",{"v":5,"d":"5 "}," "," "," ",{"v":5,"d":"5 "}," "," "," "," "," "," "," "," "," "," "]
["Payments for Legal Settlements"," "," "," "," "," "," "," "," "," ",{"v":1900,"d":"$ 1,900"}," "," "," "," "," "," "," "]
["Insurance Recoveries"," "," "," "," "," "," ",{"v":25,"d":"$ 25"}," ",{"v":34,"d":"34 "}," "," "," "," "," "," "," "," "]
["Opioid Lawsuits [Member] | Subsequent Event"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Loss Contingencies [Line Items]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Payments for Legal Settlements"," "," "," "," "," "," "," "," "," "," ",{"v":4400,"d":"$ 4,400"}," "," "," "," "," "," "]
["Opioid Lawsuits [Member] | WEST VIRGINIA"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Loss Contingencies [Line Items]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Loss Contingency, Estimate of Possible Loss"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," ",{"v":124,"d":"$ 124"}," "]
["Opioid Lawsuits [Member] | ALABAMA"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Loss Contingencies [Line Items]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Litigation Settlement, Loss"," "," "," "," "," "," "," "," ",{"v":22,"d":"$ 22"}," "," "," "," "," "," "," "," "]
["Loss Contingency, Estimate of Possible Loss"," "," "," "," "," "," "," "," "," "," "," "," "," ",{"v":123,"d":"$ 123"}," "," "," "]
["Opioid Lawsuits [Member] | Native American tribes"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Loss Contingencies [Line Items]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Loss Contingency, Estimate of Possible Loss"," "," "," "," "," "," "," "," "," "," "," "," "," "," ",{"v":136,"d":"$ 136"}," "," "]
["Opioid Lawsuits [Member] | City of Baltimore"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Loss Contingencies [Line Items]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Loss Contingency, Estimate of Possible Loss"," "," "," "," "," "," "," "," "," "," "," "," ",{"v":153,"d":"$ 153"}," "," "," "," "]
["Opioid Lawsuits [Member] | Private Parties [Member] | Subsequent Event"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Loss Contingencies [Line Items]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Loss Contingency, Lawsuits, Number | lawsuit"," "," "," "," "," "," "," "," "," "," "," ",{"v":330,"d":"330 "}," "," "," "," "," "]
["Opioid Lawsuits [Member] | Class Action Lawsuits [Member] | Private Parties [Member]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Loss Contingencies [Line Items]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Estimated Litigation Liability"," "," ",{"v":213,"d":"$ 213"}," "," "," ",{"v":213,"d":"$ 213"}," "," "," "," "," "," "," "," "," "," "]
["Opioid Lawsuits [Member] | Class Action Lawsuits [Member] | Private Parties [Member] | Subsequent Event"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Loss Contingencies [Line Items]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Loss Contingency, Lawsuits, Number | lawsuit"," "," "," "," "," "," "," "," "," "," "," ",{"v":100,"d":"100 "}," "," "," "," "," "]
["Product Liability Lawsuits"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Loss Contingencies [Line Items]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Product Liability Accrual, Period Expense"," "," "," "," ",{"v":-103,"d":"$ (103)"}," "," "," "," "," "," "," "," "," "," "," "," "]
["Product Liability Lawsuits | IVC April 2023 Agreement"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Loss Contingencies [Line Items]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Loss Contingency, Estimate of Possible Loss",{"v":275,"d":"$ 275"}," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Payments for Legal Settlements"," "," "," "," ",{"v":74,"d":"$ 74"},{"v":275,"d":"$ 275"}," "," "," "," "," "," "," "," "," "," "," "]
["CVS Health"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Loss Contingencies [Line Items]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Long-term Purchase Commitment, Period"," ","10 years"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]

{"sheet":"Income Taxes (Narrative) (Detai","index":45,"n_rows":14,"n_cols":7,"rows_kept":14,"merged":[[0,0,1,0],[0,1,0,3],[0,5,0,6]]}
["Income Taxes (Narrative) (Details) - USD ($) $ in Millions","3 Months Ended",null,null,"6 Months Ended","9 Months Ended"]
[null,"Mar. 31, 2025","Mar. 31, 2024","Sep. 30, 2023","Jun. 30, 2024","Mar. 31, 2025","Mar. 31, 2024"]
["Income Taxes"," "," "," "," "," "," "]
["Effective Income Tax Rate Reconciliation, Percent",{"v":0.236,"d":"23.60%"},{"v":0.233,"d":"23.30%"}," "," ",{"v":0.228,"d":"22.80%"},{"v":0.234,"d":"23.40%"}]
["Income Tax Expense (Benefit)",{"v":157,"d":"$ 157"},{"v":80,"d":"$ 80"}," "," ",{"v":391,"d":"$ 391"},{"v":190,"d":"$ 190"}]
["Unrecognized tax benefits",{"v":890,"d":"890 "}," "," ",{"v":981,"d":"$ 981"},{"v":890,"d":"890 "}," "]
["Unrecognized tax benefits that would impact effective tax rate",{"v":865,"d":"865 "}," "," ",{"v":882,"d":"882 "},{"v":865,"d":"865 "}," "]
["Unrecognized tax benefits, interest and penalties accrued",{"v":64,"d":"$ 64"}," "," ",{"v":65,"d":"65 "},{"v":64,"d":"$ 64"}," "]
["Global Medical Products and Distribution"," "," "," "," "," "," "]
["Income Taxes"," "," "," "," "," "," "]
["Goodwill impairment"," ",{"v":90,"d":"$ 90"},{"v":585,"d":"$ 585"}," "," ",{"v":675,"d":"675 "}]
["Global Medical Products and Distribution"," "," "," "," "," "," "]
["Income Taxes"," "," "," "," "," "," "]
["Income Tax Expense (Benefit)"," "," "," ",{"v":36,"d":"$ 36"}," ",{"v":-56,"d":"$ (56)"}]

{"sheet":"Fair Value Measurements (Fair V","index":46,"n_rows":35,"n_cols":4,"rows_kept":35}
["Fair Value Measurements (Fair Value of Assets and Liabilities Measured on a Recurring Basis) (Details) - USD ($) $ in Millions","Mar. 31, 2025","Jun. 30, 2024","Jul. 10, 2023"]
["Transaction Data System Investment"," "," "," "]
["Assets:"," "," "," "]
["Equity Method Investment, Ownership Percentage",{"v":0.16,"d":"16%"}," "," "]
["Recurring"," "," "," "]
["Assets:"," "," "," "]
["Cash equivalents",{"v":949,"d":"$ 949"},{"v":1442,"d":"$ 1,442"}," "]
["Other investments",{"v":99,"d":"99 "},{"v":108,"d":"108 "}," "]
["Forward Contract",{"v":-43,"d":"(43)"},{"v":-87,"d":"(87)"}," "]
["Liabilities:"," "," "," "]
["Forward Contract",{"v":-43,"d":"(43)"},{"v":-87,"d":"(87)"}," "]
["Level 1 | Recurring"," "," "," "]
["Assets:"," "," "," "]
["Cash equivalents",{"v":949,"d":"949 "},{"v":1442,"d":"1,442 "}," "]
["Other investments",{"v":99,"d":"99 "},{"v":108,"d":"108 "}," "]
["Forward Contract",{"v":0,"d":"0 "},{"v":0,"d":"0 "}," "]
["Liabilities:"," "," "," "]
["Forward Contract",{"v":0,"d":"0 "},{"v":0,"d":"0 "}," "]
["Level 2 | Recurring"," "," "," "]
["Assets:"," "," "," "]
["Cash equivalents",{"v":0,"d":"0 "},{"v":0,"d":"0 "}," "]
["Other investments",{"v":0,"d":"0 "},{"v":0,"d":"0 "}," "]
["Forward Contract",{"v":-43,"d":"(43)"},{"v":-87,"d":"(87)"}," "]
["Liabilities:"," "," "," "]
["Forward Contract",{"v":-43,"d":"(43)"},{"v":-87,"d":"(87)"}," "]
["Level 3 | Recurring"," "," "," "]
["Assets:"," "," "," "]
["Cash equivalents",{"v":0,"d":"0 "},{"v":0,"d":"0 "}," "]
["Other investments",{"v":0,"d":"0 "},{"v":0,"d":"0 "}," "]
["Forward Contract",{"v":0,"d":"0 "},{"v":0,"d":"0 "}," "]
["Liabilities:"," "," "," "]
["Forward Contract",{"v":0,"d":"$ 0"},{"v":0,"d":"$ 0"}," "]
["Level 3 | Fair Value, Nonrecurring | Transaction Data System Investment"," "," "," "]
["Assets:"," "," "," "]
["Equity Method Investments, Fair Value Disclosure"," "," ",{"v":147,"d":"$ 147"}]

{"sheet":"Financial Instruments (Narrativ","index":47,"n_rows":48,"n_cols":11,"rows_kept":48,"merged":[[0,0,1,0],[0,1,0,2],[0,3,0,4],[0,6,0,7],[0,8,0,9]]}
["Financial Instruments (Narrative) (Details) € in Millions, ¥ in Millions, $ in Millions","3 Months Ended",null,"9 Months Ended",null,"12 Months Ended"]
[null,"Mar. 31, 2025 USD ($)","Mar. 31, 2024 USD ($)","Mar. 31, 2025 USD ($)","Mar. 31, 2024 USD ($)","Dec. 31, 2025 USD ($)","Mar. 31, 2025 EUR (€)","Mar. 31, 2025 JPY (¥)","Jun. 30, 2024 USD ($)","Jun. 30, 2024 JPY (¥)","Mar. 31, 2024 JPY (¥)"]
["Derivative [Line Items]"," "," "," "," "," "," "," "," "," "," "]
["Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments",{"v":0,"d":"$ 0"},{"v":0,"d":"$ 0"},{"v":0,"d":"$ 0"},{"v":0,"d":"$ 0"}," "," "," "," "," "," "]
["Proceeds from net investment hedge terminations"," "," ",{"v":2,"d":"2 "},{"v":28,"d":"28 "}," "," "," "," "," "," "]
["January 2023"," "," "," "," "," "," "," "," "," "," "]
["Derivative [Line Items]"," "," "," "," "," "," "," "," "," "," "]
["Proceeds from net investment hedge terminations"," "," ",{"v":28,"d":"28 "}," "," "," "," "," "," "," "]
["March 2025"," "," "," "," "," "," "," "," "," "," "]
["Derivative [Line Items]"," "," "," "," "," "," "," "," "," "," "]
["Proceeds from Hedge, Financing Activities"," "," ",{"v":2,"d":"2 "}," "," "," "," "," "," "," "]
["Cash Flow Hedging [Member]"," "," "," "," "," "," "," "," "," "," "]
["Derivative [Line Items]"," "," "," "," "," "," "," "," "," "," "]
["Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax",{"v":-4,"d":"(4)"},{"v":-1,"d":"(1)"},{"v":5,"d":"5 "},{"v":2,"d":"2 "}," "," "," "," "," "," "]
["Cash Flow Hedging [Member] | Foreign Exchange Contract [Member]"," "," "," "," "," "," "," "," "," "," "]
["Derivative [Line Items]"," "," "," "," "," "," "," "," "," "," "]
["Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax"," ",{"v":-2,"d":"(2)"},{"v":-3,"d":"(3)"},{"v":-4,"d":"(4)"}," "," "," "," "," "," "]
["Cash Flow Hedging [Member] | Foreign Exchange Contract [Member] | Forecast [Member] | Subsequent Event"," "," "," "," "," "," "," "," "," "," "]
["Derivative [Line Items]"," "," "," "," "," "," "," "," "," "," "]
["Cash Flow Hedge Gain (Loss) to be Reclassified within 12 Months"," "," "," "," ",{"v":1,"d":"$ 1"}," "," "," "," "," "]
["Designated as Hedging Instrument | Fair Value Hedging | Interest Rate Swap"," "," "," "," "," "," "," "," "," "," "]
["Derivative [Line Items]"," "," "," "," "," "," "," "," "," "," "]
["Derivative Liability, Notional Amount"," ",{"v":500,"d":"500 "}," ",{"v":500,"d":"500 "}," "," "," "," "," "," "]
["Designated as Hedging Instrument | Net Investment Hedging [Member] | Currency Swap [Member]"," "," "," "," "," "," "," "," "," "," "]
["Derivative [Line Items]"," "," "," "," "," "," "," "," "," "," "]
["Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax",{"v":-16,"d":"(16)"},{"v":-19,"d":"(19)"},{"v":-11,"d":"(11)"},{"v":-14,"d":"(14)"}," "," "," "," "," "," "]
["Gain (Loss) from Components Excluded from Assessment of Fair Value Hedge Effectiveness, Net",{"v":-3,"d":"(3)"}," ",{"v":-7,"d":"(7)"},{"v":-10,"d":"(10)"}," "," "," "," "," "," "]
["Designated as Hedging Instrument | Net Investment Hedging [Member] | Currency Swap [Member] | January 2023"," "," "," "," "," "," "," "," "," "," "]
["Derivative [Line Items]"," "," "," "," "," "," "," "," "," "," "]
["Derivatives, Hedge Discontinuances, Termination of Hedging Instrument, Notional Amount",{"v":300,"d":"300 "}," ",{"v":300,"d":"300 "}," "," "," ",{"v":38000,"d":"¥ 38,000"}," "," "," "]
["Designated as Hedging Instrument | Net Investment Hedging [Member] | Currency Swap [Member] | September 2023"," "," "," "," "," "," "," "," "," "," "]
["Derivative [Line Items]"," "," "," "," "," "," "," "," "," "," "]
["Derivatives, Hedge Discontinuances, Termination of Hedging Instrument, Notional Amount"," "," "," "," "," "," "," ",{"v":120,"d":"$ 120"},{"v":18000,"d":"¥ 18,000"}," "]
["Designated as Hedging Instrument | Net Investment Hedging [Member] | Currency Swap [Member] | September 2025"," "," "," "," "," "," "," "," "," "," "]
["Derivative [Line Items]"," "," "," "," "," "," "," "," "," "," "]
["Derivative, Notional Amount",{"v":120,"d":"120 "}," ",{"v":120,"d":"120 "}," "," "," ",{"v":18000,"d":"¥ 18,000"}," "," "," "]
["Designated as Hedging Instrument | Net Investment Hedging [Member] | Currency Swap [Member] | June 2027"," "," "," "," "," "," "," "," "," "," "]
["Derivative [Line Items]"," "," "," "," "," "," "," "," "," "," "]
["Derivative, Notional Amount"," ",{"v":120,"d":"$ 120"}," ",{"v":120,"d":"$ 120"}," "," "," "," "," ",{"v":18000,"d":"¥ 18,000"}]
["Designated as Hedging Instrument | Net Investment Hedging [Member] | Currency Swap [Member] | February 2027"," "," "," "," "," "," "," "," "," "," "]
["Derivative [Line Items]"," "," "," "," "," "," "," "," "," "," "]
["Derivative, Notional Amount",{"v":105,"d":"105 "}," ",{"v":105,"d":"105 "}," "," ",{"v":100,"d":"€ 100"}," "," "," "," "]
["Designated as Hedging Instrument | Net Investment Hedging [Member] | Currency Swap [Member] | March 2025"," "," "," "," "," "," "," "," "," "," "]
["Derivative [Line Items]"," "," "," "," "," "," "," "," "," "," "]
["Derivative, Notional Amount",{"v":107,"d":"107 "}," ",{"v":107,"d":"107 "}," "," ",{"v":100,"d":"€ 100"}," "," "," "," "]
["Other Nonoperating Income (Expense) [Member] | Not Designated as Hedging Instrument [Member] | Foreign Exchange Contract [Member]"," "," "," "," "," "," "," "," "," "," "]
["Derivative [Line Items]"," "," "," "," "," "," "," "," "," "," "]
["Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net",{"v":3,"d":"$ 3"}," ",{"v":-1,"d":"$ (1)"}," "," "," "," "," "," "," "]

{"sheet":"Financial Instruments Summary o","index":48,"n_rows":6,"n_cols":3,"rows_kept":6}
["Financial Instruments Summary of Estimated Fair Value of Long-term Obligations and Other Short-term Borrowings (Details) - USD ($) $ in Millions","Mar. 31, 2025","Jun. 30, 2024"]
["Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"," "," "]
["Carrying Amount of Long-Term and other Short-Term Borrowings",{"v":7679,"d":"$ 7,679"},{"v":5092,"d":"$ 5,092"}]
["Level 2"," "," "]
["Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"," "," "]
["Estimated fair value",{"v":7511,"d":"$ 7,511"},{"v":4891,"d":"$ 4,891"}]

{"sheet":"Shareholders' Equity (Narrative","index":49,"n_rows":35,"n_cols":16,"rows_kept":35,"merged":[[0,0,1,0],[0,5,0,6],[0,7,0,10],[0,11,0,12],[0,14,0,15]]}
["Shareholders' Equity (Narrative) (Details) - USD ($) $ / shares in Units, shares in Millions, $ in Millions",{"$nulls":4},"2 Months Ended",null,"3 Months Ended",{"$nulls":3},"4 Months Ended",null,"6 Months Ended","9 Months Ended"]
[null,"Mar. 11, 2025","Oct. 30, 2024","Dec. 13, 2023","Oct. 31, 2023","Mar. 11, 2025","Dec. 13, 2023","Mar. 31, 2025","Dec. 31, 2024","Dec. 31, 2023","Sep. 30, 2023","Oct. 30, 2024","Oct. 31, 2023","Dec. 31, 2024","Mar. 31, 2025","Mar. 31, 2024"]
["Class of Stock [Line Items]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Purchase of treasury shares"," "," "," "," "," "," "," "," "," "," "," "," "," ",{"v":765,"d":"$ 765"},{"v":750,"d":"$ 750"}]
["Retirement of treasury stock"," "," "," "," "," "," "," "," "," "," "," "," "," ",{"v":0,"d":"0 "}," "]
["$250 million share repurchase program [Member]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Class of Stock [Line Items]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Purchase of treasury shares"," "," "," "," "," "," "," "," ",{"v":250,"d":"$ 250"}," "," "," "," "," "," "]
["$500 million share repurchase program [Domain]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Class of Stock [Line Items]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Purchase of treasury shares"," "," "," "," "," "," "," "," "," ",{"v":500,"d":"$ 500"}," "," "," "," "," "]
["$375 million share repurchase program"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Class of Stock [Line Items]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Purchase of treasury shares"," "," "," "," "," "," ",{"v":375,"d":"$ 375"},{"v":375,"d":"$ 375"}," "," "," "," "," "," "," "]
["Share Repurchase Programs"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Class of Stock [Line Items]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Share Repurchase Program, Excise Tax"," "," "," "," "," "," "," "," "," "," "," "," "," ",{"v":15,"d":"$ 15"}," "]
["Share Repurchase Program, Excise Tax"," "," "," "," "," "," "," "," "," "," "," "," "," ",{"v":15,"d":"15 "}," "]
["Treasury Stock, Common"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Class of Stock [Line Items]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Purchase of treasury shares"," "," "," "," "," "," "," "," "," "," "," "," "," ",{"v":750,"d":"$ 750"}," "]
["Treasury Stock, Shares, Acquired"," "," "," "," "," "," ",{"v":-3,"d":"(3)"}," "," "," "," "," "," ",{"v":-6,"d":"(6)"},{"v":-9,"d":"(9)"}]
["Retirement of treasury stock"," "," "," "," "," "," ",{"v":56,"d":"56 "}," "," "," "," "," "," ",{"v":56,"d":"56 "}," "]
["Treasury Stock, Common | $250 million share repurchase program [Member]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Class of Stock [Line Items]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Treasury Stock, Shares, Acquired"," "," ",{"v":-0.4,"d":"(0.4)"}," "," "," "," "," ",{"v":-2,"d":"(2)"}," "," "," "," "," "," "]
["Treasury shares acquired, average price per share (in usd per share)"," "," "," "," "," ",{"v":103.67,"d":"$ 103.67"}," "," ",{"v":101.66,"d":"$ 101.66"}," "," "," "," "," "," "]
["Treasury Stock, Common | $500 million share repurchase program [Domain]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Class of Stock [Line Items]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Treasury Stock, Shares, Acquired"," "," "," ",{"v":-1.3,"d":"(1.3)"}," "," "," "," "," ",{"v":-4.4,"d":"(4.4)"}," "," "," "," "," "]
["Treasury shares acquired, average price per share (in usd per share)"," "," "," "," "," "," "," "," "," ",{"v":90.57,"d":"$ 90.57"}," ",{"v":88.22,"d":"$ 88.22"}," "," "," "]
["Treasury Stock, Common | $375 million share repurchase program"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Class of Stock [Line Items]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Treasury Stock, Shares, Acquired",{"v":-0.6,"d":"(0.6)"},{"v":-0.7,"d":"(0.7)"}," "," "," "," ",{"v":-2.4,"d":"(2.4)"},{"v":-2.7,"d":"(2.7)"}," "," "," "," "," "," "," "]
["Treasury shares acquired, average price per share (in usd per share)"," "," "," "," ",{"v":125.87,"d":"$ 125.87"}," ",{"v":125.33,"d":"$ 125.33"}," "," "," ",{"v":110.1,"d":"$ 110.10"}," ",{"v":109.65,"d":"$ 109.65"}," "," "]

{"sheet":"Shareholders' Equity (Changes i","index":50,"n_rows":32,"n_cols":5,"rows_kept":32,"merged":[[0,0,1,0],[0,1,0,2],[0,3,0,4]]}
["Shareholders' Equity (Changes in the Accumulated Other Comprehensive Income (Loss)) (Details) - USD ($) $ in Millions","3 Months Ended",null,"9 Months Ended"]
[null,"Mar. 31, 2025","Mar. 31, 2024","Mar. 31, 2025","Mar. 31, 2024"]
["AOCI, Net of Tax [Roll Forward]"," "," "," "," "]
["Balance at beginning of period",{"v":-2921,"d":"$ (2,921)"},{"v":-3547,"d":"$ (3,547)"},{"v":-3212,"d":"$ (3,212)"},{"v":-2957,"d":"$ (2,957)"}]
["Other Comprehensive Income (Loss), Tax"," "," ",{"v":2,"d":"2 "},{"v":-4,"d":"(4)"}]
["Total other comprehensive income/(loss), net of tax",{"v":4,"d":"4 "},{"v":-5,"d":"(5)"},{"v":-9,"d":"(9)"},{"v":-9,"d":"(9)"}]
["Balance at end of period",{"v":-1898,"d":"(1,898)"},{"v":-3359,"d":"(3,359)"},{"v":-1898,"d":"(1,898)"},{"v":-3359,"d":"(3,359)"}]
["Foreign Currency Translation Adjustments"," "," "," "," "]
["AOCI, Net of Tax [Roll Forward]"," "," "," "," "]
["Balance at beginning of period"," "," ",{"v":-138,"d":"(138)"},{"v":-137,"d":"(137)"}]
["Other Comprehensive Income (Loss), before Reclassifications, Net of Tax"," "," ",{"v":-13,"d":"(13)"},{"v":-4,"d":"(4)"}]
["Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax"," "," ",{"v":0,"d":"0 "},{"v":0,"d":"0 "}]
["Total other comprehensive income/(loss), net of tax"," "," ",{"v":-13,"d":"(13)"},{"v":-4,"d":"(4)"}]
["Balance at end of period",{"v":-151,"d":"(151)"},{"v":-141,"d":"(141)"},{"v":-151,"d":"(151)"},{"v":-141,"d":"(141)"}]
["Accumulated Other Comprehensive Loss"," "," "," "," "]
["AOCI, Net of Tax [Roll Forward]"," "," "," "," "]
["Balance at beginning of period"," "," ",{"v":-167,"d":"(167)"},{"v":-151,"d":"(151)"}]
["Total other comprehensive income/(loss), net of tax"," "," ",{"v":-9,"d":"(9)"},{"v":-9,"d":"(9)"}]
["Balance at end of period",{"v":-176,"d":"(176)"},{"v":-160,"d":"(160)"},{"v":-176,"d":"(176)"},{"v":-160,"d":"(160)"}]
["AOCI Attributable to Parent"," "," "," "," "]
["AOCI, Net of Tax [Roll Forward]"," "," "," "," "]
["Balance at beginning of period",{"v":-180,"d":"(180)"},{"v":-155,"d":"(155)"},{"v":-167,"d":"(167)"},{"v":-151,"d":"(151)"}]
["Other Comprehensive Income (Loss), before Reclassifications, Net of Tax"," "," ",{"v":-10,"d":"(10)"},{"v":-3,"d":"(3)"}]
["Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax"," "," ",{"v":1,"d":"1 "},{"v":-6,"d":"(6)"}]
["Balance at end of period",{"v":-176,"d":"(176)"},{"v":-160,"d":"(160)"},{"v":-176,"d":"(176)"},{"v":-160,"d":"(160)"}]
["Accumulated Gain (Loss), Net, Cash Flow Hedge, Noncontrolling Interest"," "," "," "," "]
["AOCI, Net of Tax [Roll Forward]"," "," "," "," "]
["Balance at beginning of period"," "," ",{"v":-29,"d":"(29)"},{"v":-14,"d":"(14)"}]
["Other Comprehensive Income (Loss), before Reclassifications, Net of Tax"," "," ",{"v":3,"d":"3 "},{"v":1,"d":"1 "}]
["Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax"," "," ",{"v":1,"d":"1 "},{"v":-6,"d":"(6)"}]
["Total other comprehensive income/(loss), net of tax"," "," ",{"v":4,"d":"4 "},{"v":-5,"d":"(5)"}]
["Balance at end of period",{"v":-25,"d":"$ (25)"},{"v":-19,"d":"$ (19)"},{"v":-25,"d":"$ (25)"},{"v":-19,"d":"$ (19)"}]

{"sheet":"Earnings Per Share Attributab_3","index":51,"n_rows":7,"n_cols":5,"rows_kept":7,"merged":[[0,0,1,0],[0,1,0,2],[0,3,0,4]]}
["Earnings Per Share Attributable to Cardinal Health, Inc. (Reconciliation of Common Shares Used to Compute Basic and Diluted EPS) (Details) - shares shares in Millions","3 Months Ended",null,"9 Months Ended"]
[null,"Mar. 31, 2025","Mar. 31, 2024","Mar. 31, 2025","Mar. 31, 2024"]
["Earnings Per Share [Abstract]"," "," "," "," "]
["Weighted-average common shares–basic (in shares)",{"v":240,"d":"240 "},{"v":243,"d":"243 "},{"v":242,"d":"242 "},{"v":245,"d":"245 "}]
["Effect of dilutive securities:"," "," "," "," "]
["Employee stock options, restricted share units, and performance share units (in shares)",{"v":1,"d":"1 "},{"v":2,"d":"2 "},{"v":1,"d":"1 "},{"v":2,"d":"2 "}]
["Weighted-average common shares–diluted (in shares)",{"v":241,"d":"241 "},{"v":245,"d":"245 "},{"v":243,"d":"243 "},{"v":247,"d":"247 "}]

{"sheet":"Segment Information (Narrative)","index":52,"n_rows":11,"n_cols":6,"rows_kept":11,"merged":[[0,0,1,0],[0,1,0,3],[0,4,0,5]]}
["Segment Information (Narrative) (Details) $ in Millions","3 Months Ended",null,null,"9 Months Ended"]
[null,"Mar. 31, 2025 USD ($)","Mar. 31, 2024 USD ($)","Sep. 30, 2023 USD ($)","Mar. 31, 2025 USD ($) Segments segment","Mar. 31, 2024 USD ($)"]
["Segment Reporting Information [Line Items]"," "," "," "," "," "]
["Number of reportable segments | segment"," "," "," ",{"v":2,"d":"2 "}," "]
["Project costs on investment and other spending",{"v":15,"d":"$ 15"},{"v":17,"d":"$ 17"}," ",{"v":42,"d":"$ 42"},{"v":37,"d":"$ 37"}]
["Global Medical Products and Distribution"," "," "," "," "," "]
["Segment Reporting Information [Line Items]"," "," "," "," "," "]
["Goodwill impairment"," ",{"v":90,"d":"$ 90"},{"v":585,"d":"$ 585"}," ",{"v":675,"d":"$ 675"}]
["Other Segments"," "," "," "," "," "]
["Segment Reporting Information [Line Items]"," "," "," "," "," "]
["Number of operating segments | Segments"," "," "," ",{"v":3,"d":"3 "}," "]

{"sheet":"Segment Information (Revenue by","index":53,"n_rows":28,"n_cols":5,"rows_kept":28,"merged":[[0,0,1,0],[0,1,0,2],[0,3,0,4]]}
["Segment Information (Revenue by Reportable Segment) (Details) - USD ($) $ in Millions","3 Months Ended",null,"9 Months Ended"]
[null,"Mar. 31, 2025","Mar. 31, 2024","Mar. 31, 2025","Mar. 31, 2024"]
["Segment Reporting Information [Line Items]"," "," "," "," "]
["Total revenue",{"v":54878,"d":"$ 54,878"},{"v":54868,"d":"$ 54,868"},{"v":162419,"d":"$ 162,419"},{"v":166960,"d":"$ 166,960"}]
["Operating Segments"," "," "," "," "]
["Segment Reporting Information [Line Items]"," "," "," "," "]
["Total revenue",{"v":54897,"d":"54,897 "},{"v":54889,"d":"54,889 "},{"v":162482,"d":"162,482 "},{"v":167024,"d":"167,024 "}]
["Operating Segments | Pharmaceutical and Specialty Solutions"," "," "," "," "]
["Segment Reporting Information [Line Items]"," "," "," "," "]
["Total revenue",{"v":50433,"d":"50,433 "},{"v":50622,"d":"50,622 "},{"v":149272,"d":"149,272 "},{"v":154412,"d":"154,412 "}]
["Operating Segments | Global Medical Products and Distribution"," "," "," "," "]
["Segment Reporting Information [Line Items]"," "," "," "," "]
["Total revenue",{"v":3160,"d":"3,160 "},{"v":3113,"d":"3,113 "},{"v":9437,"d":"9,437 "},{"v":9272,"d":"9,272 "}]
["Operating Segments | Other Segments"," "," "," "," "]
["Segment Reporting Information [Line Items]"," "," "," "," "]
["Total revenue",{"v":1304,"d":"1,304 "},{"v":1154,"d":"1,154 "},{"v":3773,"d":"3,773 "},{"v":3340,"d":"3,340 "}]
["Corporate"," "," "," "," "]
["Segment Reporting Information [Line Items]"," "," "," "," "]
["Total revenue",{"v":-19,"d":"(19)"},{"v":-21,"d":"(21)"},{"v":-63,"d":"(63)"},{"v":-64,"d":"(64)"}]
["Nuclear Precision Health Services [Member] | Operating Segments | Other Segments"," "," "," "," "]
["Segment Reporting Information [Line Items]"," "," "," "," "]
["Total revenue",{"v":403,"d":"403 "},{"v":352,"d":"352 "},{"v":1148,"d":"1,148 "},{"v":1006,"d":"1,006 "}]
["OptiFreight Logistics [Member] | Operating Segments | Other Segments"," "," "," "," "]
["Segment Reporting Information [Line Items]"," "," "," "," "]
["Total revenue",{"v":84,"d":"84 "},{"v":72,"d":"72 "},{"v":234,"d":"234 "},{"v":198,"d":"198 "}]
["at-Home Solutions [Member] | Operating Segments | Other Segments"," "," "," "," "]
["Segment Reporting Information [Line Items]"," "," "," "," "]
["Total revenue",{"v":817,"d":"$ 817"},{"v":730,"d":"$ 730"},{"v":2391,"d":"$ 2,391"},{"v":2136,"d":"$ 2,136"}]

{"sheet":"Segment Information Revenue Fro","index":54,"n_rows":16,"n_cols":5,"rows_kept":16,"merged":[[0,0,1,0],[0,1,0,2],[0,3,0,4]]}
["Segment Information Revenue From External Customers By Geographic Areas (Details) - USD ($) $ in Millions","3 Months Ended",null,"9 Months Ended"]
[null,"Mar. 31, 2025","Mar. 31, 2024","Mar. 31, 2025","Mar. 31, 2024"]
["Segment Revenue from External Customers by Geographic Area [Line Items]"," "," "," "," "]
["Revenue",{"v":54878,"d":"$ 54,878"},{"v":54868,"d":"$ 54,868"},{"v":162419,"d":"$ 162,419"},{"v":166960,"d":"$ 166,960"}]
["UNITED STATES"," "," "," "," "]
["Segment Revenue from External Customers by Geographic Area [Line Items]"," "," "," "," "]
["Revenue",{"v":54498,"d":"54,498 "},{"v":54464,"d":"54,464 "},{"v":161247,"d":"161,247 "},{"v":165783,"d":"165,783 "}]
["Non-US [Member]"," "," "," "," "]
["Segment Revenue from External Customers by Geographic Area [Line Items]"," "," "," "," "]
["Revenue",{"v":399,"d":"399 "},{"v":425,"d":"425 "},{"v":1235,"d":"1,235 "},{"v":1241,"d":"1,241 "}]
["Operating Segments"," "," "," "," "]
["Segment Revenue from External Customers by Geographic Area [Line Items]"," "," "," "," "]
["Revenue",{"v":54897,"d":"54,897 "},{"v":54889,"d":"54,889 "},{"v":162482,"d":"162,482 "},{"v":167024,"d":"167,024 "}]
["Corporate"," "," "," "," "]
["Segment Revenue from External Customers by Geographic Area [Line Items]"," "," "," "," "]
["Revenue",{"v":-19,"d":"$ (19)"},{"v":-21,"d":"$ (21)"},{"v":-63,"d":"$ (63)"},{"v":-64,"d":"$ (64)"}]

{"sheet":"Segment Information (Segment Pr","index":55,"n_rows":19,"n_cols":5,"rows_kept":19,"merged":[[0,0,1,0],[0,1,0,2],[0,3,0,4]]}
["Segment Information (Segment Profit by Reportable Segment) (Details) - USD ($) $ in Millions","3 Months Ended",null,"9 Months Ended"]
[null,"Mar. 31, 2025","Mar. 31, 2024","Mar. 31, 2025","Mar. 31, 2024"]
["Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]"," "," "," "," "]
["Total operating earnings",{"v":730,"d":"$ 730"},{"v":369,"d":"$ 369"},{"v":1847,"d":"$ 1,847"},{"v":842,"d":"$ 842"}]
["Operating Segments"," "," "," "," "]
["Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]"," "," "," "," "]
["Total operating earnings",{"v":835,"d":"835 "},{"v":714,"d":"714 "},{"v":2144,"d":"2,144 "},{"v":1890,"d":"1,890 "}]
["Operating Segments | Pharmaceutical and Specialty Solutions"," "," "," "," "]
["Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]"," "," "," "," "]
["Total operating earnings",{"v":662,"d":"662 "},{"v":582,"d":"582 "},{"v":1723,"d":"1,723 "},{"v":1533,"d":"1,533 "}]
["Operating Segments | Global Medical Products and Distribution"," "," "," "," "]
["Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]"," "," "," "," "]
["Total operating earnings",{"v":39,"d":"39 "},{"v":22,"d":"22 "},{"v":65,"d":"65 "},{"v":45,"d":"45 "}]
["Operating Segments | Other Segments"," "," "," "," "]
["Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]"," "," "," "," "]
["Total operating earnings",{"v":134,"d":"134 "},{"v":110,"d":"110 "},{"v":356,"d":"356 "},{"v":312,"d":"312 "}]
["Corporate"," "," "," "," "]
["Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]"," "," "," "," "]
["Total operating earnings",{"v":-105,"d":"$ (105)"},{"v":-345,"d":"$ (345)"},{"v":-297,"d":"$ (297)"},{"v":-1048,"d":"$ (1,048)"}]

{"sheet":"Segment Information (Assets by ","index":56,"n_rows":15,"n_cols":3,"rows_kept":15}
["Segment Information (Assets by Reportable Segment) (Details) - USD ($) $ in Millions","Mar. 31, 2025","Jun. 30, 2024"]
["Segment Reporting Information [Line Items]"," "," "]
["Total assets",{"v":49871,"d":"$ 49,871"},{"v":45121,"d":"$ 45,121"}]
["Operating Segments | Pharmaceutical and Specialty Solutions"," "," "]
["Segment Reporting Information [Line Items]"," "," "]
["Total assets",{"v":35734,"d":"35,734 "},{"v":29149,"d":"29,149 "}]
["Operating Segments | Global Medical Products and Distribution"," "," "]
["Segment Reporting Information [Line Items]"," "," "]
["Total assets",{"v":7201,"d":"7,201 "},{"v":7047,"d":"7,047 "}]
["Operating Segments | Other Segments"," "," "]
["Segment Reporting Information [Line Items]"," "," "]
["Total assets",{"v":2726,"d":"2,726 "},{"v":2606,"d":"2,606 "}]
["Corporate"," "," "]
["Segment Reporting Information [Line Items]"," "," "]
["Total assets",{"v":4210,"d":"$ 4,210"},{"v":6319,"d":"$ 6,319"}]

{"sheet":"Share-Based Compensation (Narra","index":57,"n_rows":21,"n_cols":5,"rows_kept":21,"merged":[[0,0,1,0],[0,1,0,2],[0,3,0,4]]}
["Share-Based Compensation (Narrative) (Details) shares in Thousands, $ in Millions","3 Months Ended",null,"9 Months Ended"]
[null,"Mar. 31, 2025 USD ($) shares","Mar. 31, 2024 USD ($)","Mar. 31, 2025 USD ($) yr shares","Mar. 31, 2024 USD ($)"]
["Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"," "," "," "," "]
["Tax benefit related to share-based compensation",{"v":4,"d":"$ 4"},{"v":4,"d":"$ 4"},{"v":11,"d":"$ 11"},{"v":12,"d":"$ 12"}]
["Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant | shares",{"v":15000,"d":"15,000 "}," ",{"v":15000,"d":"15,000 "}," "]
["Restricted Share Units"," "," "," "," "]
["Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"," "," "," "," "]
["Award vesting period (in years)"," "," ","3 years"," "]
["Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",{"v":79,"d":"$ 79"}," ",{"v":79,"d":"$ 79"}," "]
["Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition"," "," ","2 years"," "]
["Performance Share Units"," "," "," "," "]
["Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"," "," "," "," "]
["Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",{"v":53,"d":"$ 53"}," ",{"v":53,"d":"$ 53"}," "]
["Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition"," "," ","2 years"," "]
["Vesting Period in years for Shares | yr"," "," ",{"v":3,"d":"3 "}," "]
["Performance Share Units | Minimum"," "," "," "," "]
["Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"," "," "," "," "]
["Target performance goal (as a percent)"," "," ",{"v":0,"d":"0%"},{"v":0,"d":"0%"}]
["Performance Share Units | Maximum"," "," "," "," "]
["Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"," "," "," "," "]
["Target performance goal (as a percent)"," "," ",{"v":2.4,"d":"240%"},{"v":2.4,"d":"240%"}]

{"sheet":"Share-Based Compensation (Sched","index":58,"n_rows":10,"n_cols":5,"rows_kept":10,"merged":[[0,0,1,0],[0,1,0,2],[0,3,0,4]]}
["Share-Based Compensation (Schedule of Total Share-Based Compensation Expense by Type of Award) (Details) - USD ($) $ in Millions","3 Months Ended",null,"9 Months Ended"]
[null,"Mar. 31, 2025","Mar. 31, 2024","Mar. 31, 2025","Mar. 31, 2024"]
["Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"," "," "," "," "]
["Total share-based compensation",{"v":32,"d":"$ 32"},{"v":31,"d":"$ 31"},{"v":91,"d":"$ 91"},{"v":88,"d":"$ 88"}]
["Restricted Share Unit"," "," "," "," "]
["Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"," "," "," "," "]
["Total share-based compensation",{"v":18,"d":"18 "},{"v":20,"d":"20 "},{"v":54,"d":"54 "},{"v":58,"d":"58 "}]
["Performance Share Unit"," "," "," "," "]
["Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"," "," "," "," "]
["Total share-based compensation",{"v":14,"d":"$ 14"},{"v":11,"d":"$ 11"},{"v":37,"d":"$ 37"},{"v":30,"d":"$ 30"}]

{"sheet":"Share-Based Compensation (Sch_2","index":59,"n_rows":21,"n_cols":5,"rows_kept":21,"merged":[[0,0,1,0],[0,1,0,2],[0,3,0,4]]}
["Share-Based Compensation (Schedule of All Transactions Related to Restricted Share Units Under the Plans) (Details) - USD ($) $ / shares in Units, shares in Millions, $ in Millions","3 Months Ended",null,"9 Months Ended"]
[null,"Mar. 31, 2025","Mar. 31, 2024","Mar. 31, 2025","Mar. 31, 2024"]
["Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"," "," "," "," "]
["Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Vested",{"v":17,"d":"$ 17"}," ",{"v":17,"d":"$ 17"}," "]
["Restricted Share Units"," "," "," "," "]
["Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"," "," "," "," "]
["Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Vested",{"v":3,"d":"3 "},{"v":4,"d":"$ 4"},{"v":67,"d":"67 "},{"v":66,"d":"$ 66"}]
["Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",{"v":79,"d":"$ 79"}," ",{"v":79,"d":"$ 79"}," "]
["Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition"," "," ","2 years"," "]
["Restricted Share Units"," "," "," "," "]
["Nonvested at beginning of period (in shares)"," "," ",1.7," "]
["Granted (in shares)"," "," ",0.7," "]
["Vested (in shares)"," "," ",{"v":-0.9,"d":"(0.9)"}," "]
["Canceled and forfeited (in shares)"," "," ",{"v":-0.1,"d":"(0.1)"}," "]
["Nonvested at end of period (in shares)",1.4," ",1.4," "]
["Weighted-Average Grant Date Fair Value per Share"," "," "," "," "]
["Nonvested at beginning of period (in usd per share)"," "," ",{"v":70.98,"d":"$ 70.98"}," "]
["Granted (in usd per share)"," "," ",{"v":108.2,"d":"108.20"}," "]
["Vested (in usd per share)"," "," ",71.74," "]
["Canceled and forfeited (in usd per share)"," "," ",93.05," "]
["Nonvested at end of period (in usd per share)",{"v":85.45,"d":"$ 85.45"}," ",{"v":85.45,"d":"$ 85.45"}," "]

{"sheet":"Share-Based Compensation (Sch_3","index":60,"n_rows":21,"n_cols":5,"rows_kept":21,"merged":[[0,0,1,0],[0,1,0,2],[0,3,0,4]]}
["Share-Based Compensation (Schedule of All Transactions Related to Performance Share Units Under the Plans) (Details) - USD ($) $ / shares in Units, shares in Millions, $ in Millions","3 Months Ended",null,"9 Months Ended"]
[null,"Mar. 31, 2025","Mar. 31, 2024","Mar. 31, 2025","Mar. 31, 2024"]
["Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"," "," "," "," "]
["Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Vested",{"v":17,"d":"$ 17"}," ",{"v":17,"d":"$ 17"}," "]
["Performance Share Units"," "," "," "," "]
["Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"," "," "," "," "]
["Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Vested",{"v":0,"d":"$ 0"},{"v":0,"d":"$ 0"},{"v":41,"d":"$ 41"},{"v":24,"d":"$ 24"}]
["Performance Share Units"," "," "," "," "]
["Nonvested at beginning of period (in shares)"," "," ",1.3," "]
["Granted (in shares)"," "," ",0.5," "]
["Vested (in shares)"," "," ",{"v":-0.3,"d":"(0.3)"}," "]
["Canceled and forfeited (in shares)"," "," ",{"v":0,"d":"0 "}," "]
["Nonvested at end of period (in shares)",1.5," ",1.5," "]
["Weighted-Average Grant Date Fair Value per Share"," "," "," "," "]
["Nonvested at beginning of period (in usd per share)"," "," ",{"v":97.03,"d":"$ 97.03"}," "]
["Granted (in usd per share)"," "," ",113.88," "]
["Vested (in usd per share)"," "," ",108.79," "]
["Canceled and forfeited (in usd per share)"," "," ",{"v":0,"d":"0 "}," "]
["Nonvested at end of period (in usd per share)",{"v":99.53,"d":"$ 99.53"}," ",{"v":99.53,"d":"$ 99.53"}," "]
["Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",{"v":53,"d":"$ 53"}," ",{"v":53,"d":"$ 53"}," "]
["Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition"," "," ","2 years"," "]

{"sheet":"Share-Based Compensation GIA (D","index":61,"n_rows":66,"n_cols":7,"rows_kept":66,"merged":[[0,0,1,0],[0,2,0,3],[0,4,0,5]]}
["Share-Based Compensation GIA (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands","2 Months Ended","3 Months Ended",null,"9 Months Ended"]
[null,"Mar. 31, 2025","Mar. 31, 2025","Mar. 31, 2024","Mar. 31, 2025","Mar. 31, 2024","Jan. 30, 2025"]
["Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"," "," "," "," "," "," "]
["Total share-based compensation"," ",{"v":32000,"d":"$ 32,000"},{"v":31000,"d":"$ 31,000"},{"v":91000,"d":"$ 91,000"},{"v":88000,"d":"$ 88,000"}," "]
["Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Vested"," ",{"v":17000,"d":"17,000 "}," ",{"v":17000,"d":"17,000 "}," "," "]
["GIA [Member]"," "," "," "," "," "," "]
["Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"," "," "," "," "," "," "]
["Business Combination, Voting Equity Interest Acquired, Percentage"," "," "," "," "," ",{"v":0.73,"d":"73%"}]
["GIA Common Units"," "," "," "," "," "," "]
["Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"," "," "," "," "," "," "]
["Total share-based compensation",{"v":17000,"d":"$ 17,000"}," "," "," "," "," "]
["Share-Based Payment Arrangement, Acquisition Related Expense",{"v":16000,"d":"16,000 "}," "," "," "," "," "]
["Share-Based Payment Arrangement, Non-Acquisition-Related Expense",{"v":1000,"d":"1,000 "}," "," "," "," "," "]
["Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Vested"," ",{"v":17000,"d":"17,000 "}," "," "," "," "]
["Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",{"v":174000,"d":"$ 174,000"},{"v":174000,"d":"$ 174,000"}," ",{"v":174000,"d":"$ 174,000"}," ",{"v":168000,"d":"$ 168,000"}]
["Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition"," "," "," ","3 years"," "," "]
["GIA Common Units"," "," "," "," "," "," "]
["Nonvested at beginning of period (in shares)",{"v":115000,"d":"115,000 "}," "," "," "," "," "]
["Granted (in shares)",{"v":16000,"d":"16,000 "}," "," "," "," "," "]
["Vested (in shares)",{"v":-12000,"d":"(12,000)"}," "," "," "," "," "]
["Canceled and forfeited (in shares)",{"v":0,"d":"0 "}," "," "," "," "," "]
["Nonvested at end of period (in shares)",{"v":119000,"d":"119,000 "},{"v":119000,"d":"119,000 "}," ",{"v":119000,"d":"119,000 "}," "," "]
["Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Outstanding, Number",{"v":618000,"d":"618,000 "},{"v":618000,"d":"618,000 "}," ",{"v":618000,"d":"618,000 "}," "," "]
["Weighted-Average Grant Date Fair Value per Share"," "," "," "," "," "," "]
["Nonvested at beginning of period (in usd per share)",{"v":1.46,"d":"$ 1.46"}," "," "," "," "," "]
["Granted (in usd per share)",1.46," "," "," "," "," "]
["Vested (in usd per share)",1.46," "," "," "," "," "]
["Canceled and forfeited (in usd per share)",{"v":0,"d":"0 "}," "," "," "," "," "]
["Nonvested at end of period (in usd per share)",1.46,{"v":1.46,"d":"$ 1.46"}," ",{"v":1.46,"d":"$ 1.46"}," "," "]
["Vested at end of period (in usd per share)",{"v":1.46,"d":"$ 1.46"},{"v":1.46,"d":"$ 1.46"}," ",{"v":1.46,"d":"$ 1.46"}," "," "]
["Performance Share Units"," "," "," "," "," "," "]
["Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"," "," "," "," "," "," "]
["Total share-based compensation"," ",{"v":14000,"d":"$ 14,000"},{"v":11000,"d":"11,000 "},{"v":37000,"d":"$ 37,000"},{"v":30000,"d":"30,000 "}," "]
["Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Vested"," ",{"v":0,"d":"0 "},{"v":0,"d":"0 "},{"v":41000,"d":"41,000 "},{"v":24000,"d":"24,000 "}," "]
["Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",{"v":53000,"d":"$ 53,000"},{"v":53000,"d":"$ 53,000"}," ",{"v":53000,"d":"$ 53,000"}," "," "]
["Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition"," "," "," ","2 years"," "," "]
["GIA Common Units"," "," "," "," "," "," "]
["Nonvested at beginning of period (in shares)"," "," "," ",{"v":1300,"d":"1,300 "}," "," "]
["Granted (in shares)"," "," "," ",{"v":500,"d":"500 "}," "," "]
["Vested (in shares)"," "," "," ",{"v":-300,"d":"(300)"}," "," "]
["Canceled and forfeited (in shares)"," "," "," ",{"v":0,"d":"0 "}," "," "]
["Nonvested at end of period (in shares)",{"v":1500,"d":"1,500 "},{"v":1500,"d":"1,500 "}," ",{"v":1500,"d":"1,500 "}," "," "]
["Weighted-Average Grant Date Fair Value per Share"," "," "," "," "," "," "]
["Nonvested at beginning of period (in usd per share)"," "," "," ",{"v":97.03,"d":"$ 97.03"}," "," "]
["Granted (in usd per share)"," "," "," ",113.88," "," "]
["Vested (in usd per share)"," "," "," ",108.79," "," "]
["Canceled and forfeited (in usd per share)"," "," "," ",{"v":0,"d":"0 "}," "," "]
["Nonvested at end of period (in usd per share)",{"v":99.53,"d":"$ 99.53"},{"v":99.53,"d":"$ 99.53"}," ",{"v":99.53,"d":"$ 99.53"}," "," "]
["Restricted Share Units"," "," "," "," "," "," "]
["Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"," "," "," "," "," "," "]
["Total share-based compensation"," ",{"v":18000,"d":"$ 18,000"},{"v":20000,"d":"20,000 "},{"v":54000,"d":"$ 54,000"},{"v":58000,"d":"58,000 "}," "]
["Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Vested"," ",{"v":3000,"d":"3,000 "},{"v":4000,"d":"$ 4,000"},{"v":67000,"d":"67,000 "},{"v":66000,"d":"$ 66,000"}," "]
["Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",{"v":79000,"d":"$ 79,000"},{"v":79000,"d":"$ 79,000"}," ",{"v":79000,"d":"$ 79,000"}," "," "]
["Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition"," "," "," ","2 years"," "," "]
["GIA Common Units"," "," "," "," "," "," "]
["Nonvested at beginning of period (in shares)"," "," "," ",{"v":1700,"d":"1,700 "}," "," "]
["Granted (in shares)"," "," "," ",{"v":700,"d":"700 "}," "," "]
["Vested (in shares)"," "," "," ",{"v":-900,"d":"(900)"}," "," "]
["Canceled and forfeited (in shares)"," "," "," ",{"v":-100,"d":"(100)"}," "," "]
["Nonvested at end of period (in shares)",{"v":1400,"d":"1,400 "},{"v":1400,"d":"1,400 "}," ",{"v":1400,"d":"1,400 "}," "," "]
["Weighted-Average Grant Date Fair Value per Share"," "," "," "," "," "," "]
["Nonvested at beginning of period (in usd per share)"," "," "," ",{"v":70.98,"d":"$ 70.98"}," "," "]
["Granted (in usd per share)"," "," "," ",{"v":108.2,"d":"108.20"}," "," "]
["Vested (in usd per share)"," "," "," ",71.74," "," "]
["Canceled and forfeited (in usd per share)"," "," "," ",93.05," "," "]
["Nonvested at end of period (in usd per share)",{"v":85.45,"d":"$ 85.45"},{"v":85.45,"d":"$ 85.45"}," ",{"v":85.45,"d":"$ 85.45"}," "," "]